<SEC-DOCUMENT>0001178913-25-002111.txt : 20250605
<SEC-HEADER>0001178913-25-002111.hdr.sgml : 20250605
<ACCEPTANCE-DATETIME>20250605160529
ACCESSION NUMBER:		0001178913-25-002111
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250605
FILED AS OF DATE:		20250605
DATE AS OF CHANGE:		20250605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		251027092

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>zk2533282.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:entx="http://www.enterabio.com/20241231"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Entera Bio Ltd. - 1638097 - 2025</title></head><body style="font-size:10pt;font-family:Times New Roman, Times, serif;"><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" contextRef="C_20240101to20241231" id="Fxbrl_20250528100047787">DEF 14A</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20241231" id="F20250528042836232_0">0001638097</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20241231" id="F20250528042836232_1">false</ix:nonNumeric><ix:footnote id="FN20250528115937877" xml:lang="en-US">The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.</ix:footnote>
<ix:footnote id="FN20250528120032302" xml:lang="en-US">The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</ix:footnote>
<ix:footnote id="FN20250528120053271" xml:lang="en-US">The dollar amounts reported below represent the amount of &#8220;compensation actually paid&#8221; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year. For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#8220;compensation actually paid&#8221; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant. The following table details the applicable adjustments that were made to the determine &#8220;compensation actually paid&#8221; (all amounts are averages for Non-PEO NEOs).</ix:footnote>
<ix:footnote id="FN20250528120119793" xml:lang="en-US">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</ix:footnote>
<ix:footnote id="FN20250528120204617" xml:lang="en-US">Cumulative total stockholder return (&#8220;TSR&#8221;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</ix:footnote>
<ix:footnote id="FN20250528120224259" xml:lang="en-US">Net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="entx-20241231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20240101to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ecdMeasureAxis_1"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ecd:MeasureAxis"><ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20250528111816153" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528111816153" toRefs="FN20250528120032302"/><ix:relationship fromRefs="Fxbrl_20250528111840911" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528111840911" toRefs="FN20250528120053271"/><ix:relationship fromRefs="Fxbrl_20250528111909715" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528111909715" toRefs="FN20250528120119793"/><ix:relationship fromRefs="Fxbrl_20250528111932493" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528111932493" toRefs="FN20250528120053271"/><ix:relationship fromRefs="Fxbrl_20250528112422091" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112422091" toRefs="FN20250528120204617"/><ix:relationship fromRefs="Fxbrl_20250528112502844" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112502844" toRefs="FN20250528120224259"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528112502844" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528112502844" toRefs="FN20250528120224259"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528112422091" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528112422091" toRefs="FN20250528120204617"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111932493" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111932493" toRefs="FN20250528120053271"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111909715" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111909715" toRefs="FN20250528120119793"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111840911" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111840911" toRefs="FN20250528120053271"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111816153" toRefs="FN20250528115937877"/><ix:relationship fromRefs="Fxbrl_20250528112826678_xbrl_20250528111816153" toRefs="FN20250528120032302"/></ix:resources></ix:header></div><div>
  <div>
    <div>
      <div style="text-align:center;line-height:1.25;font-weight:bold">
        <hr style="border:none;border-bottom:1px solid #000000;border-top:4px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
      </div>
      <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNITED STATES</span></span></div>
      <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:14pt"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">SECURITIES AND EXCHANGE COMMISSION</span></span></div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Washington, D.C. 20549</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_________________</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:14pt"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">SCHEDULE <span style="-sec-ix-hidden:Fxbrl_20250528100047787">14A</span> INFORMATION</span></span></div>
      <div style="text-align:center;line-height:1.25"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Proxy Statement Pursuant to Section 14(a) of the</span><br/><span style="font-weight:bold">Securities Exchange Act of 1934</span><br/><span style="font-weight:bold">(Amendment No. )</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_______________________________</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed by the Registrant &#9746;</span></span></div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed by a Party other than the Registrant &#9744;</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Check the appropriate box:</span></span></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:2.56%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.89%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:96.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preliminary Proxy Statement</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.56%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.89%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:96.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.56%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9746;</span></span></div>
            </td>
            <td style="width:0.89%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:96.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Definitive Proxy Statement</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.56%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.89%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:96.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Definitive Additional Materials</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.56%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.89%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:96.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Soliciting Material under &#167;240.14a-12</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:16pt"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250528100107936" name="dei:EntityRegistrantName" contextRef="C_20240101to20241231">ENTERA BIO LTD.</ix:nonNumeric></span></span></div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Name of Registrant as Specified In Its Charter)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">___________________________________________________________</span></span></div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payment of Filing Fee (Check all boxes that apply):</span></span></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:2.06%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9746;</span></span></div>
            </td>
            <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:97.22%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">No fee required.</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.06%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:97.22%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fee paid previously with preliminary materials</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:2.06%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
            </td>
            <td style="width:0.72%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:97.22%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</span></span></div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:36%;vertical-align:top">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25">&#160;</span><img src="image0.jpg" alt="image0.jpg" height="50" width="89"/></div>
            </td>
            <td style="width:1.59%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:62%;vertical-align:top">
              <div style="text-align:right;line-height:1.25">Kiryat Hadassah</div>
              <div style="text-align:right;line-height:1.25">Minrav Building - Fifth Floor</div>
              <div style="text-align:right;line-height:1.25">Jerusalem, Israel</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align:top;border-top:2px solid rgb(0, 0, 0);border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-size:12pt;font-weight:bold">NOTICE OF 2025 ANNUAL MEETING OF SHAREHOLDERS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">June 5, 2025</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) of Entera Bio Ltd., a company formed under the laws of the State of Israel (&#8220;we,&#8221; &#8220;Entera,&#8221; or the &#8220;Company&#8221;), will be held on July 16, 2025 at 08:00 AM Eastern Time, at our offices located at Kiryat Hadassah, Minrav Building &#8211; Fifth Floor, Jerusalem Israel 9112002, for the following Agenda Items:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">1.</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div>To elect <span style="font-family:'Times New Roman',Times,serif">Ms. Haya Taitel to serve as a Class II director of the Company until the Company&#8217;s annual general meeting of shareholders to be held in 2028;</span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">2.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Ms. <ix:nonNumeric id="Fxbrl_20250528113155573" name="ecd:PeoName" contextRef="C_20240101to20241231">Miranda Toledano</ix:nonNumeric>, our Chief Executive Officer and a Director;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">3.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Dr. Gregory Burshtein, our Chief of Research and Development;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">4.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Ms. Dana Yaacov-Garbeli, our Chief Financial Officer;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">5.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To ratify and approve the amended and restated compensation policy for the directors and officers of the Company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">6.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To consider and vote on the advisory resolution regarding the compensation of our named executive officers;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">7.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To ratify and approve the appointment of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year ending December 31, 2025, and authorize the Company&#8217;s board of directors (the &#8220;Board&#8221;), or the Audit Committee, if authorized by the Board, to determine the compensation of the auditors in accordance with the volume and nature of their services; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:42pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">8.</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>To consider any other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In addition, our shareholders will be requested to consider at the Annual Meeting our audited consolidated financial statements for the fiscal year ended December&#160;31, 2024.<span style="font-family:'Times New Roman',Times,serif">&#160;No vote is required regarding this item.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The foregoing proposals<span style="font-family:'Times New Roman',Times,serif">&#160;are described more fully in the enclosed proxy statement, which we urge you to read in its entirety.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Only holders of record of our ordinary shares, par value NIS 0.0000769 per share (the &#8220;Ordinary Shares&#8221;), at the close of business on Tuesday, May 20, 2025, are entitled to notice of and to attend and vote at the Annual Meeting and any adjournments thereof. The vote required to approve the resolutions to be presented is set forth in each proposal brought for shareholders&#8217; approval in the accompanying proxy statement.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Whether or not you expect to be present at the Annual Meeting, please vote using the Internet, or by mail, in each case by following the instructions in our proxy statement. Shareholders who execute a proxy may nevertheless attend the Annual Meeting, revoke their proxy and vote their shares in person.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">Shareholders of record, who do not expect to attend the Annual Meeting in person, are kindly requested to mark, date, sign and mail the enclosed proxy card in the accompanying pre-addressed, postage-paid envelope as promptly as possible to our address below, c/o Dana Yaacov-Garbeli, our Chief Financial Officer.&#160;You may also vote your shares through the internet by going to <span style="font-weight:bold;font-style:italic">www.voteproxy.com</span> and following the on-screen instructions or scanning the QR code, located on the proxy card, with your smartphone. Please have your proxy card available when you access the webpage. Internet voting is available until 11:59 p.m. Eastern Time on July 15, 2025. If voting by mail, the proxy must be received at our registered office at least four (4) hours prior to the Annual Meeting (that is, by 04:00 a.m. (Eastern time), Wednesday, July 16, 2025) to be validly included in the tally of Ordinary Shares voted at the Annual Meeting. Detailed proxy voting instructions are provided both in the proxy statement and on the enclosed proxy card.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">If you are the record holder of your Ordinary Shares, you can also authorize the voting of your shares over the Internet by following the instructions provided above or in the proxy statement. Ordinary Shares can be voted at the Annual Meeting only if the holder is present or represented by proxy.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We will be using the U.S. Securities and Exchange Commission&#8217;s &#8220;Notice and Access&#8221; rules, which allows us to make the Notice of the Annual Meeting, proxy statement and 2024 Annual Report (as defined in the proxy statement) (collectively, the &#8220;Proxy Materials&#8221;) available on the Internet, as the primary means of furnishing Proxy Materials to our shareholders. On or about June 5, 2025, we will mail to all of our shareholders a Notice of Internet Availability of Proxy Materials, which contains instructions for accessing our Proxy Materials on the Internet and voting by telephone or on the Internet. The Notice of Internet Availability of Proxy Materials also contains instructions for requesting a printed set of Proxy Materials. The Proxy Materials are available online at http://www.astproxyportal.com/ast/22270.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">A Notice of Internet Availability of Proxy Materials, this proxy statement, including the form of proxy and our 2024 Annual Report are first being made available to shareholders on or about June 5, 2025.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:97.55%;vertical-align:bottom">
              <div style="line-height:1.25">BY ORDER OF THE BOARD OF DIRECTORS</div>
            </td>
          </tr>
          <tr>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:97.55%;vertical-align:bottom;border-bottom:#000000 2px solid">
              <div style="line-height:1.25"><span style="font-style:italic">/s/ </span><span style="font-family:'Times New Roman',Times,serif">Gerald Lieberman</span></div>
            </td>
          </tr>
          <tr>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:97.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">Gerald Lieberman</div>
            </td>
          </tr>
          <tr>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:1.23%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:97.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-style:italic">Chairman of the Board</div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-family:'Times New Roman',Times,serif;font-weight:normal;font-style:normal">- ii -</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td colspan="3" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">TABLE OF CONTENTS</div>
            </td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Page</div>
            </td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#PROXY">PROXY STATEMENT</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">1</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#INFORMATION">INFORMATION ABOUT OUR ANNUAL MEETING</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">1</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#DIRECTORS">DIRECTORS AND EXECUTIVE OFFICERS</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">6</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#CORPORATE">CORPORATE GOVERNANCE</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">9</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#OWNERSHIP">SECURITY OWNERSHIP</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">19</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25"><a href="#SECTION16">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">21</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PLANS">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">22</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#EXECUTIVE">EXECUTIVE COMPENSATION</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">23</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_ONE">PROPOSAL ONE &#8211; ELECTION OF DIRECTOR</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">35</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_TWO">PROPOSAL TWO &#8211; RATIFICATION AND APPROVAL OF COMPENSATION TERMS TO MIRANDA TOLEDANO, OUR CHIEF EXECUTIVE OFFICER AND A DIRECTOR</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">36</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_THREE">PROPOSAL THREE&#160;&#8212; RATIFICATION AND APPROVAL OF COMPENSATION TERMS TO GREGORY BURSHTEIN, OUR CHIEF OF RESEARCH &amp; DEVELOPMENT</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">39</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_FOUR">PROPOSAL FOUR &#8211; RATIFICATION AND APPROVAL OF COMPENSATION TERMS TO DANA YAACOV-GARBELI, OUR CHIEF FINANCIAL OFFICER</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">41</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_FIVE">PROPOSAL FIVE &#8211; RATIFICATION AND APPROVAL OF AN AMENDED AND RESTATED COMPENSATION POLICY</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">43</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_SIX">PROPOSAL SIX&#160;&#8212; ADVISORY RESOLUTION REGARDING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">45</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#PROPOSAL_SEVEN">PROPOSAL SEVEN &#8211; APPOINTMENT AND COMPENSATION OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">46</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#AUDIT">AUDIT COMMITTEE REPORT</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">48</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#WHERE">WHERE TO OBTAIN ADDITIONAL INFORMATION</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">50</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#EXPENSES">EXPENSES RELATING TO THIS PROXY STATEMENT</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">50</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#STATEMENTS">STATEMENTS OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2024</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;text-align:center">50</td>
          </tr>
          <tr>
            <td style="width:94%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><a href="#OTHER">OTHER BUSINESS</a></div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:5%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">50</td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:36%;vertical-align:top">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25">&#160;</span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><img src="image0.jpg" alt="image0.jpg" height="50" width="89"/></div>
            </td>
            <td style="width:1.58%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:62%;vertical-align:top">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25">&#160;</span></div>
              <div style="text-align:right;line-height:1.25">Kiryat Hadassah</div>
              <div style="text-align:right;line-height:1.25">Minrav Building - Fifth Floor</div>
              <div style="text-align:right;line-height:1.25">Jerusalem, Israel</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;border-top:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25;font-size:12pt;font-weight:bold"><span id="PROXY"><!-- anchor --></span>PROXY&#160;STATEMENT</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold">Proxy Statement for Annual Meeting of Shareholders</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">You are receiving this proxy statement and the enclosed proxy card because you owned ordinary shares, par value NIS 0.0000769 per share (the &#8220;Ordinary Shares&#8221;), of Entera Bio Ltd. (referred to as the &#8220;Company,&#8221; &#8220;Entera,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), as of the close of business on Tuesday, May 20, 2025&#160;(the &#8220;Record Date&#8221;), which entitles you to attend and vote at the 2025 Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;). The Company&#8217;s board of directors (the &#8220;Board&#8221;) is soliciting proxies from shareholders who wish to vote at the Annual Meeting. By use of a proxy, you can vote even if you do not attend the Annual Meeting. This proxy statement describes the matters on which you are being asked to vote and provides information on those matters so that you can make an informed decision.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25"><span style="font-weight:bold">Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting</span><br/><span style="font-weight:bold">to be Held on July 16, 2025</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">This proxy statement and our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2024 (the &#8220;2024 Annual Report&#8221;) are available online at http://www.astproxyportal.com/ast/22270.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We will be using the U.S. Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;)&#160;&#8220;Notice and Access&#8221; rules, which allows us to make the Notice of the Annual Meeting, proxy statement and 2024 Annual Report (collectively, the &#8220;Proxy Materials&#8221;) available on the Internet, as the primary means of furnishing Proxy Materials to our shareholders. On or about June 5, 2025, we began mailing to all of our shareholders a Notice of Internet Availability of Proxy Materials, which contains instructions for accessing our Proxy Materials on the Internet and voting by telephone or on the Internet. The Notice of Internet Availability of Proxy Materials also contains instructions for requesting a printed set of Proxy Materials.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We believe the electronic method of delivery under the&#160;&#8220;Notice and Access&#8221; model will decrease postage and printing expenses, expedite delivery of Proxy Materials to you and reduce our environmental impact. We encourage you to take advantage of the availability of the Proxy Materials on the Internet. If you received the Notice but would like to receive a full printed set of the Proxy Materials in the mail, you may follow the instructions in the Notice of Internet Availability of Proxy Materials for requesting such materials.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold">Date, Time and Place of the Annual Meeting</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We will hold the Annual Meeting on Wednesday, July 16, 2025, at 8:00 a.m. Eastern Time at Kiryat Hadassah, Minrav Building &#8211; Fifth Floor, Jerusalem Israel 9112002.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold"><span id="INFORMATION"><!-- anchor --></span>INFORMATION ABOUT OUR ANNUAL MEETING</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Who may vote at the Annual Meeting?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">You may vote all of the Ordinary Shares that you owned at the close of business the Record Date, which is Tuesday, May 20, 2025. On the Record Date, there were 45,452,167 Ordinary Shares outstanding and entitled to be voted at the Annual Meeting. You may cast one vote for each Ordinary Share held by you as of the Record Date on all matters presented at the Annual Meeting for shareholders&#8217; approval.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:0pt;margin-left:24pt;line-height:1.25">You do not need to attend the Annual Meeting to vote your Ordinary Shares. Ordinary Shares represented by valid proxies, received in time for the Annual Meeting and not revoked prior to the Annual Meeting, will be voted at the Annual Meeting. See &#8220;How do I vote?&#8221; below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">1</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What constitutes a quorum, and why is a quorum required?</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">A quorum is required to conduct business at the Annual Meeting. Pursuant to our Amended and Restated Articles of Association (&#8220;Articles&#8221;), the presence, in person or by proxy, of at least two shareholders who hold in the aggregate at least 25% of the voting power of our issued and outstanding shares constitutes a quorum. A proxy may be deemed to be two (2) or more shareholders pursuant to the number of shareholders it represents. Under applicable Nasdaq rules, however, a quorum must consist of not less than an aggregate of 33 1/3% of the voting power of our issued and outstanding shares.&#160; Therefore, notwithstanding the lower percentage set forth in our Articles, we will require the greater percentage mandated by Nasdaq in order to determine the presence of a quorum.&#160; If a quorum is not present within half an hour following the time scheduled for the Annual Meeting, the Annual Meeting will be adjourned to the same day in the following week (at the same time and place), or to a later time and date if so specified in the notice of the Annual Meeting, unless such day shall fall on a statutory holiday (either in Israel or in the United States), in which case the Annual Meeting will be adjourned to the first business day afterwards. If at such adjourned meeting a quorum as specified above is not present within half an hour following the time designated for holding the Annual Meeting, subject to certain exceptions, the Articles allow that any two shareholders present in person or by proxy shall constitute a quorum. Under applicable Nasdaq rules, however, a quorum must consist of not less than an aggregate of 33 1/3% of the voting power of our issued and outstanding shares.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What is the difference between a shareholder of record and a beneficial owner?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">If your Ordinary Shares are registered directly in your name with our transfer agent, Equiniti Trust Company, LLC, then you are the &#8220;shareholder of record&#8221; with respect to those Ordinary Shares. If your Ordinary Shares are held by a brokerage firm, bank, trustee or other agent (a &#8220;nominee&#8221;), then you are the &#8220;beneficial owner&#8221; of Ordinary Shares held in &#8220;street name.&#8221;&#160; If you hold your Ordinary Shares through a nominee, then the Notice of Internet Availability of Proxy Materials, and, if applicable, this proxy statement, the Notice of Annual Meeting, the accompanying proxy and the 2024 Annual Report have been forwarded to you by that nominee who is considered, with respect to those Ordinary Shares, the shareholder of record. As the beneficial owner, you have the right to direct your nominee on how to vote your Ordinary Shares by following the instructions provided by your nominee for voting.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">If you hold Ordinary Shares through a nominee, it is critical that you instruct the nominee how to vote your Ordinary Shares if you want your Ordinary Shares to be voted. See &#8220;What if I am a beneficial shareholder and I do not give the nominee voting instructions?&#8221; below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Why did I receive a &#8220;Notice of Internet Availability of Proxy Materials&#8221; but no proxy materials?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">We are distributing our Proxy Materials to certain shareholders via the Internet under the SEC&#8217;s &#8220;Notice and Access&#8221; rules. This approach conserves natural resources and reduces our distribution costs, while providing a timely and convenient method of accessing the Proxy Materials and voting. On or about June 5, 2025, we began mailing a &#8220;Notice of Internet Availability of Proxy Materials&#8221; to participating shareholders containing instructions on how to access the proxy materials on the Internet and how to vote.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;How do I vote?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">If you are a shareholder of record, you may vote:</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="margin-left:21.3pt;line-height:1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;via Internet;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="margin-left:21.3pt;line-height:1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by mail; or</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="margin-left:21.3pt;line-height:1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in person at the Annual Meeting.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:21.3pt;line-height:1.25">Shareholders of record, who do not expect to attend the <span style="font-family:'Times New Roman',Times,serif">Annual Meeting in person, are kindly requested to mark, date, sign and mail the enclosed proxy card in the accompanying pre-addressed, postage-paid envelope as promptly as possible to our address below, c/o Dana Yaacov-Garbeli, our Chief Financial Officer.&#160;You may also vote your shares through the Internet by going to&#160;<span style="font-weight:bold;font-style:italic">www.voteproxy.com</span> and following the on-screen instructions or scanning the QR code, located on the proxy card, with your smartphone. Please have your proxy card available when you access the webpage. Internet voting is available until 11:59 p.m. Eastern Time the day before the Annual Meeting. Your Internet delivery authorizes the named proxy holders to vote your shares in the same manner as if you marked, signed and returned your proxy via the mail. If voting by mail, the proxy must be received at our registered office at least four (4) hours prior to the Annual Meeting (that is, by 04:00 a.m. Eastern time, Wednesday, July 16, 2025) to be validly included in the tally of Ordinary Shares voted at the Annual Meeting. Detailed proxy voting instructions are provided both in the proxy statement and on the enclosed proxy card.</span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">2</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="text-align:justify;margin-left:21.3pt;line-height:1.25">If you hold Ordinary Shares through a nominee, you must follow the voting procedures of your nominee included with your proxy materials. If your shares are held by a nominee and you intend to vote at the Annual Meeting, please bring with you evidence of your ownership as of the Record Date (such as a letter from your nominee confirming your ownership or a bank or brokerage firm account statement).</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:21.3pt;line-height:1.25">If you provide specific instructions (by marking a box) with regard to the proposals, your shares will be voted as you instruct. If you sign and return your proxy card or voting instruction form, the persons named as proxies will vote in their discretion on any other matters that properly come before the Annual Meeting and are not included in the proposals set forth above under &#8220;Agenda Items.&#8221;&#160; Please also see &#8220;What if I sign and return my proxy without making any selections?&#8221; below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What am I voting on and what are the Board&#8217;s recommendations?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">At the Annual Meeting you will be asked to vote on the following seven proposals. Our Board recommendation for each of these proposals is set forth below.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td colspan="3" style="width:85.87%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;margin-right:3pt;line-height:1.25;font-weight:bold">Proposal</div>
            </td>
            <td style="width:0.55%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:13.58%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Board Recommendation</div>
            </td>
          </tr>
          <tr>
            <td style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25">1.</div>
            </td>
            <td style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To elect Ms. Haya Taitel to serve as a Class II director of the Company until the Company&#8217;s annual general meeting of Shareholders to be held in 2028;</div>
            </td>
            <td style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:13.58%;vertical-align:top;text-align:center">
              <div style="line-height:1.25;font-weight:bold">FOR</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
          </tr>
          <tr>
            <td style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-indent:-10pt;margin-left:10pt;line-height:1.25">2.</div>
            </td>
            <td style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To ratify and approve the compensation terms to Ms. Miranda Toledano, our Chief Executive Officer and a Director;</div>
            </td>
            <td style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">
              <div style="line-height:1.25;font-weight:bold">FOR</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">3.</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Dr. Gregory Burshtein, our Chief of <span style="font-family:'Times New Roman',Times,serif">Research and Development;</span></div>
            </td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">FOR</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">4.</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To ratify and approve the compensation terms, as described in the accompanying proxy statement, to Ms. Dana Yaacov-Garbeli, our Chief Financial Officer;</div>
            </td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">FOR</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">5.</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To ratify and approve the amended and restated compensation policy for the directors and officers of the Company;</div>
            </td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">FOR</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">6.</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To consider and vote on the advisory resolution regarding the compensation of our named executive officers;</div>
            </td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">FOR</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">&#160;</td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:1.38%;vertical-align:top;font-family:'Times New Roman',Times,serif">7.</td>
            <td rowspan="1" style="width:0.46%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:84.03%;vertical-align:top">
              <div style="text-align:justify;line-height:1.25">To ratify and approve the appointment of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year ending December 31, 2025, and authorize the Board, or the Audit Committee, if authorized by the Board, to determine the compensation of the auditors in accordance with the volume and nature of their services.</div>
            </td>
            <td rowspan="1" style="width:0.55%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td rowspan="1" style="width:13.58%;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center;font-weight:bold">FOR</td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align:justify;margin-left:22.5pt;line-height:1.25">In addition, we will review and discuss our consolidated financial statements for the fiscal year ended December&#160;31, 2024. We will also consider other business that properly comes before the Annual Meeting in accordance with the Israeli Companies Law, 1999 and the regulations promulgated thereunder (together, the &#8220;Israeli Companies Law&#8221;) and our Articles.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What happens if additional matters are presented at the Annual Meeting?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Other than the items of business described in this proxy statement, we are not aware of any other business to be acted upon at the Annual Meeting. If you grant a proxy, the persons named as attorneys-in-fact, agents and proxy holders, Miranda Toledano and Dana Yaacov-Garbeli, will have the discretion to vote your Ordinary Shares on any additional matters properly presented for a vote at the Annual Meeting in accordance with the Israeli Companies Law and our Articles.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What if I abstain on a proposal?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">If you sign and return your proxy marked &#8220;abstain&#8221; on any proposal, your Ordinary Shares will not be voted on that proposal. Abstentions and broker non-votes will have no effect on the outcome of the vote. However, your Ordinary Shares will be counted for purposes of determining whether a quorum is present.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">3</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What if I sign and return my proxy without making any selections?</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">If you sign and return your proxy without making any selections, your Ordinary Shares will be voted &#8220;FOR&#8221; Proposals 1-7 described in this proxy statement. If other matters properly come before the Annual Meeting, Miranda Toledano and Dana Yaacov-Garbeli will have the authority to vote on those matters for you at their discretion. As of the date of this proxy statement, we are not aware of any matters that will come before the Annual Meeting other than those disclosed in this proxy statement.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;What if I am a beneficial shareholder and I do not give the nominee voting instructions?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">If you are a beneficial shareholder and your Ordinary Shares are held in the name of a nominee, the nominee is bound by the rules of the New York Stock Exchange regarding whether or not it can exercise discretionary voting power for any particular proposal if the broker has not received voting instructions from you. Nominees have the authority to vote shares for which their customers do not provide voting instructions if the matter is a &#8220;routine&#8221; matter. Only Proposal Seven, ratification and approval of the re-appointment of our independent registered public accountants, is considered a routine matter. As a result, your nominee is not permitted to exercise discretion and vote your Ordinary Shares for or against any of the other proposals described in this proxy statement. A &#8220;broker non-vote&#8221; occurs when a nominee who holds shares for a beneficial owner submits a proxy but does not vote on a particular item because the nominee does not have discretionary voting authority for that item and has not received instructions from the beneficial owner of the shares. Broker non-votes are included in the calculation of the number of votes considered to be present at the Annual Meeting for purposes of determining the presence of a quorum but are not counted as votes cast for or against any matter with respect to a matter on which the nominee has not voted.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Can I change my vote or revoke my proxy after I have delivered my proxy?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Yes, you may change your vote or revoke your proxy prior to the Annual Meeting. If you are a shareholder of record, you may change your vote by delivering to our Chief Financial Officer, at the address set forth under &#8220;Where to Obtain Additional Information&#8221;, a written notice of revocation or a duly executed proxy bearing a later date (but not less than 24 hours before the Annual Meeting) or by attending the Annual Meeting and voting in person. Attendance at the Annual Meeting will not in and of itself constitute revocation of a vote. If you are a beneficial owner, you must contact your nominee to change your vote or obtain a legal proxy to vote your shares if you wish to cast your vote in person at the Annual Meeting.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Who can attend the Annual Meeting?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Only shareholders of record as of the Record Date and our invited guests may attend the Annual Meeting. To gain admittance, you must bring a form of personal identification to the Annual Meeting, where your name will be verified against our shareholder list. If a broker or other nominee holds your Ordinary Shares and you plan to attend the Annual Meeting, you should bring a recent brokerage statement showing your ownership of the Ordinary Shares as of the Record Date, a letter from the broker confirming such ownership, and a form of personal identification.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;If I plan to attend the Annual Meeting, should I still vote by proxy?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Yes. Casting your vote in advance does not affect your right to attend the Annual Meeting.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">If you vote in advance and also attend the Annual Meeting, you do not need to vote again at the Annual Meeting unless you want to change your vote. Written ballots will be available at the Annual Meeting for shareholders of record.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">Beneficial shareholders who wish to vote in person must request a legal proxy from the broker or other nominee and bring that legal proxy to the Annual Meeting.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;How many votes are required for approval of each of the proposals?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Each of Proposals One, Two, Three, Four, Five and Seven requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy at the Annual Meeting, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; a given proposal. Abstentions and broker non-votes have no effect on the outcome of any proposal. In addition, while Proposal Six is an advisory proposal that is non-binding on the Company, an affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy at the Annual Meeting is required for such proposal to have been deemed approved by the Company&#8217;s shareholders. Under the Israeli Companies Law, Proposals Two, Three, Four, and Five may require, if necessary pursuant to the Israeli Companies Law and in addition to the simple majority vote described above, that either: (i)&#160;the Ordinary Shares voting in favor of the proposal include at least a majority of the shareholders who are neither controlling shareholders of the Company nor do they have a personal interest with respect to such proposal voting on the matter (excluding the vote of abstaining shareholders); or (ii)&#160;the total shareholdings of the shareholders who are not controlling shareholders of the Company and do not have a personal interest who vote against the proposal do not represent more than 2% of the voting rights in the Company. We refer to this threshold in this proxy statement as a &#8220;Special Majority.&#8221;</span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">4</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">We are not aware of any shareholders that would be deemed to be a controlling shareholder of our Company as of the date hereof for purposes of Proposals Two, Three, Four, and Five.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">The term &#8220;controlling shareholder&#8221; means a shareholder having the ability to direct the activities of a company, other than by virtue of being an &#8220;Office Holder&#8221; (as defined under the Israeli Companies Law, which includes directors, the CEO, other executive officers and any other managers directly subordinate to the CEO). Additionally, under the Israeli Companies Law, a shareholder is considered a controlling shareholder (for the purposes of calculating votes in respect of matters involving a personal interest) if the shareholder holds 25% or more of the voting rights in a company (where no other shareholder holds a greater number of voting rights) and/or is otherwise a controlling shareholder as described above.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">Under the Israeli Companies Law, a &#8220;personal interest&#8221; of a shareholder in an act or transaction of a company includes: (i)&#160;a personal benefit, gain or other interest of (a)&#160;the shareholder, (b)&#160;any relative of the shareholder; (c)&#160;a company with respect to which the shareholder (or any such relative) serves as a director or the chief executive officer, owns at least 5.0% of the shares or voting rights or has the right to appoint a director or the chief executive officer; and (d)&#160;a person acting as a proxy for the shareholder (even if the shareholder himself does not have a personal interest), and (ii)&#160;excludes an interest arising solely from the ownership of shares. The term &#8220;relative&#8221; means a spouse, sibling, parent, grandparent and child, and child, sibling or parent of a spouse or the spouse of any of the foregoing.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">The Israeli Companies Law requires that each shareholder voting on Proposals Two, Three, Four and Five indicate whether the shareholder is a controlling shareholder or has a personal interest in the approval of the proposal.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:24pt;line-height:1.25">According to the Israeli Companies Law Regulations (exemptions for companies whose securities are listed for trading on a stock exchange outside of Israel)&#160;5760-2000 (the &#8220;Relief Regulations&#8221;), by signing and submitting the accompanying proxy card, a shareholder declares and approves that it, he or she is not a controlling shareholder and has no personal interest in the approval of Proposals Two, Three, Four and Five except if such shareholder notified&#160;the Company of such personal interest in writing. If you believe that you have a personal interest in any of the items on the Annual Meeting agenda and you wish to inform that Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel, to the attention of Dana Yaacov-Garbeli, our Chief Financial Officer. Alternatively, you may also contact the representative managing your account, who could then contact us on your behalf.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Where can I find voting results of the Annual Meeting?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">We will announce at the Annual Meeting the results for the proposals voted upon, and we will publish final detailed voting results in a Current Report on Form&#160;8-K within four business days following the Annual Meeting.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q.&#160;&#160;&#160;&#160;&#160;Where can I find additional copies of this proxy statement?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Copies of this proxy statement are available on our website at https://investors.enterabio.com, under the Investors &#8211; SEC Filings tab, at <span style="text-decoration:underline">http://www.astproxyportal.com/ast/22270</span> and on the SEC website, <span style="font-style:italic">www.sec.gov</span>.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-24pt;margin-left:24pt;line-height:1.25;font-style:italic;font-weight:bold">Q:&#160;&#160;&#160;&#160;&#160;Where can I find more information?</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:-24pt;margin-left:24pt;line-height:1.25"><span style="font-weight:bold">A:&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',Times,serif">Our website is located at www.enterabio.com. We make available, free of charge, on our investors section under the heading &#8220;SEC Filings&#8221; our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed with or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website address is included in this report only as an inactive textual reference. Information contained on, or available through, our website is not incorporated by reference in, or made a part of, this report.</span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">5</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
    </div>
  </div>
<div><div> <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span id="DIRECTORS"><!-- anchor --></span>DIRECTORS AND EXECUTIVE OFFICERS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">According to our Articles, the number of members of our Board must be at least three and cannot be more than ten. Our Board is divided into three classes, with staggered three-year terms with one
        director class coming up for election each year. The Class II director has a term expiring at this Annual Meeting, and the Class I and Class III directors have terms expiring at our annual meetings in 2027 and 2026, respectively. One director has
        been nominated for election to Class II at the Annual Meeting for a three-year term expiring in 2028.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">The names of our current directors, executive officers and director nominees and their respective ages, positions and biographies are set forth below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:32.25%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="text-decoration:underline">Name</span></div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span style="text-decoration:underline">Age</span></div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="text-decoration:underline">Position</span></div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Executive Officers</div>
            </td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top">
              <div style="line-height:1.25;font-weight:bold">Miranda Toledano<span style="font-family:'Times New Roman',Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(5)</sup></span></div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">48</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Chief Executive Officer and Director</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">Gregory Burshtein</div>
            </td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">49</div>
            </td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Chief of Research and Development</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">Dana Yaacov-Garbeli</div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">41</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">Hillel Galitzer</div>
            </td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">46</div>
            </td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Chief Operating Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">Leslie Gautam</div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">44</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Chief Business Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">&#160;</td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-style:italic;font-weight:bold">Non-Employee Directors</div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">Gerald Lieberman<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup></div>
            </td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">78</div>
            </td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Director, Chairman of the Board of Directors</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top">
              <div style="line-height:1.25;font-weight:bold">Sean Ellis<span style="font-family:'Times New Roman',Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(3)(4)</sup></span></div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">50</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;background-color:#CCEEFF">
              <div style="line-height:1.25;font-weight:bold">Gerald M. Ostrov<span style="font-family:'Times New Roman',Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)(3)</sup></span></div>
            </td>
            <td style="width:8.28%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">75</div>
            </td>
            <td style="width:59.48%;vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Director, Chairman of the Audit Committee</div>
            </td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top">
              <div style="line-height:1.25;font-weight:bold">Yonatan Malca<span style="font-family:'Times New Roman',Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)(3)(5)</sup></span></div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">58</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Director, Chairman of the Compensation Committee</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width:32.25%;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top">
              <div style="line-height:1.25;font-style:italic;font-weight:bold">Non-Employee Director Nominees</div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
          </tr>
          <tr>
            <td style="width:32.25%;vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)">
              <div style="line-height:1.25;font-weight:bold">Haya Taitel<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)(4)</sup></div>
            </td>
            <td style="width:8.28%;vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)">
              <div style="line-height:1.25">62</div>
            </td>
            <td style="width:59.48%;vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)">
              <div style="text-align:justify;line-height:1.25">Director, Chairperson of the Nominating and Corporate Governance Committee</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1) </sup>Independent in accordance with applicable SEC regulations and Nasdaq rules.</div>
      <div style="text-align:justify;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)</sup><sup style="font-weight:bold;vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>Member of the Compensation Committee.</div>
      <div style="text-align:justify;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(3)</sup><sup style="font-weight:bold;vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>Member of the Audit Committee.</div>
      <div style="text-align:justify;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(4)</sup><sup style="font-weight:bold;vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>Member of the Nominating and Corporate Governance Committee.</div>
      <div style="text-align:justify;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(5)</sup><sup style="font-weight:bold;vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>Member of the Scientific Advisory Committee.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Each Board nominee has been reviewed and recommended for nomination by our Nominating and Corporate Governance Committee and has consented to serve as a director if elected.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Executive Officers</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Miranda Toledano</span><span style="font-family:'Times New Roman',Times,serif"> has served as a member of our Board of Directors since 2018, as prior Chair of the
          Audit Committee and as Member of the Scientific Advisory Committee. Ms. Toledano has served as the Company&#8217;s Chief Executive Officer, or CEO, since July 2022. Ms. Toledano has over 25 years of C-level leadership, principal investment and Wall
          Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Board Member of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody
          company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009, tovecimig) and led strategic execution, including a $117
          million China License Transaction and TRIGR&#8217;s 2021 acquisition by Compass. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV &amp; Co. (acquired by B. Riley FBR &amp; Co.), where she completed biotech equity
          financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a
          member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.</span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">6</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Gregory Burshtein, PhD</span><span style="font-family:'Times New Roman',Times,serif"> has led research and development at the Company since he joined Entera in
          September 2012, as Director of Pharmaceutical R&amp;D, and since May 2024, as our Chief of Research and Development. Dr. Burshtein is a leader in the field of oral delivery of peptides, has published in peer-reviewed journal, and holds 25 issued
          patents and has 113 pending patent applications related to development, formulation, and delivery of oral large molecules. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a
          primary focus on the challenging area of oral delivery of therapeutic peptides. Dr. Burshtein obtained his PhD. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of
          the Hebrew University of Jerusalem.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Dana Yaacov-Garbeli </span><span style="font-family:'Times New Roman',Times,serif">has served as our Chief Financial Officer since June 2019. Ms. Yaacov-Garbeli
          has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external
          and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic
          studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Hillel Galitzer, PhD</span><span style="font-weight:bold;font-style:italic">&#160;</span><span style="font-family:'Times New Roman',Times,serif">has served as our
          Chief Operating Officer since February 2014, prior to which he served as our Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a
          publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in
          Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Leslie Gautam</span><span style="font-family:'Times New Roman',Times,serif"> has over 20 years of experience in healthcare with extensive strategic advisory
          experience across biopharma, in both clinical and commercial stage companies with a particular focus in specialty therapeutic categories, including women&#8217;s health and supportive care. In December 2023, Ms. Gautam co-founded and was CEO of an
          early-stage women&#8217;s health company that provided care delivery and innovation for patients with hyperemesis gravidarum. From October 2019 to November 2023, Ms. Gautam served as a senior member of the Healthcare investment banking team&#160;at Stifel
          (via acquisition of Torreya Capital) where she provided strategic advice on a variety of biopharma transactions, including M&amp;A, independent Board advice and capital raising.&#160; Ms. Gautam was a senior banker at Houlihan Lokey from May 2016 to
          October 2019 and a member of the Business Development teams at both Purdue Pharma and Noven Pharmaceuticals. Earlier in her career, Ms. Gautam was an Institutional Investor ranked equity research analyst for UBS covering the pharmaceutical sector
          and served in the healthcare investment banking group of BMO Capital Markets. Ms. Gautam holds a B.S. in Psychobiology and Computer Programming from UCLA and an MBA in Finance from Columbia Business School.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Non-Employee Directors</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Gerald Lieberman</span><span style="font-family:'Times New Roman',Times,serif"> has served as a member of our Board since April 2014 and became our Chairman in
          July 2019. Mr. Lieberman is also a member of the Board of Directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA). He serves on the Board of Directors of DosentRx, Ltd., and is a special advisor at Reverence Capital Partners, a
          private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at AllianceBernstein L.P. primarily as the President and Chief Operating Officer when he also served as a Board
          Member. From 1998 to 2000, he was Senior Vice President, Finance and Administration at Sanford C. Bernstein &amp; Co Inc., until it was acquired by Alliance Capital in 2000. Prior to that, he served in various executive positions over six years
          at Fidelity Investments including Chief Financial Officer and Chief of Administration. Prior to Fidelity, he was in various senior positions over fourteen years at Citicorp including serving as a member of the Policy Committee. Prior to joining
          Citicorp, he was a certified public accountant with Arthur Andersen. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut. Our Board believes that Mr. Lieberman is qualified to serve as
          director based upon his experience on boards of other pharmaceutical and health care companies and his years of experience working with listed public companies and private companies.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Sean Ellis</span><span style="font-family:'Times New Roman',Times,serif"> has served as a member of our Board since June 2019. Mr. Ellis brings extensive
          knowledge of both life science industries and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary
          focus on investments in the biotech and healthcare industries. Centillion is one of Entera Bio&#8217;s earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University. Our Board believes that Mr.
          Ellis is qualified to serve as a director based upon his years as an investor in healthcare related companies.</span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">7</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Yonatan Malca </span><span style="font-family:'Times New Roman',Times,serif">has served as a member of our Board since 2011. Mr. Malca currently serves as Chief
          Executive Officer and a director of NanoGohst Ltd. From 2009 to 2021, he served as Chief Executive Officer and a director of DNA Biomedical Solutions Ltd. (TASE: DNA). Mr. Malca also serves as a director of Jungo Connectivity Ltd. (TASE: JNGO)
          and Unicorn Technologies (TASE: UNCT), both Israeli public companies. He also serves as director of BeamMed Ltd, a private medical device company. He previously served as a director of Nextgen-Biomed LTD. (TASE: NXGN) from July 2018 to April
          2019, ARKO Holdings Ltd. from August 2014 to December 2020, and Tamda Ltd. from July 2016 to September 2020. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan
          University, Israel. Our Board believes that Mr. Malca is qualified to serve as a director based upon his pharmaceutical industry experience as an executive as well as his experience on boards of multiple pharmaceutical companies.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Gerald M. Ostrov</span><span style="font-family:'Times New Roman',Times,serif"> has served as a member of our Board since January 2019. Mr. Ostrov consults and
          invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Synergio, Addon Optics, and Nuvo Group Ltd. From 2008 to 2010, he
          served as Chairman and CEO of Bausch &amp; Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch &amp; Lomb following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as
          Company Group Chairman for Johnson &amp; Johnson&#8217;s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson &amp; Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses
          in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson &amp; Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter &amp;
          Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard. Our Board believes that Mr. Ostrov is qualified to serve as a director based upon his years as an investor in healthcare related companies.&#160;</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Non-Employee Director Nominees</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">Haya Taitel </span><span style="font-family:'Times New Roman',Times,serif">has served as a member of our Board since June 2023. Ms. Taitel has over 30 years of
          global C-level biopharma commercial and strategic executive experience. She currently serves as the Head of Sanofi&#8217;s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at
          Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock&#174;, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led
          Kadmon Board&#8217;s Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson &amp; Johnson in multiple therapeutic areas, including oncology, immunology,
          neurology and women&#8217;s healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.
          Our Board believes that Ms. Taitel is qualified to serve as a director based upon her extensive biopharmaceutical industry experience and specific commercial domain expertise in women&#8217;s health.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Family Relationships</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">There are no family relationships among any of our directors or executive officers.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Involvement in Certain Legal Proceedings</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Our directors and executive officers are not parties to any material legal proceedings.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">8</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span id="CORPORATE"><!-- anchor --></span>CORPORATE GOVERNANCE</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Corporate Governance Practices</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We are incorporated under the laws of the State of Israel and therefore are subject to corporate governance practices under the Israeli Companies Law, relating to various matters, including
        financial experts, our Audit Committee, our Compensation Committee and our internal auditor. These matters are in addition to the requirements of Nasdaq and other applicable U.S. rules and securities laws.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Fiduciary Duties and Approval of Related Party Transactions</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic">Fiduciary Duties of Directors and Officers</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Israeli Companies Law imposes a duty of care and a duty of loyalty on all directors and officers of a company. The duty of care requires a director or officer to act with the level of care with
        which a reasonable director or officer in the same position would have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, under the circumstances, to obtain information on the
        advisability of a given action brought for his or her approval or performed by virtue of his or her position and other important information pertaining to such action. The duty of loyalty requires the director or officer to act in good faith and
        for the benefit of the company. The duty of loyalty includes a duty to:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>refrain from any activity that is competitive with the company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>disclose to the company any information or documents relating to the company&#8217;s affairs which the Office Holder received as a result of his or her position as an Office Holder.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic">Disclosure of Personal Interests and Approval of Related Party Transactions</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Israeli Companies Law requires that an Office Holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all related material information or
        documents concerning any existing or proposed transaction with the company. An interested Office Holder&#8217;s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is
        considered. Pursuant to the Israeli Companies Law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In the context of a transaction
        involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this
        purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, a related party transaction may be approved only if it is for the benefit of the company, and the type of approval depends upon whether the transaction is an
        &#8220;Extraordinary Transaction&#8221;.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;text-indent:14.2pt;line-height:1.25">Under the Israeli Companies Law, an Extraordinary Transaction is defined as any of the following:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:14.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>a transaction other than in the ordinary course of business;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:14.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>a transaction that is not on market terms; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:14.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>a transaction that may have a material impact on a company&#8217;s profitability, assets or liabilities.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A transaction that is not an Extraordinary Transaction in which a director or officer has a personal interest requires the approval of the board of directors, unless the Articles of Association of
        the company provide otherwise. If the transaction is an Extraordinary Transaction, it must be approved by the Audit Committee and the board of directors, and, under certain circumstances, by the shareholders of the company, as well. An
        Extraordinary Transaction is a transaction other than in the ordinary course of business, other than on market terms or that is likely to have a material impact on the company&#8217;s profitability, assets or liabilities.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">9</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">Extraordinary Transactions in which a controlling shareholder has a personal interest require the approval of the Audit Committee (or, in the case of compensation, indemnification or insurance of a
        controlling shareholder, the Compensation Committee), the board of directors, and the shareholders of the company. The shareholder approval requires the affirmative vote of a simple majority of the ordinary shares of the company voted in person or
        by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; a given proposal, and abstentions and broker non-votes have no effect on the outcome of any proposal.&#160; In addition to the simple majority vote described above, shareholder approval
        for such transactions requires further that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of
        shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company. To the extent that any such transaction with a controlling shareholder is for a period extending beyond
        three years from a company&#8217;s initial public offering, and under certain conditions, five years from a company&#8217;s initial public offering, approval is required at the end of such period unless, with respect to certain transactions, the Audit
        Committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Israeli Companies Law generally prohibits any director who has a personal interest in an Extraordinary Transaction from being present for the discussion and voting pertaining to such
        transaction in the Audit Committee or board of directors, except in circumstances where the majority of the board of directors or the Audit Committee has a personal interest in the transaction, in which case such transaction also requires
        shareholder approval.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to regulations promulgated under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other Office Holders, that
        would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval under certain conditions.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic">Approval of Director and Officer Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Israeli Companies Law requires that an Israeli company whose shares are publicly listed, such as ours, maintain a compensation policy regarding the terms of office and employment of its
        directors, executive officers (including the CEO), and any other manager who reports to the CEO. The compensation policy is required to be approved (i) by the Board upon recommendation of the Compensation Committee and (ii) by the Company&#8217;s
        shareholders, at least once every three years.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy must generally serve as the basis for decisions concerning the financial terms of employment or engagement of Office Holders, including exculpation, insurance,
        indemnification and any monetary payment and obligation of payment in respect of employment or engagement. The compensation policy must be based on certain considerations, including advancement of the company&#8217;s objectives, the company&#8217;s business
        plan and its long-term strategy, and creation of appropriate incentives for Office Holders considering, inter alia, the company&#8217;s risk management policy. It must also consider, among other things, the size and the nature of its operations, and in
        respect of variable compensation, the contribution of an Office Holder towards the company&#8217;s achievement of its objectives and the maximization of its profits, with a long-term view and in accordance with the Office Holder&#8217;s position.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy must furthermore relate to additional matters, as follows: (a) the education, skills, expertise and accomplishments of the relevant Office Holder; (b) the Office Holder&#8217;s
        position and responsibilities and prior compensation agreements with him or her; (c) the ratio between the cost of the Office Holder&#8217;s terms of office and employment and the average cost of employment of other employees of the company, including
        those employed through manpower companies, and specifically, their average and median compensation, and the impact of disparities in salary (cost of terms/employment) upon work relationships in the company; (e) as to variable components, the
        possibility of reducing variable compensation at the discretion of the board of directors and the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and (g) as to severance compensation, the period
        of service of the Office Holder, the terms of his or her office during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of
        its profits, and the circumstances under which the person is leaving the company.</div>
      <div style="text-align:justify;line-height:1.25"> <br/>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <div style="line-height:1.25">The compensation policy must also include the following matters: (a) as to variable components, (i) basing variable components of the members of the board of directors and the CEO&#8217;s compensation on long-term
          performance and measurable criteria (with the exception that a non-material portion of such variable components or all such components, if equal to no more than three monthly salaries per year for the CEO, may be based on non-measurable criteria,
          taking into consideration the contribution of the Office Holder to the company); (ii) the ratio between variable and fixed compensation, and the cap for the value of variable compensation, and as for non-cash variable equity-based compensation,
          the cap for their value at time of their grant; (b) the conditions under which an Office Holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate
          and was required to be restated in the company&#8217;s financial statements; (c) the minimum holding or vesting period for variable, equity-based compensation, including bonuses; and (d) maximum limits for severance.</div>
      </div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">10</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">Following the recommendation of our Compensation Committee, our compensation policy must be approved by our Board and shareholders, which requires the affirmative vote of a simple majority of our
        Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; such proposal, and abstentions and broker non-votes have no effect on the outcome of the vote. In addition to the simple majority vote described
        above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal
        interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company. Even if shareholders do
        not approve our compensation policy, the Board may resolve to approve the compensation policy, subject to certain conditions. Our shareholders last approved our compensation policy at our 2024 annual meeting of shareholders. Notwithstanding that
        the Company is not required to seek shareholder approval for its compensation policy until 2027, the Company has determined it is in its best interests to re-obtain approval of the compensation policy from the shareholders at the Annual Meeting
        with amendments to certain thresholds to align with market standards and to attract prospective management members such that the policy would be effective for the next three years, or such longer period as permitted and in accordance with the
        Israeli Companies Law (the &#8220;Amended Compensation Policy&#8221;). See Proposal Five.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Shareholder Duties</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power
        as a shareholder in the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>an amendment to a company&#8217;s articles of association;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>an increase of a company&#8217;s authorized share capital;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>a merger; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>the approval of related party transactions and acts of Office Holders that require shareholder approval.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A shareholder also has a general duty to refrain from discriminating against other shareholders.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In addition, certain shareholders have a duty of fairness toward the company. These shareholders include a controlling shareholder, a shareholder who knows that he or she has the power to determine
        the outcome of a shareholder vote, and a shareholder who has the power to appoint or to prevent the appointment of an Office Holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the
        duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Overall Role of the Board and Board Leadership Structure</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, our Board is responsible for setting our general policies and supervising the performance of management. Our Board may exercise all powers and may take all actions
        that are not specifically granted by the Israeli Companies Law or our Articles to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our Board.
        Our CEO is appointed by, and serves at the discretion of, our Board. All other executive officers are also appointed by our Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under our Articles, the Board must consist of at least three and no more than ten persons. Currently, our Board consists of six directors. Our Board is divided into three classes, with staggered
        three-year terms such that one class comes up for election each year. The Class II director has a term expiring at the Annual Meeting, and the Class I and Class III directors have terms expiring at our annual meetings in 2027 and 2026,
        respectively. The members of the classes as of the date hereof are as follows:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div>the Class I directors are Miranda Toledano and Yonatan Malca;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div>the Class II director is Haya Taitel; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div>the Class III directors are Gerald Lieberman, Gerald M. Ostrov and Sean Ellis.</div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">11</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="line-height:1.25">Assuming that our shareholders reelect Ms. Taitel as set forth in Proposal One, the members of the classes immediately following the Annual Meeting will remain as listed above.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The classification of our Board could have the effect of increasing the length of time necessary to change the composition of a majority of the Board. In general, at least two annual meetings of
        shareholders will be necessary for shareholders to effect a change in a majority of the members of the Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under our Articles, nominees for directors may also be proposed by any shareholder holding at least one percent (1%) of our outstanding voting power. However, any such shareholder may propose a
        nominee only if a written notice of such shareholder&#8217;s intent to propose a nominee has been given to our Chief Executive Officer.&#160; Subject to any requirements under the Israeli Companies Law, to be considered timely and thereby be added to such
        agenda, such a request must be delivered, either in person or by certified mail, postage prepaid, and received at the Company&#8217;s offices, (i) in the case of&#160; an annual meeting, no less than sixty (60) days nor more than one-hundred twenty (120) days
        prior to the date of the first anniversary of the preceding year&#8217;s annual meeting, provided, however, that, in the event that the date of the annual meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days
        after the anniversary of the preceding year&#8217;s annual meeting, notice by the proposing shareholder, in order to be timely, must be received no earlier than the close of business one-hundred twenty (120) days prior to such annual meeting and no later
        than the close of business on the later of ninety (90) days prior to such annual meeting or the tenth (10<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup>) day following the day on which public announcement of the date of such meeting is first made, and (ii) in the case of a Company
        meeting of shareholders that is an extraordinary meeting, no earlier than one-hundred twenty (120) days prior to such extraordinary meeting and no later than the close of business on the later of sixty (60) days prior to such extraordinary meeting
        or the tenth (10<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup>) day following the day on which public announcement of the date of such meeting is first made, subject to applicable law. Any such notice must include certain information, including, among other things, a description
        of all arrangements between the nominating shareholder and the proposed director nominee and any other person pursuant to which the nomination is to be made by the nominating shareholder, the consent of the proposed director nominee to serve as our
        director if elected and a declaration signed by the nominee declaring that there is no limitation under the Israeli Companies Law preventing his or her election, and that all of the information that is required under the Israeli Companies Law to be
        provided to us in connection with such election has been provided.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board is also authorized to appoint directors in order to fill vacancies, including filling empty Board seats if the number of directors is below the maximum number permitted under our
        Articles. Each of our directors will serve from the date of election or appointment until the next annual meeting of shareholders for which such director&#8217;s class is due for reelection. The approval of at least a majority of the voting power in the
        Company is generally required to remove any of our directors from office (other than external directors, then in office).</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, our Board must also determine the minimum number of directors who are required to have accounting and financial expertise. In determining the number of directors
        required to have such expertise, our Board must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our Board has determined that we require one director with accounting and financial
        expertise. Our Board has determined that Mr. Sean Ellis, Mr. Gerald M. Ostrov and Mr. Yonatan Malca each have financial and accounting expertise as defined in the regulations promulgated under the Israeli Companies Law.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Other than with respect to our directors that are also executive officers or employees, there are no arrangements or understandings between us, on the one hand, and any of our directors, on the
        other hand, providing for benefits upon termination of their service as directors of our Company. For information with respect to compensation arrangements with our directors that are also executive officers or employees, see the sections entitled
        &#8220;Executive Compensation&#8221; and &#8220;Certain Relationships and Related Party Transactions&#8221; included in this proxy statement.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Alternate Directors</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Articles provide that, as permitted under the Israeli Companies Law, any director may appoint another person, who is qualified to be appointed as a director and who is not a director or an
        alternate director, to serve as his or her alternate director, subject to the approval of a majority of the members of the Board, excluding such director. The term of an alternate director could be terminated at any time by the appointing director
        or our Board and would terminate under circumstances in which, according to our Articles, the term of any director shall terminate or automatically terminate upon the termination of the term of the appointing director. The Israeli Companies Law
        stipulates that an external director may not appoint an alternate director, except under very limited circumstances. An alternate director has the same rights and responsibilities as a director, except for the right to appoint an alternate
        director.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">12</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      </div></div>
  <div>
    <div>
      <div style="line-height:1.25;font-weight:bold">Board Structure</div>
      <div style="line-height:1.25;font-weight:bold">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board has not adopted a formal policy regarding the need to separate or combine the offices of Chairperson of the Board and Chief Executive Officer and instead the Board remains free to make this determination from time to time in a manner that seems most appropriate for the Company, subject to the Israeli Companies Law. The Board currently separates the roles of Board Chairperson and Chief Executive Officer. We believe that separation of the positions of Chairperson of the Board and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs, allows our executive officers and management, including our CEO, to focus more closely on the day-to-day operations of the Company, is more conducive to objective evaluation and oversight of management&#8217;s performance, increases management accountability, and improves the Board&#8217;s ability to monitor whether management&#8217;s actions are in the best interests of the Company and its shareholders.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Role of the Board in Risk Oversight</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board is responsible, with the assistance of management, for overseeing our risk management process. Our Board focuses on our general risk management strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our Board is also continuously apprised by management of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions. The Board&#8217;s independent oversight function is further enhanced by the fact that all of the Board&#8217;s committees are composed entirely of independent directors, the directors have complete access to management and the Board and its committees may retain their own respective advisors.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25"><span style="font-weight:bold">Director Independence</span>&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board undertook a review of the independence of each director. Based on information provided by each director concerning his or her background, employment, and affiliations, our Board has determined that the Board meets the independence standards under the applicable rules and regulations of the SEC and the listing standards of Nasdaq. The Board has affirmatively determined that the following Directors are independent, as defined in the listing standards of Nasdaq: Gerald Lieberman; Gerald M. Ostrov; Sean Ellis; Yonatan Malca; and <span style="font-family:'Times New Roman',Times,serif">Haya Taitel. In making these determinations, our Board considered the current and prior relationships that each non-employee director has or had with our Company and all other facts and circumstances our Board deemed relevant in determining such person&#8217;s independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221;</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Code of Business Conduct and Ethics</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We have adopted a Code of Business Conduct and Ethics applicable to all of our directors, executive officers and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions. The full text of the Code of Business Conduct and Ethics can be found on our website at www.enterabio.com. Information contained on, or that can be accessed through, our website does not constitute a part of this proxy statement and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Insider Trading Policy</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We have <ix:nonNumeric id="Fxbrl_20250605224610609" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="C_20240101to20241231" format="ixt:fixed-true">adopted</ix:nonNumeric> an insider trading policy (the &#8220;Insider Trading Policy&#8221;) which governs the purchase, sale and/or any other dispositions of our securities by us, our directors, officers and employees and is reasonably designed to promote compliance with insider trading laws, rules and regulations and applicable exchange listing standards. A copy of the Insider Trading Policy has been filed with our 2024 Annual Report.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Board Meetings</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Board meets regularly during the year and holds special meetings and acts by unanimous written consent whenever circumstances require. Independent directors meet at regular executive sessions without management present. During the year ended December 31, 2024, the Board held seven meetings and conducted certain business by unanimous written consent. Each of our directors attended at least 75% of the aggregate of the total number of meetings of the Board and the total number of meetings held by all committees of the Board on which such director served. All of our directors are encouraged to attend our Annual Meeting of shareholders, and our directors are expected to attend the Annual Meeting. One director attended the Company&#8217;s 2024 Annual Meeting of shareholders.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Board Committees</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Our Board has established the following committees:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">13</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="line-height:1.25;font-style:italic;font-weight:bold">Audit Committee</div>
      <div style="line-height:1.25;font-style:italic;font-weight:bold">&#160;</div>
      <div style="line-height:1.25;font-style:italic">Composition</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Nasdaq rules and SEC regulations, we are required to maintain an Audit Committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise and would qualify as an &#8220;Audit Committee financial expert&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K of the Exchange Act.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Audit Committee consists of Gerald M. Ostrov, who also serves as chairman of the committee, Yonatan Malca and Sean Ellis. The Board has determined that each of the members of our Audit Committee is an independent director in accordance with SEC regulations and satisfies the independent director requirements under the Nasdaq rules. All designated members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules and SEC regulations. Our Board has determined that Gerald M. Ostrov is an &#8220;audit committee financial expert,&#8221; as such term is defined under applicable SEC rules. During fiscal year 2024, the Audit Committee held four meetings and conducted certain business by unanimous written consent.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic">Roles, Responsibilities and Procedures</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Audit Committee assists our Board in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, cybersecurity, internal control and legal compliance functions by, among other things, pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices. Our Audit Committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent of management.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board has adopted an Audit Committee charter setting forth the responsibilities of the Audit Committee consistent with the applicable rules and regulations of the SEC and Nasdaq, as well as the requirements for such committee under the Israeli Companies Law, including (a) oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the Board in accordance with the Israeli Companies Law; (b) recommending the engagement or termination of our internal auditor; (c) recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our Board; (d) identifying deficiencies in the business management practices of our Company, including, inter alia, in consultation with our internal auditor or the independent auditor, and making recommendations to the Board as to how to correct such practices; (e) reviewing and considering the approval of related party transactions; (f) determining whether related party transactions are extraordinary or material under the Israeli Companies Law, including transactions in which an Office Holder has a &#8220;personal interest&#8221;, under the Israeli Companies Law, and whether to approve such transactions; (g) establishing the approval process for certain transactions with a controlling shareholder or in which the controlling shareholder has a &#8220;personal interest&#8221;; (h) examining and approving the working plan of the internal auditor, subject to any modifications in its discretion; (i) examining our internal audit controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his or her responsibilities; (j) examining the scope of our auditor&#8217;s work and compensation and submitting its recommendations with respect thereto to our Board or shareholders, depending on which of them is considering the appointment of our auditor; (k) establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees; and (l) reviewing the our annual audited financial statements and quarterly financial statements with management and the independent auditor, including a review of our disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A copy of the Audit Committee Charter is available on our website at www.enterabio.com.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A &#8220;personal interest&#8221; under the Israeli Companies Law includes an interest of any person in an action or transaction of a company, excluding any interest arising solely from holding the Company&#8217;s shares, but including the personal interest of such person&#8217;s spouse, sibling, parent, grandparent, descendant, spouse&#8217;s descendant, sibling or parent or the spouse of any of such persons, and the personal interest of any entity in which such person or one of the aforementioned relatives of such person serves as a director or Chief Executive Officer, owns 5% or more of such entity&#8217;s outstanding shares or voting rights or has the right to appoint one or more directors or the Chief Executive Officer. Further, in the case of a person voting by proxy, &#8220;personal interest&#8221; includes the personal interest of either the proxy holder or the shareholder granting the proxy, whether or not the proxy holder has discretion how to vote.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Audit Committee may not approve any actions requiring its approval, unless, at the time of the approval, a majority of the committee&#8217;s members are present.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">14</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="text-indent:-9.9pt;margin-left:9.9pt;line-height:1.25;font-style:italic;font-weight:bold">Compensation Committee</div>
      <div style="text-indent:-9.9pt;margin-left:9.9pt;line-height:1.25;font-style:italic;font-weight:bold">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic">Composition</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We have a Compensation Committee, the members of which are Yonatan Malca, who also serves as chairman of the committee, Gerald M. Ostrov and Haya Taitel. Each member of our Compensation Committee is independent under Nasdaq rules. During fiscal year 2024, the Compensation Committee held one meeting and conducted certain business by unanimous written consent.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Assuming that our shareholders reelect Ms. Taitel as set forth in Proposal One, the composition of the Compensation Committee immediately following the Annual Meeting shall remain the same.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic">Roles, Responsibilities and Procedures</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board has adopted a charter setting forth the Compensation Committee&#8217;s roles and responsibilities, which include (a) recommending a compensation policy regarding the terms of engagement of Office Holders, which is recommended to the Board for approval and subsequently to shareholders for their approval, in accordance with the Israeli Companies Law, and reviewing such policy from time to time, (b) recommending to the Board periodic updates to the compensation policy and whether the compensation policy should continue in effect every three years; (c) assessing the implementation of the compensation policy; (d) reviewing and approving the granting of options, restricted share units, or RSUs, and other incentive awards to the extent such authority is delegated by the Board; (e) reviewing, evaluating and making recommendations regarding the compensation and benefits for non-executive directors, (f) determining whether to approve and recommend to the Board and shareholders to approve transactions with Office Holders relating to their terms of compensation, as required under the Israeli Companies Law, (g) determining whether changes to the compensation terms of the Chief Executive Officer of the Company are material and if the changes are required to be brought to the shareholders for approval, (h) overseeing compliance reporting requirements of the SEC, (i) determining whether to recommend to the Board to adopt a share ownership policy for directors and executive officers, and (j) performing such other activities as may be required.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A copy of the Compensation Committee Charter is available on our website at www.enterabio.com.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, the compensation policy must be adopted by the Board after considering the recommendations of the Compensation Committee and then presented to, and approved by, the Company&#8217;s shareholders for approval.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy must serve as the basis for decisions concerning the terms of employment or engagement of Office Holders, including exculpation, insurance, indemnification and any monetary payment and obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the Company&#8217;s objectives, the Company&#8217;s business plan and its long-term strategy, and creation of appropriate incentives for office holders. It must also consider, inter alia, the Company&#8217;s risk management, size and the nature of its operations.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy must furthermore consider additional factors, as follows: (a) the knowledge, skills, expertise and accomplishments of the relevant Office Holder; (b) the Office Holder&#8217;s roles and responsibilities and prior compensation agreements with him or her; (c) the ratio between the terms offered and the average compensation of the other employees of the company, including those employed through manpower companies; (d) the impact of disparities in salary upon work relationships in the company; (e) the possibility of reducing variable compensation at the discretion of the Board; (f) as to variable compensation, the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and (g) as to severance compensation, the period of service of the Office Holder, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances of termination of services.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy must also include the following principles: (a) the link between variable compensation and long-term performance and measurable criteria; (b) the ratio between variable and fixed compensation, and the ceiling for the value of variable compensation; (c) the conditions under which an Office Holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements; (d) the minimum holding or vesting period for variable, equity-based compensation, including bonuses; and (e) maximum limits for severance.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">15</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, we are required to re-obtain the approval of our Compensation Committee, Board and shareholders every three years for either the continuation of our existing compensation policy or adoption of a new compensation policy. Our compensation policy was last approved by our shareholders on July 31, 2024, after having been recommended by our Compensation Committee and approved by our Board. Although approval will not be required again until 2027, the Company has determined it is in its best interests to re-obtain approval of the compensation policy from the shareholders with amendments to certain thresholds to align with market standards and to attract prospective management members such that the policy would be effective for the next three years, or such longer period as permitted and in accordance with the Israeli Companies Law. See Proposal Five.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Compensation Committee may conduct or authorize investigations into, or studies of, matters within its scope of responsibilities, and may retain or obtain the advice of a compensation consultant, legal counsel or other advisor in its sole discretion. The Compensation Committee is directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel or other advisor that it retains, at the expense of the Company. The Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other advisor to the Compensation Committee, other than in-house legal counsel, only after conducting an assessment of, and determining, the advisor&#8217;s independence, including whether the advisor&#8217;s work has raised any questions of independence or conflicts of interest, taking into consideration the Exchange Act, the factors set forth in Nasdaq rules and any other factors that the committee deems relevant.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In 2023 and 2025, in determining the compensation of certain executive officers and in determining our compensation policy, the Compensation Committee retained the services of a compensation consultant, Brightman Almagor Zohar &amp; co., a firm&#160;in the Deloitte Touche Tohmatsu Limited network, to conduct a comparative survey of the compensation of such Office Holders. The 2023 and 2025 comparative studies consisted of: (i) executive compensation benchmark analyses which included comparative data of the Company&#8217;s executive compensation, relative to the peer-group companies in Israel and (ii) executive compensation benchmark analyses which included comparative data of the Company&#8217;s executive compensation, relative to the peer-group companies in the United States.<span style="font-family:'Times New Roman',Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>&#160;</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-9.9pt;margin-left:9.9pt;line-height:1.25;font-style:italic;font-weight:bold">Nominating and Corporate Governance Committee</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-style:italic">Composition</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Nominating and Corporate Governance Committee consists of Haya Taitel, who also serves as chairperson of the committee, and Sean Ellis. Each of the members of our Nominating and Corporate Governance Committee is independent under the Nasdaq rules. During fiscal year 2024, the Nominating and Corporate Governance Committee did not hold in person meetings but conducted certain business by unanimous written consent.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Assuming that our shareholders reelect Ms. Taitel as set forth in Proposal One, the composition of the Nominating and Corporate Governance Committee immediately following the Annual Meeting shall remain the same.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic">Roles, Responsibilities and Procedures</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board has adopted a Nominating and Corporate Governance Committee Charter that sets forth the responsibilities of the Nominating and Corporate Governance Committee consistent with the rules and regulations of the SEC and Nasdaq, including (a) assisting in identifying, recruiting and, if appropriate, interviewing candidates to fill positions on the Board, including persons suggested by shareholders or others, (b) establishing procedures to be followed by shareholders in submitting recommendations for Board candidates, if appropriate, (c) reviewing the background and qualifications of individuals being considered as director candidates, while considering the candidate&#8217;s experience, skills, expertise, diversity, personal and professional integrity, character, business judgment, time availability in light of other commitments, dedication, conflicts of interest and such other relevant factors that the committee considers appropriate in the context of the needs of the Board, (d) recommending the Board nominees for election by shareholders or appointment by the Board, as the case may be, in a manner consistent with the criteria for selecting directors, as established by the Board from time to time, (e) reviewing the suitability for continued service as a director of each Board member, when the term of service of the director expires, and when the director has a change in status (including, but not limited to, an employment change) and recommending whether or not the director should be re-nominated, (f) making recommendations to the Board regarding the size and composition of each committee; and (g) overseeing the performance of the Board as a whole.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A copy of the Nominating and Corporate Governance Committee Charter is available on our website at www.enterabio.com.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">16</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age, having sufficient scientific and/or medical expertise to review and evaluate appropriately the Company&#8217;s clinical programs, research and development programs and licensing opportunities, and having the highest personal integrity and ethics. When considering director candidates, the Nominating and Corporate Governance Committee will also generally consider all other relevant qualifications of the candidates, including such factors as the candidate&#8217;s relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having relevant financial or accounting expertise, having the ability to exercise sound business judgment, having the commitment to rigorously represent the long-term interests of our shareholders and whether the Board candidates will be independent for purposes of the Nasdaq rules, as well as the current needs of the Board and the Company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">At this time, the Nominating and Corporate Governance Committee does not have a policy with regard to the consideration of director candidates recommended by shareholders. The Nominating and Corporate Governance Committee believes that it is in the best position to identify, review, evaluate and select qualified candidates for Board membership, based on the comprehensive criteria for Board membership approved by the Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In the case of incumbent directors who have stepped down or whose terms of office are set to expire, the Nominating and Corporate Governance Committee will also review, prior to nominating such directors for another term, such directors&#8217; overall service to the Company during their term. The Nominating and Corporate Governance Committee will conduct any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. We may, from time to time, engage an executive search firm to assist our Nominating and Corporate Governance Committee in identifying and recruiting potential candidates for membership on the Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-indent:-9.9pt;margin-left:9.9pt;line-height:1.25;font-style:italic;font-weight:bold">Scientific Advisory Committee</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Scientific Advisory Committee consists of Miranda Toledano, who also serves as chairperson of the committee, along with Yonatan Malca and Haya Taitel. Assuming that our shareholders reelect Ms. Taitel as set forth in Proposal One, the composition of the Scientific Advisory Committee immediately following the Annual Meeting shall remain the same.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Board has adopted a Scientific Advisory Committee Charter that sets forth the responsibilities of the Scientific Advisory Committee, including (a) reviewing, evaluating and reporting to the Board regarding strategy, plans and goals, as well as progress and performance, of the Company&#8217;s clinical programs, licensing activities, and research and development activities, (b) meeting with the Company&#8217;s R&amp;D and licensing teams to evaluate the plans, goals and performance of the Company&#8217;s clinical programs and research and development projects, and make recommendations to the Board as appropriate in the opinion of the committee to fulfill the company strategic goals, (c) identifying and discussing significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its licensing opportunities, clinical programs and research and development activities, (d) evaluating the performance of the committee, including a review of the committee&#8217;s compliance with its charter, and review and reassess the charter and submit any recommended changes to the Board for its consideration and approval, (e) forming external consulting panels to assist the committee in review of specific R&amp;D programs either current or planned and (f) such other duties and responsibilities as may be assigned to the committee, from time to time, by the Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A copy of the Scientific Advisory Committee Charter is available on our website at www.enterabio.com.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Board Diversity</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">While we do not currently have a formal diversity policy with respect to Board composition, the Board believes it is important for the Board to have gender, race and ethnicity diversity along with diversity of knowledge base, professional experience and skills. The Nominating and Corporate Governance Committee takes these qualities into account when considering director nominees for recommendation to the Board.&#160; We believe diversity enhances our effectiveness. Our Board currently has two female directors, and none of our Board members self-identified as being racially diverse. However, the Board remains committed to achieving a Board composition that represents a diversity of background and experience, inclusive of race, ethnicity, gender and sexual orientation.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Communication with our Board</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Shareholders may communicate with the Board by directing their communications in a hard copy (i.e., non-electronic) written form to the attention of one or more members of the Board, or to the Board collectively, at our principal executive offices located at Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel. Any communications received from interested parties in the manner described above will be collected and organized by our Chief Financial Officer or Chief Executive Officer and will be periodically, but in any event prior to each regularly-scheduled Board meeting, reported and/or delivered to the appropriate director or directors.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Shareholder Proposals for the 2025 Annual Meeting</div>
      <div style="line-height:1.25;font-weight:bold">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, one or more shareholders holding 1% or more of the voting rights of Entera may request to include a proposal on the agenda of a shareholders meeting, provided that certain resolutions are brought before the shareholders in such meeting, including the appointment of members to the Board, by submitting such proposal within seven days of publication of Entera&#8217;s notice with respect to our annual meeting of shareholders. Accordingly, any shareholder holding 1% or more of the voting rights of Entera may request to include a proposal on the agenda of the Annual Meeting by submitting such proposal in writing to us no later than Wednesday, May 21, 2025, at our principal executive offices located at Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">17</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="line-height:1.25;font-weight:bold">Shareholder Proposals for the 2026 Annual Meeting</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Shareholder proposals intended to be included in our proxy statement and form of proxy for use in connection with our 2026 annual meeting of shareholders pursuant to Rule 14a-8 under the Exchange Act must be received by our Chief Executive Officer, at our principal executive offices are located at Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel, no later than February 5, 2026 (120 calendar days preceding the one-year anniversary of the mailing date of this proxy statement), and must otherwise satisfy the procedures prescribed by Rule 14a&#8209;8 under the Exchange Act. In addition, one or more shareholders holding 1% or more of the voting rights of Entera may request to include a proposal (and in case of a proposal to nominate or remove of a director, at least 5% of the voting rights of Entera is required) on the agenda of the 2026 annual meeting of shareholders in the manner described above. Pursuant to Rule 14a&#8209;4 under the Exchange Act, shareholder proxies obtained by our Board in connection with our 2026 annual meeting of shareholders will confer on the proxies and attorneys-in-fact named therein discretionary authority to vote on any matters presented at such annual meeting which were not included in the Company&#8217;s proxy statement in connection with such annual meeting, unless notice of the matter to be presented at the Annual Meeting is provided to our Chief Executive Officer, no later than April 21, 2026.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In addition, for shareholder nominees for directors to be considered timely for inclusion on a universal proxy card pursuant to Rule 14a-19 under the Exchange Act, shareholders must provide notice to our Chief Executive Officer, which notice must be postmarked or transmitted electronically to us at our principal executive office no later than May 17, 2026, containing the information required by Rule 14a-19 under the Exchange Act.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Certain Relationships and Related Party Transactions</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Described below are those transactions occurring since January 1, 2023, and any currently proposed transactions to which either the Company was a party and in which:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>The amounts involved exceeded or will exceed the lesser of&#8201;(i) $120,000 and (ii) one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>A director, executive officer, holder of more than 5% of the outstanding share capital of the Company, or any member of such person&#8217;s immediate family had or will have a direct or indirect material interest.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Indemnification Agreements with Directors</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Articles provide that we may indemnify each of our directors and officers to the fullest extent permitted by the Israeli Companies Law. Accordingly, we have entered into standard indemnification agreements with each of our directors, whereby we have undertaken to indemnify each such director, in advance, for losses, damages, costs or expenses that such director may suffer or incur as a result of his or her actions or omissions in such capacity on behalf of the Company in certain circumstances and events, subject to the terms, conditions and limitations set out in the indemnification agreement.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Approval of Related Party Transactions</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Israeli Companies Law requires that an Office Holder of a company promptly disclose any personal interest that he or she may have and all related material information known to him or her, in connection with any existing or proposed transaction of the company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the Israeli Companies Law, any transaction with an Office Holder or in which the Office Holder has a personal interest (other than with respect to such Office Holder&#8217;s Terms of Office and Employment, see the section entitled &#8220;Executive Compensation&#8221;) must be brought before the Audit Committee, in order to determine whether such transaction is an Extraordinary Transaction.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the Israeli Companies Law, the Articles and Entera written policy, in the event that the Audit Committee determines that the transaction is not an Extraordinary Transaction, the transaction will require only Audit Committee approval; if, however, it is determined to be an Extraordinary Transaction, Board approval is also required and, in some circumstances, shareholder approval may also be required. Such a transaction may only be approved if it is determined to be in the best interests of Entera.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A person with a personal interest in the matter generally may not be present at meetings of the Board or certain committees where the matter is being considered and, if a member of the Board or a committee, may generally not vote on the matter.</div>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Transactions with Controlling Shareholders</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, Extraordinary Transactions with a controlling shareholder, or in which the controlling shareholder has a personal interest, and any engagement with a controlling shareholder, or a controlling shareholder&#8217;s relative, with respect to the provision of services to the company or their Terms of Office and Employment as an Office Holder or their employment, if they are not an Office Holder, generally require the approval of the Audit Committee (or with respect to Terms of Office and Employment, the Compensation Committee), the Board of Directors and the shareholders. If required, shareholder approval must include (i) at least a majority of the shareholders who do not have a personal interest in the transaction and are present and voting at the meeting (abstentions are disregarded), or, alternatively, that (ii) the total shareholdings of the disinterested shareholders who vote against the transaction do not represent more than two percent of the voting rights in the company. Transactions for a period of more than three years generally need to be brought for approval in accordance with the above procedures every three years. A shareholder who holds 25% or more of the voting rights in a company is considered a controlling shareholder for these purposes if no other shareholder holds more than 50% of the voting rights. If two or more shareholders are interested parties in the same transaction, their shareholdings are combined for the purposes of calculating percentages.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">18</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">SECURITY <span id="OWNERSHIP"><!-- anchor --></span>OWNERSHIP</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The following table sets forth information known to us with respect to the beneficial ownership of our Ordinary Shares as of May 8, 2025 by:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>each person or entity known by us to own beneficially 5% or more of our outstanding Ordinary Shares;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>each of our directors and executive officers individually; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:32.2pt;font-family:'Times New Roman',Times,serif">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>all of our executive officers and directors as a group.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">According to our transfer agent, as of May 8, 2025, there were 48 record holders of our Ordinary Shares. None of our shareholders has different voting rights from other shareholders.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The beneficial ownership of our Ordinary Shares is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership, generally, includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table and the related footnotes, unless described otherwise within the footnotes, we deem Ordinary Shares issuable pursuant to options or warrants that are currently exercisable or exercisable within 60 days as of May 8, 2025, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. The percentage of Ordinary Shares beneficially owned is based on 45,452,167 Ordinary Shares outstanding as of May 8, 2025. The beneficial ownership data provided below is based solely on information available to our Company and, in the case of major shareholders who are not otherwise officers or directors, has not been verified further. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the Ordinary Shares listed below have sole investment and voting power with respect to such shares.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Unless otherwise noted below, each shareholder&#8217;s address is c/o Entera Bio Ltd., Kiryat Hadassah, Minrav Building - Fifth Floor, Jerusalem, Israel.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Name</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Number and Percentage of</div>
              <div style="text-align:center;line-height:1.25;font-weight:bold">Ordinary Shares</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Number</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Percent</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">5% or Greater Shareholders (other than directors and executive officers)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Gakasa Holdings LLC<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">7,079,483</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">15.06</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">D.N.A Biomedical Solutions Ltd.<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)</sup></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">3,732,540</div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">8.21</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">OPKO Health Inc<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(3)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">3,685,226</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">8.11</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Point72 Asset Management, L.P<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(4)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">2,701,560</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">5.94</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Centillion Fund<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(5)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">2,396,953</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">5.28</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Executive Officers and Directors:</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Miranda Toledano<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(6)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">1,565,039</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">3.34</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Gerald Lieberman<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(7)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">713,636</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">1.56</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Hillel Galitzer<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(8)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">587,656</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">1.28</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Sean Ellis<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(9</sup><sup style="vertical-align:text-top;line-height:1;font-size:smaller">)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">523,403</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">1.14</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Yonatan Malca<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(10)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">435,935</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">*</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Gerald M. Ostrov<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(11)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">435,612</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">*</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Dana Yaacov-Garbeli<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(12)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">408,500</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">*</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Gregory Burshtein<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(13)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">281,276</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">*</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Haya Taitel<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(14)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">209,663</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">*</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="line-height:1.25">Leslie Gautaum</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">All Directors and Executive Officers as a Group (10 persons)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(15)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">5,160,720</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">10.38</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">* Less than 1%</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">19</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(1)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Pursuant to the Schedule 13G/A filed with the SEC on November 14, 2024 regarding Gasaka Holdings LLC&#8217;s holdings. This consists of: (i) 5,534,275 Ordinary Shares, (ii) 347,604 Ordinary Shares underlying Pre-Funded Warrants (iii) 1,197,604 Ordinary Shares underlying warrants to acquire Ordinary Shares. Gasaka Holdings LLC&#8217;s address is at 201 S. Biscayne Blvd suite 800, Miami, FL 33131.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(2)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>D.N.A Biomedical Solutions Ltd.&#8217;s holdings consisted of 3,762,960 Ordinary Shares. D.N.A&#8217;s address is at Shimon Hatarsi 43 St., Tel Aviv, Israel.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(3)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Pursuant to the Schedule 13G filed with the SEC on January 6, 2025 regarding Point72 Asset Management, L.P.&#8217;s holdings. Beneficial ownership includes 2,701,560 Ordinary Shares. Point72 Asset Management, L.P&#8217;s address is at 72 Cumming point road, Stamford, CT 06902.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(4)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>OPKO Health Inc. holdings consist of 3,865,226 Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(5)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Pursuant to the Schedule 13G/A filed by Centillion Fund Inc. with the SEC on August 20, 2024 regarding its holdings. As of July 19, 2024, Mr. Renat Yliagoyev purchased 100% of Centillion Fund, Inc. In addition, Mr. Yliagoyev maintains warrants to purchase up to 179,640 Ordinary Shares, at $0.71 per Ordinary Share, as disclosed in the Company&#8217;s Form 8-K filed on December 30, 2023 (the &#8220;Warrants&#8221;). The Warrants are exercisable for five (5) years from issuance. While the Warrants are not held in the name of Centillion Funds, Inc., and have not been exercised, given that Mr. Yliagoyev may be deemed as a control person, the number of shares he may ultimately be in control of is 2,576,593. Centillion Fund Inc&#8217;s address is 10 Manoel Street, Castries, Saint Lucia LC04 101.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(6)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 110,752 Ordinary Shares and (ii) 23,952<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying warrants to acquire Ordinary Shares, (iii) 124,121 Ordinary Shares underlying outstanding restricted stock units (&#8220;RSUs&#8221;) and (iv) 1,306,214 Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(7)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 324,960 Ordinary Shares and (ii) 388,676<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(8)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 34,106 Ordinary Shares, (ii) 56,467 Ordinary Shares underlying RSUs and (iii) 497,083<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(9)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 134,727 Ordinary Shares and (ii) 388,676<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(10)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 47,259 Ordinary Shares and (ii) 388,676<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(11)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 46,936 Ordinary Shares and (ii) 388,676<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(12)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 86,729 Ordinary Shares and (ii) 321,771<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(13)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 50,000 Ordinary Shares, (ii) 25,126 Ordinary Shares underlying RSUs and (iii) 206,150 Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(14)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i)<span style="font-weight:bold">&#160;</span>64,650 Ordinary Shares and (ii) 145,013<span style="font-weight:bold">&#160;</span>Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(15)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Consists of (i) 900,119 Ordinary Shares, (ii) 23,952 Ordinary Shares underlying warrant to acquire Ordinary Shares, (iii) 205,714 Ordinary Shares underlying RSUs and (iv) 4,030,935 Ordinary Shares underlying options to acquire Ordinary Shares.</div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">20</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
        </div>
      </div>
    </div>
  </div>
<div><div> <div style="line-height:1.25;font-weight:bold">SECTION 16<span id="SECTION16"><!-- anchor --></span>(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Section 16(a) of the Exchange Act and the rules thereunder require that our directors and executive officers and persons who beneficially own more than 10% of a registered class of our equity
        securities (collectively, &#8220;reporting persons&#8221;) file reports with the SEC relating to their share ownership and changes in such ownership.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Based solely upon our review of copies of filings or written representations from the reporting persons, we believe that all reporting persons timely filed all reports required by them under
        Section 16(a) of the Exchange Act with respect to the year ended December 31, 2024.</div>
      <div style="text-align:justify;line-height:1.25"> <span style="font-family:'Times New Roman',Times,serif"><br/>
        </span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">21</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION <span id="PLANS"><!-- anchor --></span>PLANS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">The following table provides certain information as of December 31, 2024, with respect to our equity compensation plans under which our equity securities are authorized for issuance:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);width:55%">
              <div style="line-height:1.25;font-weight:bold">Plan Category</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Number of securities to be issued upon exercise of outstanding options, RSUs, warrants and rights</div>
              <div style="line-height:1.25;font-weight:bold">(#)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;width:1%">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Weighted-average exercise price of outstanding options, RSUs,</div>
              <div style="line-height:1.25;font-weight:bold">warrants and rights</div>
              <div style="line-height:1.25;font-weight:bold">($)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center;width:1%">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (#)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:right;line-height:1.25;font-weight:bold"> (a)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:right;line-height:1.25;font-weight:bold">(b)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
              <div style="text-align:right;line-height:1.25;font-weight:bold">(c)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="line-height:1.25">Equity compensation plans approved by security holders</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="line-height:1.25;font-style:italic">2013 Plan</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">810,550</div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">6.31</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="line-height:1.25;font-style:italic">2018 Plan</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">7,036,576</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">1.91</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">2,068,226(1</div>
            </td>
            <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25">Equity compensation plans not approved by security holders</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:55%;vertical-align:bottom">
              <div style="line-height:1.25">Total</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">7,847,126</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">2.32</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:12%;vertical-align:bottom">
              <div style="line-height:1.25">2,068,226</div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
            </td>
            <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:2.4pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:33.6pt;vertical-align:top">(1)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>On January 1 of each calendar year, an additional number of Ordinary Shares equal to 5% of the total outstanding Ordinary Shares on such date (or any lower number of shares as determined by our Board) become available for issuance under
                the 2018 Plan.</div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">22</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="line-height:1.25;font-weight:bold"><span id="EXECUTIVE"><!-- anchor --></span>EXECUTIVE COMPENSATION</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Compensation Policy</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our compensation policy was last ratified by our shareholders on July 31, 2024, after having been recommended by our Compensation Committee and approved by our Board.&#160; Under the Israeli Companies
        Law, our compensation policy must be re-approved, amended, or replaced by a new policy every three years. Although approval will not be required again until 2027, the Company has determined it is in its best interests to re-obtain approval of the
        compensation policy from the shareholders at the Annual Meeting, with amendments to certain thresholds to align with market standards and to attract prospective management members such that the policy would be effective for the next three years, or
        such longer period as permitted and&#160;in accordance with the Israeli Companies Law, and accordingly,&#160;we are presenting the Amended Compensation Policy to our shareholders for approval. See Proposal Five. The compensation policy and the Amended
        Compensation Policy include, among other matters prescribed by the Israeli Companies Law, a framework for establishing the terms of office and employment of the directors and officers and guidelines with respect to the structure of the variable pay
        of officers.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Objectives</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our compensation policy is intended to align our objectives and work plans with appropriate goals and objectives of our officers and directors, and to ensure that the overall financial and
        strategic objectives of the Company and its shareholders are met. We recognize that strong and effective leadership is fundamental to our continued growth and success. Therefore, our compensation policy recognizes as a primary objective the need to
        attract, retain, reward and motivate highly talented officers and directors in competitive labor markets.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Officer Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">With regard to our executive officers, or &#8220;Officers,&#8221; (which includes our Named Executive Officers, as defined below) our compensation policy is designed to provide a mix of compensation to reward
        Officers for individual and company performance as well as to align their interests with the interests of shareholders. We have also designed our compensation policy to provide flexibility. It must take into consideration the fact that the
        appropriate mix of compensation may vary from period to period and from Officer to Officer. To achieve our goal of appropriately rewarding our Officers for their efforts, our compensation policy generally includes: (i) short-term incentives, such
        as an annual base salary, benefits and perquisites; (ii) short to medium-term incentives, such as an annual bonus based on target and above-target performance; and (iii) medium to long-term incentives, such as equity-based compensation and
        retirement benefits.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Base Salary</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Base salary compensates our Officers for the performance of their standard duties and reflects each Officer&#8217;s education, skills, qualifications, expertise, professional experience and
        accomplishments, as well as the position, areas and scope of responsibilities of such Officer. Adjustments to base salary are periodically reviewed by the Compensation Committee and the Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Bonuses</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Cash bonuses are generally paid annually and are intended to reward Officers based on the performance of the Company and their individual contributions. The target bonus amount and the performance
        measures and targets for each Officer are determined by the Compensation Committee and the Board at the beginning of each year for which a bonus may be paid. Additionally, the CEO has the power to determine the annual bonus performance measures and
        targets for all Officers other than for herself.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The performance measures and targets for receiving the annual bonus are intended to be measurable and quantifiable and may include, without limitation: (i) objectives such as capital investment,
        cash balance relative to equity, obtaining approval from the authorities in the target markets; and (ii) key performance indicators, determined for each Officer separately, according to the Officer&#8217;s position. The annual bonus also includes a
        non-measurable, qualitative component of up to 20% of an Officer&#8217;s annual bonus, which is based on an evaluation of such Officer in accordance with qualitative measures provided in the annual bonus grant.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In addition to the annual bonus, the Compensation Committee and the Board may elect to pay each Officer a special bonus, based on non-measurable criteria (e.g., criteria or milestones not based on
        quantifiable measures), in recognition of a significant achievement or for completion of an assignment, such as completion of a major transaction or achieving a major milestone with material impact on our business. Under our compensation policy, a
        special bonus is limited to six times the monthly base salary for a given Officer, other than our CEO, for whom a special bonus is limited to three times the monthly base salary, determined by non-measurable criteria.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">23</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Equity-based Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our compensation policy also includes an equity incentive component designed to retain Officers, align Officers and shareholders&#8217; interests and incentivize Officers to attain business achievements
        without taking unreasonable risk, under which the Company may grant Officers options to purchase shares, share appreciation rights, restricted shares, restricted share units, performance awards or other share-based awards (collectively referred to
        as &#8220;equity awards&#8221;). The equity awards are determined individually by our Compensation Committee and the Board and awarded from time to time based on, among other elements, each Officer&#8217;s (a) contribution to the Company's performance, (b) ability
        to influence the Company&#8217;s future and performance and (c) the Officer&#8217;s skills, qualifications, experience, roles and personal responsibilities. Additionally, the Compensation Committee and the Board award equity-based compensation based upon the
        desired mix of compensation components and the mix of equity awards, as well as the desired competitive levels and dilution or pool limits.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our compensation policy currently limits the annual value of equity awards granted to an Officer, measured at the applicable grant date, to 18 times the monthly base salary of such Officer; should
        the amended compensation policy be approved by the shareholders, such annual value of equity awards granted to an Officer shall be limited to 25 times the monthly base salary of such Officer. See Proposal Five. These options may be granted with
        terms of not more than 10 years following the grant date. For option grants and share appreciation rights, the exercise price shall be no less than the fair market value of the underlying Ordinary Shares on the date of grant and subject to
        applicable law.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Hedging and Pledging</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the terms of our compensation policy and Insider Trading Policy, Officers and directors are prohibited from hedging or pledging their equity awards and any other Company securities. The
        no-hedging policy applies to each director and Officer until one year following termination of such director&#8217;s term of office or such Officer&#8217;s termination of employment, as applicable. Furthermore, Officers and directors may not pledge or use
        their equity awards or any other Company securities held by them as collateral for loans unless otherwise approved by the Compensation Committee and Board.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Policies and Practices Related to the Grant of Certain Equity Awards</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In response to Item 402(x)(1) of Regulation S-K, we have not granted new awards of stock options, stock appreciation rights, or similar option-like instruments within four business days before or
        one business day after the release of a Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or Current Report on Form 8-K that discloses material nonpublic information. While the Company does not have a formal policy in place, it is the
        Company's practice to typically award equity grants to executive officers and non-employee directors at the beginning of each fiscal year, subject to the Company not being in possession of any material non-public information.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Benefits and Perquisites</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the compensation policy, our Officers are entitled to certain fringe benefits that we believe are commonly provided to similarly situated executives in our industry. These benefits allow us
        to compete for talent and are therefore important to our ability to attract and retain top-level executive management. This includes vacation days, paid sick leave, as well as additional benefits such as, but not limited to, health insurance, a
        company car and cell phone, company-provided health insurance and meals.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">For Officers residing in Israel, these benefits may also include contributions to a pension fund, provident fund or insurance policy in accordance with Israeli law, contributions to an education
        fund of 7.5% of the Officer&#8217;s monthly salary and recuperation pay as required under applicable law. An &#8216;education fund&#8217; is a medium-term savings scheme that takes advantage of a unique tax break granted under Israeli law, whereby a company&#8217;s
        contributions to such fund (which, despite its misleading name, may be used by the employee for any purpose), as well as all capital gains accrued on such contributions, are free of tax if (a) the company contributes an amount equal to 7.5% of the
        employee&#8217;s salary to such fund, up to a certain limit, and the employee further contributes 2.5% of his salary at his expense, and (b) the fund remains undrawn for a period of at least six years from the time of the first contribution. While some
        of these contributions and benefits are not mandatory under Israeli law, the nature and amount of the benefits provided to our Israeli Officers are customary and prevalent in the Israeli high-tech and bio-pharma market, especially among executives.
        Non-Israeli Officers may receive similar, comparable or customary benefits as applicable in the jurisdiction in which they are employed.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">24</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Termination</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Officers are further entitled to certain termination payments and benefits. Officers are entitled to an advance notice period, severance payments and retirement and termination awards. The
        retirement and termination awards are subject to the Compensation Committee and the Board&#8217;s approval, and may be provided only: (a) in certain change of control related cases; (b) if the Officer has made a special contribution to the advancement of
        the Company&#8217;s business during his employment period as shall be determined by the Compensation Committee; or (c) in respect of Officers other than the CEO, if the CEO has recommended granting a retirement bonus.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Director Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The compensation policy provides that non-employee directors&#8217; compensation packages are determined pursuant to the provisions of the Israeli Companies Law in accordance with the Company&#8217;s objective
        to attract and retain talented directors with excellent educational background, qualifications, skills, expertise, professional experience and achievements, by providing a fair and competitive compensation program. Our non-employee directors may be
        eligible to receive an annual Board membership fee, annual Committee membership fee and equity-based compensation. Non-employee directors may also be entitled to receive insurance, indemnification and release arrangements. The chair of the Board
        and the chairs of the Board committees may also receive additional annual cash payments for their service in such capacities, subject to the provisions of applicable law.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In May 2021, we elected to be exempt from the Israeli Companies Law requirement that we appoint external directors or otherwise comply with the Israeli Companies Law requirements related to the
        composition of the Audit Committee and Compensation Committee. Our eligibility for that exemption is conditioned upon: (i) the continued listing of our Ordinary Shares on the Nasdaq Capital Market (or one of a few select other non-Israeli stock
        exchanges); (ii) there not being a controlling shareholder of our company under the Israeli Companies Law; and (iii) our compliance with Nasdaq requirements as to the composition of (a) our Board of Directors, which require that we maintain a
        majority of independent directors, and (b) the Audit and Compensation Committees, which require that such committees consist solely of independent directors (at least three and two members, respectively). At the time that it was determined to
        exempt our Company from the external director requirement, our Board affirmatively determined that we met the conditions for exemption from the external director requirement. As of the date hereof, we continue to meet the conditions for exemption
        from the external director requirement.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As a result of our election to be exempt from the external director requirement under the Israeli Companies Law, none of our directors are categorized as external directors; therefore, the
        requirements and restrictions relating to external directors (including certain compensation related provisions) do not apply.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold">Clawback Policy</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On November 30, 2023, the Board adopted an <span style="font-family:'Times New Roman',Times,serif">Executive Officer Clawback&#160;Policy (the &#8220;Clawback&#160;Policy&#8221;) in compliance with Rule 10D-1 under
          the Exchange Act and the appliable Nasdaq rules. In the event of an accounting restatement, under the Clawback&#160;Policy, the Board, or another committee designated by the Board, is required to recover certain incentive-based compensation paid to an
          executive officer of the Company, subject to the terms of the Clawback&#160;Policy, to the extent such incentive-based compensation was in excess of the compensation that would have otherwise been payable based upon the restated financials. The
          clawback period extends for three years prior to the restatement. The Clawback&#160;Policy is in addition to Section 304 of the Sarbanes-Oxley Act of 2002, which permits the SEC to order the disgorgement of bonuses and incentive-based compensation
          earned by a registrant issuer&#8217;s chief executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required to restate because of misconduct, and the reimbursement of those funds to
          the issuer. A copy of the Clawback Policy has been filed as an exhibit to our 2024 Annual Report.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Summary Compensation Table</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The table and summary below outline the compensation granted to our named executive officers (&#8220;Named Executive Officers&#8221;) during our fiscal years ended December 31, 2024 and December 31, 2023. As a
        &#8220;smaller reporting company,&#8221; we are required to provide executive compensation information for the following individuals: (i) all individuals who served as the Company&#8217;s principal executive officer (&#8220;PEO&#8221;), during the last completed fiscal year,
        regardless of compensation; (ii) the two most highly compensated executive officers (other than the PEO) who were serving as executive officers of the Company at the end of the last completed fiscal year and whose total compensation was greater
        than $100,000; and (iii) up to two additional persons who served as executive officers (other than as the PEO) during the last completed fiscal year but who were not serving in that capacity at the end of the fiscal year if their total compensation
        is higher than any of the other two Named Executive Officers in the preceding group.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">25</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;text-indent:18pt;line-height:1.25">The below figures are represented in thousands.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25;font-weight:bold">Name and Principal Position</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Year</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Salary ($)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Bonus ($)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Option</div>
              <div style="line-height:1.25;font-weight:bold">Award(s)</div>
              <div style="line-height:1.25;font-weight:bold">($)(1)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"> RSU Award(s)</div>
              <div style="line-height:1.25;font-weight:bold">($)(2)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">All Other</div>
              <div style="line-height:1.25;font-weight:bold">Compensation</div>
              <div style="line-height:1.25;font-weight:bold">($)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Total ($)</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Miranda Toledano&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2024</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">419</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">538</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">156</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">36</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">1,149</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;vertical-align:bottom">
              <div style="line-height:1.25;font-style:italic;margin-left:9pt">Chief Executive Officer and director</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2023</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">338</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">532</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">80</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">950</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Hillel Galitzer</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2024</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">259</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">175</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">54</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">43</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">531</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;vertical-align:bottom">
              <div style="line-height:1.25;font-style:italic;margin-left:9pt">Chief Operating Officer</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2023</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">245</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">163</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">31</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">459</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Dana Yaacov-Garbeli&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2024</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">226</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">158</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">54</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">438</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:18%;vertical-align:bottom">
              <div style="line-height:1.25;font-style:italic;margin-left:9pt">Chief Finance Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:1%;vertical-align:bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:9%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">2023</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">193</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">118</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">311</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(1)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Reflects the associated annual expense recorded in our financial statements based on the grant date fair value of the share-based compensation granted in exchange for the directors&#8217; and officers&#8217; services computed in accordance with
                Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, Compensation - Stock Compensation (&#8220;ASC Topic 718&#8221;). The assumptions used in calculating the amounts are discussed in Note 6 to the Company&#8217;s
                audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report. The fair value amount is recognized as an expense over the course of the vesting period of the options (subject to any applicable
                accounting adjustments during that period).</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(2)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Reflects the associate annual expenses for RSUs granted in place of annual bonus in cash recorded in our financial statements based on the fair value of the share-based compensation grant date market computed in accordance with ASC Topic
                718. The fair value amount is recognized as an expense over the course of the vesting period of the RSUs in the Company&#8217;s audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Outstanding Equity Awards at Fiscal Year End</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The following table sets forth the outstanding equity awards at December 31, 2024 for our Named Executive Officers.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;padding-bottom:2px;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Number of Securities<br/>
                Underlying<br/>
                Unexercised Options</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:bottom;text-align:center;padding-bottom:2px;width:11%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Option</div>
              <div style="line-height:1.25;font-weight:bold">Expiration</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);width:65%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Name</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Exercisable</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Unexercisable</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Date</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">Miranda Toledano</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">33,638</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">17/1/2029</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="margin-left:9pt;line-height:1.25;font-style:italic">Chief Executive Officer and director</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">35,852</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">1/1/2031</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">98,594</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">8,963</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">1/1/2031</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">312,500</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">187,500(1</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">16/05/2032</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">337,500</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">262,500(2</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">15/07/2032</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">131,250</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">218,750(3</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">24/04/2033</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">-<br/>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">500,000(4</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">62,016</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">62,061(5</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:65%;vertical-align:bottom">
              <div style="line-height:1.25">Hillel Galitzer</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">175,000</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">16/3/2030</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="margin-left:9pt;line-height:1.25;font-style:italic">Chief Operating Officer</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">109,375</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,625(6</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">21/4/2031</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">41,250</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">18,750(7</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">24/3/2032</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">78,750</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">131,250(8</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">24/04/2033</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">130,000(9</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,076</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,076(10</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">Dana Yaacov-Garbeli</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">35,000</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">25/06/2030</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="margin-left:9pt;line-height:1.25;font-style:italic">Chief Finance Officer</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">105,000</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,000(11</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">21/04/2031</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">19,688</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,313(12</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">31/03/2032</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">71,250</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">118,750(13</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">24/04/2033</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">130,000(14</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:65%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,076</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">15,076(15</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">)</div>
            </td>
            <td style="vertical-align:middle;font-family:'Times New Roman',Times,serif;width:11%;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25">19/04/2034</div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">26</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(1)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>The 187,500 unexercisable options as of December 31, 2024 will vest in six equal quarterly installments beginning on February 16, 2025.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:36pt;vertical-align:top">(2)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>The 262,500 unexercisable options as of December 31, 2024 will vest in seven equal quarterly installments beginning on January 15, 2025.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;text-indent:-18pt;margin-left:18pt;line-height:1.25">(3)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;text-indent:-18pt;margin-left:18pt;line-height:1.25">The 218,750 unexercisable options as of December 31, 2024 will vest in ten equal quarterly installments beginning on January 24, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(4)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">Of the 500,000 unexercisable options as of December 31, 2024, 25% vest on April 19, 2025, the first anniversary of the grant date, and the remaining 75% vesting in 8 equal quarterly
                  installments over the following two years.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(5)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 62,061 unexercisable RSUs as of December 31, 2024 will vest in two equal quarterly installments beginning on January 19, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(6)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 15,625 unexercisable options as of December 31, 2024 will vest in two equal quarterly installments beginning on January 16, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(7)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 18,750 unexercisable options as of December 31, 2024 will vest in five equal quarterly installments beginning on March 31, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(8)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 131,250 unexercisable options as of December 31, 2024 will vest in ten equal quarterly installments beginning January 24, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(9)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">Of the 130,000 unexercisable options as of December 31, 2024, 25% vest on April 19, 2025, the first anniversary of the grant date, and the remaining 75% vesting in 8 equal quarterly
                  installments over the following two years.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(10)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 15,076 unexercisable RSUs as of December 31, 2024 will vest in two equal quarterly installments beginning on January 19, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(11)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 15,000 unexercisable options as of December 31, 2024 will vest in two equal quarterly installments beginning on January 16, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(12)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 10,938 unexercisable options as of December 31, 2024 will vest in five equal quarterly installments beginning on March 31, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(13)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 118,750 unexercisable options as of December 31, 2024 will vest in ten equal quarterly installments beginning January 24, 2025. The 15,076 unexercisable RSUs as of December 31, 2024
                  will vest in two equal quarterly installments beginning on January 19, 2025.</div>
              </td>
            </tr>

        </table>
        <div> <br/>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(14)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">Of the 130,000 unexercisable options as of December 31, 2024, 25% vest on April 19, 2025, the first anniversary of the grant date, and the remaining 75% vesting in 8 equal quarterly
                  installments over the following two years</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

            <tr style="vertical-align:top">
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25">(15)</div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <div style="text-align:justify;line-height:1.25">The 15,076 unexercisable RSUs as of December 31, 2024 will vest in two equal quarterly installments beginning on January 19, 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">27</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      <div style="line-height:1.25;font-weight:bold">Director Compensation Table</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Under the Israeli Companies Law, our directors can be paid for their services as directors to the extent such payments are in accordance with the compensation policy adopted by the Company after
        approval by the Compensation Committee, our Board and our shareholders by ordinary majority, or, if their compensation deviates from our compensation policy, after approval by the Compensation Committee, our Board and our shareholders by a Special
        Majority, to the extent applicable, in accordance with the provisions of the Israeli Companies Law.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The table below outlines compensation earned by our non-employee directors for the fiscal year ended December 31, 2024, including fees earned in cash and options awarded for services provided as a
        director. To help the Company maintain sufficient cash for operations, the Company&#8217;s shareholders approved a revised compensation structure for non-executive directors, which was implemented to enhance the Company&#8217;s financial flexibility and align
        directors&#8217; interests with those of shareholders. This revised structure involves granting fully vested Ordinary Shares quarterly instead of quarterly cash payments, effective retroactively as of January 1, 2024. Under this arrangement, each
        non-executive director receives a quarterly grant of fully vested Ordinary Shares. The value of these shares is equivalent to their respective cash compensation for board and committee services, calculated based on the average daily closing share
        price of the Ordinary Shares during the applicable fiscal quarter. Directors who serve only part of a quarter receive a pro rata portion of the shares.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Name</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Fees</div>
              <div style="line-height:1.25;font-weight:bold">Earned</div>
              <div style="line-height:1.25;font-weight:bold">or Paid</div>
              <div style="line-height:1.25;font-weight:bold">in Cash</div>
              <div style="line-height:1.25;font-weight:bold">($)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Option</div>
              <div style="line-height:1.25;font-weight:bold">Awards</div>
              <div style="line-height:1.25;font-weight:bold">($)(1)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25;font-weight:bold">Equity</div>
              <div style="line-height:1.25;font-weight:bold">Awards</div>
              <div style="line-height:1.25;font-weight:bold">($)(2)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">All Other</div>
              <div style="line-height:1.25;font-weight:bold">Compensation</div>
              <div style="line-height:1.25;font-weight:bold">($)</div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold">Total</div>
              <div style="line-height:1.25;font-weight:bold">($)</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Gerald Lieberman <br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">57,162</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">67,736</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">124,898</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;vertical-align:bottom">
              <div style="line-height:1.25">Yonatan Malca<br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">57,162</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">55,838</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">113,000</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Gerald M. Ostrov<br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">57,162</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">50,803</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">107,965</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;vertical-align:bottom">
              <div style="line-height:1.25">Sean Ellis<br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">57,162</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">44,877</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">102,039</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Roger J. Garceau(3)<br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">3,615</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">33,346</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">36,961</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;vertical-align:bottom">
              <div style="line-height:1.25">Ron Mayron(3)<br/>
              </div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">4,409</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">33,346</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">37,775</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Haya Taitel</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">57,162</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="line-height:1.25"></span></div>
              <div style="line-height:1.25">39,841</div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">-</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">97,003</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:25pt;vertical-align:top">(1)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Reflects the associated annual expense recorded in our financial statements based on the grant date fair value of the share-based compensation granted in exchange for the directors&#8217; and officers&#8217; services computed in accordance with ASC
                Topic 718. The assumptions used in calculating the amounts are discussed in Note 6 of the Company&#8217;s audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report. The fair value amount is recognized as
                an expense over the course of the vesting period of the options (subject to any applicable accounting adjustments during that period).</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:25pt;vertical-align:top">(2)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Reflects the associated annual expenses for fully vested Ordinary Shares granted in lieu of cash fees during 2024, based on the grant date market value.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:18pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:25pt;vertical-align:top">(3)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Former board member whose term expired at the 2024 Annual Meeting of Shareholders.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The table below sets forth the aggregate number of options to purchase Ordinary Shares of each current non-employee director outstanding as of December&#160;31, 2024:</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">28</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">Name</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Share Options</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Gerald Lieberman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">374,421</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;vertical-align:bottom">
              <div style="line-height:1.25">Yonatan Malca&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">374,421</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Gerald M. Ostrov&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">374,421</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;vertical-align:bottom">
              <div style="line-height:1.25">Sean Ellis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">374,421</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">Haya Taitel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">141,971</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Employment Agreements</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We have entered into employment agreements with our Named Executive Officers. A summary of the material terms of these agreements with each of our Named Executive Officers is set forth below. The
        below descriptions of employment agreements and separation agreements, as applicable, are only summaries and are qualified in their entirety by reference to the full text of the applicable agreement, which are filed as exhibits to our 2024 Annual
        Report on Form 10-K.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="text-decoration:underline">Miranda Toledano</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Ms. Toledano has served on the Board of Directors at Entera since September 2018. Between May and July 2022, Ms. Toledano served as Chief Business Officer, Chief Financial Officer and Head of
        Corporate Strategy at Entera. In July 2022, Ms. Toledano was appointed Chief Executive Officer at Entera.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In connection with Ms. Toledano&#8217;s appointment&#160;as<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy in May 2022, Ms. Toledano entered into an employment
        agreement (the &#8220;Original Employment Agreement&#8221;) with the Company, providing for an annual employer cost of $350,000 inclusive of base salary, pension payments, severance and disability benefits as required under Israeli law. Additionally, Ms.
        Toledano was entitled to a grant of options pursuant to the Company&#8217;s 2018 Equity Incentive Plan to purchase 500,000 Ordinary Shares of the Company&#8217;s Ordinary Shares at an exercise price of $2.02 per share, the closing price of the Ordinary Shares
        on the date the option was approved by the Board. The options vest over four years, with 25% of the options vesting on May 16, 2023 and the remaining 75% vesting in quarterly increments over the remaining three-year period, subject to Ms.
        Toledano&#8217;s continued employment. In addition, Ms. Toledano was eligible to receive an annual bonus in an amount equal to 50% of her annual base salary. Under the Original Employment Agreement, Ms. Toledano also agreed to customary non-disclosure
        and non-competition covenants.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In connection with Ms. Toledano&#8217;s appointment Chief Executive Officer, on July 15, 2022, Ms. Toledano and the Company entered into an amended and restated employment agreement (the &#8220;A&amp;R
        Employment Agreement&#8221;), which amends and restates the Original Employment Agreement. The material terms of the Original Employment Agreement remain unchanged, except that the A&amp;R Employment Agreement provides for (i) Ms. Toledano&#8217;s service as
        Chief Executive Officer, (ii) an annual employer cost of $380,000 inclusive of base salary, pension payments, severance and disability benefits as required under Israeli law, (iii) eligibility to receive an annual bonus in an amount equal to 60% of
        Ms. Toledano&#8217;s annual base salary, (iv) a one-time separation payment in the total amount of 12 months of salary and an extension of the exercise period with respect to vested options for a period of up to two-years post-termination, in each case
        in the event of the termination of Ms. Toledano&#8217;s employment by the Company for any reason other than for Cause (as defined in the A&amp;R Employment Agreement), (v) an additional grant of options (the &#8220;Options&#8221;) pursuant to the Company&#8217;s 2018
        Equity Incentive Plan to purchase 600,000 Ordinary Shares at an exercise price of $1.40, which was the closing price of the Ordinary Shares on the date the Board approved such option grant and (vi), upon the Company&#8217;s achievement of certain
        performance or financial milestones, a grant of options (the &#8220;Additional Options&#8221;) to purchase an additional 200,000 Ordinary Shares pursuant to the Company&#8217;s 2018 Equity Incentive Plan at an exercise price equal to the closing price of the
        Ordinary Shares on the date the Board approves such option grant. The Options will vest over four years, with 25% of the Options vesting on July 15, 2023 and the remaining 75% vesting in quarterly increments over the remaining three-year period,
        subject to Ms. Toledano&#8217;s continued employment. The Additional Options will vest over four years, with 25% of the Additional Options vesting on the first anniversary of the grant date and the remaining 75% vesting in quarterly increments over the
        remaining three-year period, subject to Ms. Toledano&#8217;s continued employment.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">29</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">On April 24, 2023, the Compensation Committee and the Board voted to approve, and on September 13, 2023, the shareholders of the Company ratified and confirmed, (i) a salary increase for Ms.
        Toledano, according to which her annual employer cost would be increased to $480,000, and (ii) a one-time grant of options to purchase 350,000 Ordinary Shares, at an option exercise price of $0.795 per Ordinary Share, under the Company&#8217;s 2018
        Equity Incentive Plan (the &#8220;2018 Plan&#8221;), both of which were deemed by the Board to be inside the respective ranges set in the Company&#8217;s compensation policy. For the sake of good corporate governance, the Company and Ms. Toledano executed an
        amendment to Ms. Toledano&#8217;s employment agreement in January 2024, under the terms of which the salary increase became effective on January 1, 2024.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="text-decoration:underline">Hillel Galitzer</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In March 2014, we entered into an employment agreement with our Chief Operating Officer, Mr. Hillel Galitzer. Pursuant to the terms of his employment, and within the discretion granted to the
        Board, Mr. Galitzer was entitled to an annual gross base salary of $230,725 for both 2022 and 2023, which represents an increase in base salary from the original terms of the employment agreement approved by the Board. In 2024, the Board approved
        an increase to Mr. Galitzer&#8217;s annual salary, and he is currently entitled to an annual gross base salary of $246,000. Additionally, pursuant to the terms of his employment agreement, Mr. Galitzer is eligible to participate in the Company&#8217;s standard
        full-time employment benefits that are offered by the Company from time to time, which currently include short-term disability and pension fund benefits. Mr. Galitzer is also generally entitled to reimbursement for travel and other business
        expenses and other benefits, including, vacation, holidays, company car and sick leave. Subject to applicable law, Mr. Galitzer is also covered by our D&amp;O insurance policy. Pursuant to the terms of his employment agreement, Mr. Galitzer is
        eligible to receive equity awards under the Company&#8217;s existing and future incentive plans, on such amount and terms as shall be approved by the Board. Pursuant to the terms of his employment agreement, Mr. Galitzer also agreed to customary
        non-disclosure and non-competition covenants.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="text-decoration:underline">Dana Yaacov-Garbeli</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In June 2019, we entered into a consulting agreement with A2Z Counseling Ltd. (&#8220;A2Z&#8221;), in connection with the appointment of Ms. Yaacov-Garbeli as our Chief Financial Officer, which was further
        amended in June 2020, October 2021 and April 2023 (as amended, the &#8220;consulting agreement&#8221;). Under the terms of the consulting agreement, both parties may terminate the agreement for any reason upon 30 days&#8217; notice. In addition, the Company has the
        ability to terminate the agreement immediately upon the occurrence of certain limited circumstances, such as breach of contract. In 2022 and 2023, pursuant to the terms of the consulting agreement, Ms. Yaacov-Garbeli was entitled to an annual
        payment of $193,200. Ms. Yaacov-Garbeli&#8217;s annual payment was raised to $225,000 for fiscal year 2024. In addition, Ms. Yaacov-Garbeli is reimbursed for reasonable out of pocket expenses which were pre-approved in writing in connection with her
        duties as Chief Financial Officer. Pursuant to the terms the consulting agreement, Ms. Yaacov-Garbeli also agreed to customary non-disclosure and non-competition covenants.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Employee Equity Incentive Plans</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Share Incentive Plan</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On March 17, 2013, our Board approved our 2013 Plan for the granting of stock options, restricted share units, restricted share awards and performance-based awards, in order to provide incentives
        to our employees, directors, consultants and/or service providers. As of December 31, 2024, 810,550 Ordinary Shares were issuable upon the exercise of outstanding awards under the 2013 Plan, at a weighted-average exercise price of $6.31 per share.
        As of December 31, 2024, all of the foregoing outstanding options had vested under the 2013 Plan. The 2013 Plan is administered by our Board or by a committee appointed by our Board. Upon the completion of our initial public offering, the remaining
        pool of reserved Ordinary Shares under the 2013 Plan was cancelled, and the only reserved Ordinary Shares available for grants to our employees, directors, consultants and service providers in the future are those under the 2018 Plan (which is
        described below).</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">2018 Equity Incentive Plan</div>
      <div style="line-height:1.25;font-weight:bold"> <br/>
      </div>
      <div style="text-align:justify;line-height:1.25">On July 2, 2018, in connection with the consummation of our initial public offering, our Board approved our 2018 Plan, with the purpose of advancing the interests of our shareholders by enhancing
        our ability to attract, retain and motivate individuals to perform at the highest level. The 2018 Plan governs issuances of equity incentive awards from and after the closing of our initial public offering. The maximum number of Ordinary Shares
        initially available for issuance under equity incentive awards granted pursuant to the 2018 Plan could not exceed 12% of the total outstanding Ordinary Shares as of the time of adoption. On January 1, 2019, and on January 1 of each calendar year
        thereafter, an additional number of shares equal to 5% of the total outstanding Ordinary Shares on such date (or any lower number of shares as determined by our Board) have and will become available for issuance under the 2018 Plan. At our
        shareholders meeting held on September 7, 2022, our shareholders approved an amendment to the 2018 Plan to increase the number of Ordinary Shares issuable under the 2018 Plan by a one-time additional amount of 576,188 Ordinary Shares. In addition,
        at our shareholders meeting held on July 31, 2024, our shareholders approved an amendment to the 2018 Plan to increase the number of Ordinary Shares issuable under the 2018 Plan by a one-time additional amount of 1,788,515 Ordinary Shares. As of
        December 31, 2024, a total of 2,068,226 Ordinary Shares representing 5.3% of the total outstanding shares as of that date remained available for issuance under the 2018 Plan. On January 1, 2025, pursuant to the annual evergreen provision and
        following the approval of our Board, an additional 1,941,859 Ordinary Shares, equal to 5% of the total outstanding shares as of January 1, 2025, became available for issuance under the 2018 Plan. As of January 1, 2025, a total of 4,009,815 Ordinary
        Shares representing 10% of the total outstanding shares as of that date remained available for issuance under the 2018 Plan.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">30</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      </div></div>
      <div>
        <div>
          <div style="text-align:justify;line-height:1.25">Equity incentive awards may be granted to our employees, non-employee directors, consultants or other advisors, as well as holders of equity compensation awards granted by a company that may be acquired by us in the future. Awards under the 2018 Plan may be granted in the form of options, share appreciation rights, restricted shares, restricted share units, performance awards or other share-based awards. Options and share appreciation rights will have an exercise price determined by the administrator but that is no less than fair market value of the underlying Ordinary Shares on the date of grant.</div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">As of December 31, 2024, 6,842,103 Ordinary Shares were issuable upon the exercise of outstanding options under the 2018 Plan, at a weighted-average exercise price of&#8201;$1.91<span style="font-family:'Times New Roman',Times,serif">&#160;per share. Of the foregoing outstanding awards, as of December 31, 2024, options to purchase&#160;4,183,659 Ordinary Shares, in the aggregate, had vested under the 2018 Plan, with a weighted-average exercise price of&#8201;$2.05&#160;per share. In addition, as of December 31, 2024, 104,775 Ordinary Shares are issuable upon the vesting of outstanding RSUs under the 2018 Plan.</span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">The vesting conditions for grants under the 2018 Plan will be determined by the administrator and, in the case of restricted shares and restricted share units, will be set forth in the applicable award documentation.</div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">In the event of a participant&#8217;s termination of employment, the administrator may, in its discretion, determine the extent to which an equity incentive award may be exercised, settled, vested, paid or forfeited. In the event of a &#8220;Change in Control&#8221; (as defined in the 2018 Plan) of the Company, the Compensation Committee may, in its discretion, take a number of actions with respect to awards outstanding under the 2018 Plan, including the following: (i) continuing awards or converting such awards into an award or right with respect to shares of the successor or surviving corporation; (ii) immediately vesting and settling awards (or in the case of options and share appreciation rights, providing that such awards will become fully exercisable); (iii) cancelling unvested awards for no consideration; (iv) terminating or cancelling awards in exchange for a cash payment; and (v) providing that awards may be assumed, exchanged, replaced or continued by the successor or surviving corporation with cash, securities, rights or other property. In the event of a structural change of the Company (i.e., a transaction in which the Company&#8217;s shares immediately prior to the transaction are converted into or exchanged for shares that represent at least a majority of the share capital of the surviving corporation, such as a re-domestication of the Company or a share flip), outstanding awards will be exchanged or converted into awards to acquire shares of the company (if it is the surviving corporation) or the successor company in accordance with the applicable exchange ratio.</div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">The 2018 Plan is administered by the Board, provided that the Board may delegate its authority to the Compensation Committee to administer the 2018 Plan.</div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25">The 2018 Plan provides for granting awards in compliance with Section 102 of the Israeli Income Tax Ordinance, 5721-1961 (the &#8220;Ordinance&#8221;), which provides to employees, directors and officers of the Company, who are not controlling shareholders (as defined in the Ordinance) of the Company and are Israeli residents, potential favorable tax treatment for compensation in the form of shares or equity awards issued or granted, as applicable, to a trustee under the Capital Gains Track for the benefit of the relevant employee, director or officer, subject to compliance with the terms and conditions of such tax track. Under the Capital Gains Track, any accounting expense with respect to the grant or issuance of such shares or awards which relates to gain taxed as capital gains is not allowed as a deduction for tax purposes.</div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <ix:nonNumeric id="Fxbrl_20250528101351118" name="ecd:PvpTableTextBlock" contextRef="C_20240101to20241231" continuedAt="F20250528132954019" escape="true">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pay versus Performance</span></span></div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are required by SEC rules to disclose the following information regarding compensation paid to our Principal Executive Officer (the &#8220;PEO&#8221;) and our other Named Executive Officers (such other Named Executive Officers collectively referred to hereinafter as the &#8220;Non-PEO NEOs&#8221;). The amounts set forth below under the headings &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to Non-PEO NEOs&#8221; have been calculated in a manner prescribed by the SEC rules and do not necessarily align with how we or the compensation committee views the link between our performance and pay of our named executive officers. The footnotes below set forth the adjustments from the total compensation for each of our NEOs reported in the Summary Compensation Table above. As permitted under the rules applicable to smaller reporting companies, we are including two years of data and are not including a peer group total shareholder return or company-selected measure, as contemplated under Item 402(v) of Regulation S-K. For further information concerning our executive compensation philosophy and how executive compensation is aligned with the Company&#8217;s performance, refer to the section entitled &#8220;Executive Compensation&#8221; included in this proxy statement.</span></span></div>
              </div>
            </div>
          </ix:nonNumeric>
          <div style="display:none">
            <ix:continuation id="F20250528132954019" continuedAt="F20250528101406081">
              <div>&#160;</div>
            </ix:continuation>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="width:100%">
              <div>
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
              </div>
            </div>
            <div style="text-align:center"><span style="font-weight:normal;font-style:normal">31</span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <ix:continuation id="F20250528101406081" continuedAt="F20250528133100439">
            <div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>PEO and Non-PEO NEOs&#8217; compensation is designed to provide a mix of compensation to reward Officers for individual and company performance as well as to align their interests with the interests of shareholders. To achieve our goal of appropriately rewarding our Officers for their efforts, the compensation generally includes: (i) annual base salary, benefits and perquisites; (ii) annual bonus based on target and above-target performance; and (iii) equity-based compensation and retirement benefits.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the years 2023 and 2024, in order to preserve Company&#8217;s cash, PEO and Non-PEO NEOs were granted RSUs in lieu of an annual cash bonus.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A significant portion of the PEO and Non-PEO NEOs total compensation is &#8220;at-risk&#8221; in the form of equity compensation and is directly tied to the Company&#8217;s share performance<span style="font-weight:bold">.</span> As a result, this component of compensation aligns the PEO and Non-PEO NEOs interests with those of shareholders by linking potential rewards to long-term stock price appreciation.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table sets forth additional compensation information of our PEO and Non-PEO NEOs, along with total shareholder return, and net loss results for the years ended December 31, 2024 and 2023:</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Year(1)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Summary</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Table Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>for PEO<br/>(in 000s)(2)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Actually Paid</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>to PEO<br/>(in 000s)(3)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Summary</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Table Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>for Non-PEO</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>NEOs<br/>(in 000s)(4)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Actually Paid</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>to Non-PEO</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>NEOs<br/>(in 000s)(3)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Value of</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Initial Fixed</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$100</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Investment</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Based on</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shareholder</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Return(5)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Net Loss</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>(in 000s)(6)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528111816153" name="ecd:PeoTotalCompAmt" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528111840911" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,187</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528111909715" name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528111932493" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112422091" name="ecd:TotalShareholderRtnAmt" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250528112502844" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,541</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528111816153" name="ecd:PeoTotalCompAmt" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528111840911" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528111909715" name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528111932493" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528112422091" name="ecd:TotalShareholderRtnAmt" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20250528112826678_xbrl_20250528112502844" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,889</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(3)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="Fxbrl_20250528113329169" name="ecd:Additional402vDisclosureTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported below represent the amount of &#8220;compensation actually paid&#8221; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year.</span></ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20250528113425486" name="ecd:EquityValuationAssumptionDifferenceFnTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#8220;compensation actually paid&#8221; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant.</span></ix:nonNumeric> The following table details the applicable adjustments that were made to the determine &#8220;compensation actually paid&#8221; (all amounts are averages for Non-PEO NEOs).</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </ix:continuation>
          <div style="display:none">
            <ix:continuation id="F20250528133100439" continuedAt="F20250528101457196">
              <div>&#160;</div>
            </ix:continuation>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="width:100%">
              <div>
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
              </div>
            </div>
            <div style="text-align:center"><span style="font-weight:normal;font-style:normal">32</span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
          <ix:continuation id="F20250528101457196" continuedAt="F20250528133459402">
            <div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The below figures are represented in thousands.</span></span></div>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.85pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.15pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250528120504161" name="ecd:NamedExecutiveOfficersFnTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</span></ix:nonNumeric></span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.8pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250528120600942" name="ecd:PeerGroupIssuersFnTextBlock" contextRef="C_20240101to20241231" escape="true"><span style="font-size:10pt;font-family:Times New Roman">Cumulative total stockholder return (&#8220;TSR&#8221;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</span></ix:nonNumeric></span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.8pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250528120647757" name="ecd:MeasureName" contextRef="C_20240101to20241231_ecdMeasureAxis_1">Net loss</ix:nonNumeric> is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <ix:nonNumeric id="Fxbrl_20250528114213620" name="ecd:AdjToNonPeoNeoCompFnTextBlock" contextRef="C_20240101to20241231" escape="true"><ix:nonNumeric id="Fxbrl_20250528114049594" name="ecd:AdjToPeoCompFnTextBlock" contextRef="C_20240101to20241231" escape="true">
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">PEO</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">Non-PEO NEO Average</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Summary Compensation Table Total</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114431879" name="ecd:PeoTotalCompAmt" contextRef="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114442031" name="ecd:PeoTotalCompAmt" contextRef="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114446705" name="ecd:PeoTotalCompAmt" contextRef="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114508564" name="ecd:PeoTotalCompAmt" contextRef="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">-the fair value of equity awards granted that are reported in the Summary Compensation Table</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528114728782" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">742</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528114904139" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">532</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528114805203" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">246</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528115009047" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">141</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114738319" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">360</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114920317" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114816681" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528115016165" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114749141" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">863</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528114928847" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">81</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114820959" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250528115022336" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114754065" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114943565" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114825572" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528115029871" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the vesting date (from</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">the end of the prior fiscal year) of any awards</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">granted in any prior fiscal year for which all</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">applicable vesting conditions were satisfied at the</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25">end of or during the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114759616" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">445</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114957783" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528114840025" name="ecd:AdjToCompAmt" contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528115035703" name="ecd:AdjToCompAmt" contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
                          <div style="line-height:1.25;font-weight:bold">Compensation Actually Paid</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528115208330" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,187</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20250528115305065" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250528115259742" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20250528115315683" name="ecd:PeoActuallyPaidCompAmt" contextRef="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314</ix:nonFraction></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </ix:nonNumeric></ix:nonNumeric>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;margin-right:7.9pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pay versus Performance Comparative Disclosure</span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with SEC rules, the Company is providing the following narrative disclosure regarding the relationships between information presented in the pay versus performance tables above.</span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20250528120736418" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" contextRef="C_20240101to20241231" continuedAt="F20250528133825349" escape="true">
                <div style="font-size:10pt;font-family:Times New Roman">
                  <div>
                    <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation Actually Paid and Cumulative Total Shareholder Return</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023 and 2024, compensation actually paid (&#8220;CAP&#8221;) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024.</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years.</span></span></div>
                  </div>
                </div>
              </ix:nonNumeric>
              <div style="display:none">
                <ix:continuation id="F20250528133825349" continuedAt="F20250528120748422">
                  <div>&#160;</div>
                </ix:continuation>
              </div>
            </div>
          </ix:continuation>
          <div style="display:none">
            <ix:continuation id="F20250528133459402" continuedAt="F20250528102928144">
              <div>&#160;</div>
            </ix:continuation>
          </div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="width:100%">
              <div>
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
              </div>
            </div>
            <div style="text-align:center"><span style="font-weight:normal;font-style:normal">33</span></div>
            <div style="page-break-after:always">
              <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
            </div>
          </div>
          <ix:continuation id="F20250528102928144">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
                <ix:continuation id="F20250528120748422"><img src="image1.jpg" alt="image1.jpg" height="363" width="603"/></ix:continuation>
              </div>
              <div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic">&#160;</div>
              <div>
                <ix:nonNumeric id="Fxbrl_20250528120815262" name="ecd:CompActuallyPaidVsNetIncomeTextBlock" contextRef="C_20240101to20241231" escape="true">
                  <div style="font-size:10pt;font-family:Times New Roman">
                    <div>
                      <div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic">Compensation Actually Paid and Net Loss</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="text-align:justify;line-height:1.25">During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).</div>
                    </div>
                  </div>
                </ix:nonNumeric>
              </div>
            </div>
          </ix:continuation>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="width:100%">
              <div>
                <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
              </div>
            </div>
            <div style="text-align:center"><span style="font-weight:normal;font-style:normal">34</span></div>
            <div style="page-break-after:always">
              <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
            </div>
          </div>
        </div>
      </div>
    <div><div> <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span id="PROPOSAL_ONE"><!-- anchor --></span>PROPOSAL ONE&#160;&#8212; ELECTION OF DIRECTORS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Director Nominees</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In accordance with the Israeli Companies Law and without derogating from the appointment requirements listed above, each of the nominees has certified to us that he meets all the requirements of
        the Israeli Companies Law for election as a director of a public company, possesses the necessary qualifications and has sufficient time in order to fulfill his duties as our director, taking into account our size and special needs.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Shareholders are being asked to elect the director nominees listed below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

            <tr>
              <td style="width:20%;border-bottom:2px solid rgb(0, 0, 0)">Name</td>
              <td colspan="1" style="width:5%;padding-bottom:2px">&#160;</td>
              <td style="width:20%;border-bottom:2px solid rgb(0, 0, 0)"><span style="font-family:'Times New Roman',Times,serif">Term Expires</span></td>
              <td colspan="1" style="width:55%;padding-bottom:2px">&#160;</td>
            </tr>
            <tr>
              <td style="width:20%"><br/>
              </td>
              <td colspan="1" style="width:5%">&#160;</td>
              <td style="width:20%"><br/>
              </td>
              <td colspan="1" style="width:55%">&#160;</td>
            </tr>
            <tr>
              <td style="width:20%">Haya Taitel</td>
              <td colspan="1" style="width:5%">&#160;</td>
              <td colspan="2" rowspan="1" style="width:20%"><span style="font-family:'Times New Roman',Times,serif">2028 Annual Meeting of shareholders</span></td>
            </tr>

        </table>
      </div>
      <br/>
      <div style="text-align:justify;line-height:1.25">Unless otherwise instructed, the proxy holders will vote the proxies received by them for the director nominees listed above. In the event that any nominee is unable or declines to serve as a
        director at the time of the Annual Meeting, the proxies will be voted for any nominee who shall be designated by the present Board to fill the vacancy. It is not expected that any nominee will be unable or will decline to serve as a director.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The section titled &#8220;Directors &amp; Executive Officers&#8221; of this proxy contains more information about the leadership skills and other experience that caused the Nominating and Corporate Governance
        Committee and the Board to determine that Ms. Taitel should serve as the Class II director of the Company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We believe that Ms. Taitel possesses the experience, skills, and qualities to fully perform her duty as a director and contribute to our success. Ms. Taitel has been nominated because she possesses
        the highest standards of personal integrity, interpersonal and communication skills, is highly accomplished in her field, she understands the interests and issues that are important to our shareholders, and she is able to dedicate sufficient time
        to fulfilling their obligations as director. Our directors complement each other with their respective experiences, skills, and qualities. While our directors make up a diverse group in terms of age, gender and professional experience, together
        they comprise a cohesive body in terms of Board process and collaboration.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Shareholders are being asked to adopt the following resolutions:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:7.85pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:28.15pt;vertical-align:top">(a)</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>&#8220;RESOLVED, that Ms. Haya Taitel is hereby elected to serve as a Class II member of the Board until the 2028 Annual Meeting.&#8221;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Election of the above-named director nominees requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than
        &#8220;against&#8221; each director nominee in Proposal One. Each director nominee shall be voted separately. Abstentions and broker non-votes will have no effect on the outcome of Proposal One.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">The Board recommends that our shareholders vote &#8220;FOR&#8221; the election of each of the directors nominated for service under this proposal.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">35</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="PROPOSAL_TWO"><!-- anchor --></span>PROPOSAL TWO&#160;&#8212; RATIFICATION AND APPROVAL OF REVISED COMPENSATION TERMS AND ONE-TIME GRANT OF COMPENSATION TO MIRANDA TOLEDANO, OUR
                CHIEF EXECUTIVE OFFICER AND A DIRECTOR</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Background </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve revised compensation terms and one-time grant of compensation for Ms. Toledano in
        accordance with the terms below, which were deemed by the Board to be outside the range set in the Company&#8217;s compensation policy but in line with comparable standards as detailed in the 2025 comparative executive compensation benchmark analyses,
        which included comparative data of the Company&#8217;s executive compensation relative to the peer-group companies in Israel and in the United States. <span style="font-weight:bold">The 2025 comparative executive compensation benchmark analysis found
          that the compensation terms, especially current annual salary of $419,000 of our CEO are materially below that of similar companies within the market. </span>The update in compensation terms is therefore critical to provide an effective
        retention incentive. As a result of the conclusions of the 2025 comparative executive compensation benchmark analysis, our Compensation Committee and Board have determined that, it would be advisable for the Company to increase Ms. Toledano&#8217;s
        compensation terms in order to better reflect the terms being offered by companies in a similar sector and of a similar size to the Company. The Compensation Committee and Board have further determined that it would be in the best interests of the
        Company to update and amend the Company&#8217;s compensation policy, as outlined in Proposal Five below. Had the updated compensation policy, to be approved per Proposal Five below, been in effect as of the date hereof, the revised compensation terms
        below would be considered materially consistent with our compensation policy.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">A significant portion of the CEO&#8217;s total compensation is &#8220;at-risk&#8221; in the form of equity compensation and is directly tied to the Company&#8217;s share performance.</span><span style="font-family:'Times New Roman',Times,serif"> As a result, this component of compensation aligns the CEO&#8217;s interests with those of shareholders by linking potential rewards to long-term stock price appreciation.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the <span style="font-family:'Times New Roman',Times,serif">Israeli Companies Law, any transaction between us and a member of our Board, relating to his or her terms of compensation,
          must generally be consistent with our compensation policy, and must be approved by the Compensation Committee, the Board and a Special Majority of our shareholders, to the extent applicable, in accordance with the provisions of the Israeli
          Companies Law.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Terms of Revised Compensation and One-time Grant of Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve for Ms. Toledano (i) an RSU grant in place of a cash bonus, (ii) an option grant,
        (iii) a salary increase, including a one-time RSU grant in place of a portion of Ms. Toledano&#8217;s salary, in accordance with the terms below, which were deemed by the Board to be outside the range set in the Company&#8217;s compensation policy but in line
        with comparable standards as detailed in the 2025 comparative executive compensation benchmark analyses, which included comparative data of the Company&#8217;s executive compensation relative to the peer-group companies in Israel and in the United
        States.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Compensation Committee and Board believe that it is in the best interest of the Company and our shareholders to approve the<span style="font-family:'Times New Roman',Times,serif"> one-time
          grant of compensation and salary increase to Ms. Toledano, our Chief Executive Officer.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">36</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">The terms of the<span style="font-family:'Times New Roman',Times,serif"> compensation to Ms. Toledano, effective as of the approval of our shareholders at this Annual Meeting, would be as
          follows:</span></div>
      <div style="text-align:justify;line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"> <br/>
        </span></div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(i)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Option Grant</span>. Ms. Toledano will be entitled to receive an additional one-time grant of options to purchase an additional <span style="font-family:'Times New Roman',Times,serif">500,000 Ordinary Shares (the &#8220;2025 Options&#8221;),
                  at an exercise price of $2.28&#160;per Ordinary Share, under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Options shall vest as follows: provided that Ms. Toledano has not undergone a Termination
                  of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Options shall vest over a three (3) year period, with a third of the 2025 Options vesting at the end of a 12-month period following April 28, 2025 and
                  the remaining two-thirds of the 2025 Options shall vest in eight substantially equal portions over the next two (2) year period thereafter, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the
                  last such quarterly installment, the number of 2025 Options that vest in the installment shall be such that Ms. Toledano will be fully vested in the total number of 2025 Options listed above as of such applicable quarterly anniversary
                  (i.e., such that one hundred percent (100%) of the 2025 Options shall become fully vested on April 28, 2028); provided further, however, that in the event of a Change in Control (as defined in the 2018 Plan) in which Ms. Toledano
                  continues to provide services to the Company on the date of consummation of such Change in Control, 100% of any unvested 2025 Options at the time of the consummation of such Change in Control shall become fully vested and exercisable. The
                  expiration date of the 2025 Options shall be April 28, 2035, or such earlier date in accordance with the 2018 Plan or the Company&#8217;s option agreement.</span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(ii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 RSU Grant in Lieu of Cash Bonus</span>. Ms. Toledano will be entitled to receive a one-time grant of 136,842 RSUs in lieu of cash bonus (the &#8220;2025 RSUs&#8221;) under the 2018 Plan, and subject to the requirements of applicable laws and
                regulations. The 2025 RSUs shall vest as follows: provided that Ms. Toledano has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 RSUs shall vest over a one (1) year period,
                with 100% of the 2025 RSUs vesting in four substantially equal portions over the 12 month period following April 28, 2025, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly
                installment, the number of 2025 RSUs that vest in the installment shall be such that Ms. Toledano will be fully vested in the total number of 2025 RSUs listed above as of such applicable quarterly anniversary (i.e., such that one hundred
                percent (100%) of the 2025 RSUs shall become fully vested on April 28, 2026); provided further, however, that in the event of the Change in Control in which Ms. Toledano continues to provide services to the Company on the date of
                consummation of such Change in Control, 100% of any unvested 2025 RSUs at the time of the consummation of such Change in Control shall become fully vested.</div>
            </td>
          </tr>

      </table>
      <div> <br/>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(iii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Salary Increase</span>. Ms. Toledano will be entitled to an annual salary of $600,000 (the &#8220;Updated Salary&#8221;), effective as of April 1, 2025, in accordance with the Company&#8217;s regular payroll practice in effect from time to time. For
                the avoidance of doubt, all other terms and social benefits under the A&amp;R Employment Agreement affected by a base salary shall be updated in accordance with the Updated Salary effective as of April 1, 2025. Notwithstanding the
                foregoing, with respect to the 12-month period beginning April 1, 2025<span style="font-weight:bold">, in order to preserve Company cash, Ms. Toledano will be entitled to receive a one-time grant of 43,860 RSUs in place of $100,000 of her
                  Updated Salary in lieu of cash payment</span> for such one (1) year period (the &#8220;2025 Salary RSUs&#8221;) under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Salary RSUs shall vest as follows:
                provided that Ms. Toledano has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Salary RSUs shall vest over a one (1) year period, with 100% of the 2025 Salary RSUs vesting
                in four substantially equal portions over the 12 month period following April 1, 2025, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly installment, the number of 2025
                Salary RSUs that vest in the installment shall be such that Ms. Toledano will be fully vested in the total number of 2025 Salary RSUs listed above as of such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of
                the 2025 Salary RSUs shall become fully vested on April 1, 2026); provided further, however, that in the event of the Change in Control in which Ms. Toledano continues to provide services to the Company on the date of consummation of such
                Change in Control, 100% of any unvested 2025 Salary RSUs at the time of the consummation of such Change in Control shall become fully vested.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">37</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the revised compensation terms and one-time grant of compensation to Miranda Toledano, our Chief Executive Officer, as described in Proposal Two of the Company&#8217;s&#160;Proxy&#160;Statement&#160;for
        the Company&#8217;s 2025 Annual Meeting, be, and are hereby, ratified and approved.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Proposal Two requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Two, and
        abstentions and broker non-votes have no effect on the outcome of Proposal Two.&#160; In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the Israeli
        Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in clause
        (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As part of the Special Majority vote, you must indicate whether you are a controlling shareholder or have a personal interest in the approval of this proposal. According to the Relief Regulations,
        by signing and submitting the accompanying proxy card, you declare and approve that you have no personal interest in the approval of this proposal, unless you have notified&#160;the Company of such personal interest in writing. If you believe that you
        have a personal interest in this Proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to Dana Yaacov-Garbeli, our Chief Financial Officer.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">The Board recommends that our shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">38</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:#000000 2px solid">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="PROPOSAL_THREE"><!-- anchor --></span>PROPOSAL THREE&#160;&#8212; RATIFICATION AND APPROVAL OF REVISED COMPENSATION TERMS TO GREGORY BURSHTEIN, OUR CHIEF OF RESEARCH
                &amp;DEVELOPMENT</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Background</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve revised compensation terms and one-time grant of compensation for Dr. Burshtein in
        accordance with the terms below, which were deemed by the Board to be outside the range set in the Company&#8217;s compensation policy but in line with comparable standards as detailed in the 2025 comparative executive compensation benchmark analyses,
        which included comparative data of the Company&#8217;s executive compensation relative to the peer-group companies in Israel and in the United States. <span style="font-weight:bold">The 2025 comparative executive compensation benchmark analysis found
          that the compensation terms, especially current annual salary of $160,000, of our Chief of Research &amp; Development are materially below that of similar companies within the market.</span> The update in compensation terms is therefore critical
        to provide an effective retention incentive. As a result of the conclusions of the 2025 comparative executive compensation benchmark analysis, our Compensation Committee and Board have determined that, it would be advisable for the Company to
        increase dr. Burshtein&#8217;s compensation terms in order to better reflect the terms being offered by companies in a similar sector and of a similar size to the Company. The Compensation Committee and Board have further determined that it would be in
        the best interests of the Company to update and amend the Company&#8217;s compensation policy, as outlined in Proposal Five below. Had the updated compensation policy, to be approved per Proposal Five below, been in effect as of the date hereof, the
        revised compensation terms below would be considered materially consistent with our compensation policy and would thereby not require shareholder approval.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">A significant portion of the Chief of Research &amp; Development&#8217;s total compensation is &#8220;at-risk&#8221; in the form of equity compensation and is directly tied to the
          Company&#8217;s share performance.</span><span style="font-family:'Times New Roman',Times,serif"> As a result, this component of compensation aligns the Chief of Research &amp; Development&#8217;s interests with those of shareholders by linking potential
          rewards to long-term stock price appreciation.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the <span style="font-family:'Times New Roman',Times,serif">Israeli Companies Law, any transaction between us and an office holder (as defined in the Companies Law), relating to his
          or her terms of compensation, must generally be consistent with our compensation policy, and must be approved by the Compensation Committee, the Board and a Special Majority of our shareholders, to the extent applicable, in accordance with the
          provisions of the Israeli Companies Law.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Terms of Revised Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The terms of the<span style="font-family:'Times New Roman',Times,serif"> revised compensation to Dr. Burshtein, effective as of the approval of our shareholders at this Annual Meeting, would be
          as follows:</span></div>
      <div style="text-align:justify;line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"> <br/>
        </span></div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(i)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Option Grant</span>. Dr. Burshtein will be entitled to receive an additional one-time grant of options to purchase an additional <span style="font-family:'Times New Roman',Times,serif">200,000 Ordinary Shares (the &#8220;2025
                  Options&#8221;), at an exercise price of $2.28&#160;per Ordinary Share, under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Options shall vest as follows: provided that Dr. Burshtein has not undergone a
                  Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Options shall vest over a three (3) year period, with a third of the 2025 Options vesting at the end of a 12-month period following April
                  28, 2025, and the remaining two-thirds of the 2025 Options shall vest in eight substantially equal portions over the next two (2) year period thereafter, on a quarterly basis, rounded down to the nearest whole share, provided, that with
                  respect to the last such quarterly installment, the number of 2025 Options that vest in the installment shall be such that Dr. Burshtein will be fully vested in the total number of 2025 Options listed above as of such applicable quarterly
                  anniversary (i.e., such that one hundred percent (100%) of the 2025 Options shall become fully vested on April 28, 2028).</span></div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">39</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(ii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 RSU Grant</span>. Dr. Burshtein will be entitled to receive a one-time grant of 26,316 RSUs (the &#8220;2025 RSUs&#8221;) in lieu of a cash bonus for 2024 under the 2018 Plan, and subject to the requirements of applicable laws and regulations.
                The 2025 RSUs shall vest as follows: provided that Dr. Burshtein has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 RSUs shall vest over a one (1) year period, with 100%
                of the 2025 RSUs vesting in four substantially equal portions over the 12 month period following April 28, 2025, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly
                installment, the number of 2025 RSUs that vest in the installment shall be such that Dr. Burshtein will be fully vested in the total number of 2025 RSUs listed above as of such applicable quarterly anniversary (i.e., such that one hundred
                percent (100%) of the 2025 RSUs shall become fully vested on April 28, 2026).</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(iii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Salary Increase</span>. Dr. Burshtein will be entitled to an annual gross base salary of $200,000 (the &#8220;Updated Salary&#8221;), effective as of April 1, 2025, in accordance with the Company&#8217;s regular payroll practice in effect from time
                to time. For the avoidance of doubt, all other terms and social benefits under his employment agreement affected by a base salary shall be updated in accordance with the Updated Salary effective as of April 1, 2025.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the revised compensation terms to Gregory Burshtein, our Chief of Research &amp; Development, as described in Proposal Three of the Company&#8217;s&#160;Proxy&#160;Statement&#160;for the Company&#8217;s 2025
        Annual Meeting, be, and are hereby, ratified and approved.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Proposal Three requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Three,
        and abstentions and broker non-votes have no effect on the outcome of Proposal Three.&#160; In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the
        Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in
        clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As part of the Special Majority vote, you must indicate whether you are a controlling shareholder or have a personal interest in the approval of this proposal. According to the Relief Regulations,
        by signing and submitting the accompanying proxy card, you declare and approve that you have no personal interest in the approval of this proposal, unless you have notified&#160;the Company of such personal interest in writing. If you believe that you
        have a personal interest in this Proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to Dana Yaacov-Garbeli, our Chief Financial Officer.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">The Board recommends that our shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">40</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:#000000 2px solid">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="PROPOSAL_FOUR"><!-- anchor --></span>PROPOSAL FOUR&#160;&#8212; RATIFICATION AND APPROVAL OF COMPENSATION TERMS TO DANA YAACOV-GARBELI, OUR CHIEF FINANCIAL OFFICER</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Background</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve revised compensation terms and one-time grant of compensation for Ms. Yaacov-Garbeli
        in accordance with the terms below, which were deemed by the Board to be outside the range set in the Company&#8217;s compensation policy but in line with comparable standards as detailed in the 2025 comparative executive compensation benchmark analyses,
        which included comparative data of the Company&#8217;s executive compensation relative to the peer-group companies in Israel and in the United States. <span style="font-weight:bold">The 2025 comparative executive compensation benchmark analysis found
          that the compensation terms, especially current annual cash consideration of $225,000, of our CFO are materially below that of similar companies within the market.</span> The update in compensation terms is therefore critical to provide an
        effective retention incentive. As a result of the conclusions of the 2025 comparative executive compensation benchmark analysis, our Compensation Committee and Board have determined that, it would be advisable for the Company to increase Ms.
        Yaacov-Garbeli&#8217;s compensation terms in order to better reflect the terms being offered by companies in a similar sector and of a similar size to the Company. The Compensation Committee and Board have further determined that it would be in the best
        interests of the Company to update and amend the Company&#8217;s compensation policy, as outlined in Proposal Five below. Had the updated compensation policy, to be approved per Proposal Five below, been in effect as of the date hereof, the revised
        compensation terms below would be considered materially consistent with our compensation policy and would thereby not require shareholder approval.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">A significant portion of the Chief Financial Officer&#8217;s total compensation is &#8220;at-risk&#8221; in the form of equity compensation and is directly tied to the Company&#8217;s
          share performance.</span><span style="font-family:'Times New Roman',Times,serif"> As a result, this component of compensation aligns the Chief Financial Officer&#8217;s interests with those of shareholders by linking potential rewards to long-term
          stock price appreciation.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the <span style="font-family:'Times New Roman',Times,serif">Israeli Companies Law, any transaction between us and an office holder (as defined in the Companies Law), relating to his
          or her terms of compensation, must generally be consistent with our compensation policy, and must be approved by the Compensation Committee, the Board and a Special Majority of our shareholders, to the extent applicable, in accordance with the
          provisions of the Israeli Companies Law.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Terms of Revised Compensation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The terms of the revised compensation to Ms. <span style="font-family:'Times New Roman',Times,serif">Yaacov-Garbeli, effective as of the approval of our shareholders at this Annual Meeting,
          would be as follows:</span></div>
      <div style="text-align:justify;line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"> <br/>
        </span></div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(i)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Option Grant</span>. Ms. <span style="font-family:'Times New Roman',Times,serif">Yaacov-Garbeli will be entitled to receive an additional one-time grant of options to purchase an additional 130,000 Ordinary Shares (the &#8220;2025
                  Options&#8221;), at an exercise price of $2.28 per Ordinary Share, under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Options shall vest as follows: provided that Ms. Yaacov-Garbeli has not
                  undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Options shall vest over a three (3) year period, with a third of the 2025 Options vesting at the end of a 12-month period
                  following April 28, 2025, and the remaining two-thirds of the 2025 Options shall vest in eight substantially equal portions over the next two (2) year period thereafter, on a quarterly basis, rounded down to the nearest whole share,
                  provided, that with respect to the last such quarterly installment, the number of 2025 Options that vest in the installment shall be such that Ms. Yaacov-Garbeli will be fully vested in the total number of 2025 Options listed above as of
                  such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of the 2025 Options shall become fully vested on April 28, 2028); provided further, however, that in the event of a Change in Control (as defined in the
                  2018 Plan) in which Ms. Yaacov-Garbeli continues to provide services to the Company on the date of consummation of such Change in Control, 100% of any unvested 2025 Options at the time of the consummation of such Change in Control shall
                  become fully vested and exercisable. The expiration date of the 2025 Options shall be April 28, 2035, or such earlier date in accordance with the 2018 Plan or the Company&#8217;s option agreement.</span></div>
            </td>
          </tr>

      </table>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">41</span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(ii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 RSU Grant</span>. Ms. <span style="font-family:'Times New Roman',Times,serif">Yaacov-Garbeli will be entitled to receive a one-time grant of 26,316 RSUs (the &#8220;2025 RSUs&#8221;) in lieu of cash bonus for 2024 under the 2018 Plan, and
                  subject to the requirements of applicable laws and regulations. The 2025 RSUs shall vest as follows: provided that Ms. Yaacov-Garbeli has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting
                  date, the 2025 RSUs shall vest over a one (1) year period, with 100% of the 2025 RSUs vesting in four substantially equal portions over the 12 month period following April 28, 2025, on a quarterly basis, rounded down to the nearest whole
                  share, provided, that with respect to the last such quarterly installment, the number of 2025 RSUs that vest in the installment shall be such that Ms. Yaacov-Garbeli will be fully vested in the total number of 2025 RSUs listed above as of
                  such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of the 2025 RSUs shall become fully vested on April 28, 2026); provided further, however, that in the event of the Change in Control in which Ms.
                  Yaacov-Garbeli continues to provide services to the Company on the date of consummation of such Change in Control, 100% of any unvested 2025 RSUs at the time of the consummation of such Change in Control shall become fully vested.</span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:38.5pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:36pt;vertical-align:top">(iii)</td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="text-decoration:underline">2025 Cash Compensation Increase</span>. Ms. <span style="font-family:'Times New Roman',Times,serif">Yaacov-Garbeli will be entitled to an annual cash consideration of $251,983 (the &#8220;Updated Cash Compensation&#8221;), effective as of April
                  1, 2025, in accordance with the terms of her consulting agreement. For the avoidance of doubt, given the nature of her consulting agreement, the abovementioned Updated Cash Compensation reflects the full payment in cash to Ms.
                  Yaacov-Garbeli in consideration for her services, except for any reasonable out of pocket expenses which were pre-approved in writing in connection with her duties as Chief Financial Officer.</span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the revised compensation terms to Dana Yaacov-Garbeli, our Chief Financial Officer, as described in Proposal Four of the Company&#8217;s&#160;Proxy&#160;Statement&#160;for the Company&#8217;s 2025 Annual
        Meeting, be, and are hereby, ratified and approved.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Proposal Four requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Four, and
        abstentions and broker non-votes have no effect on the outcome of Proposal Four.&#160; In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the
        Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in
        clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company.</div>
      <div style="text-align:justify;line-height:1.25"> <br/>
      </div>
      <div style="text-align:justify;line-height:1.25">As part of the Special Majority vote, you must indicate whether you are a controlling shareholder or have a personal interest in the approval of this proposal. According to the Relief Regulations,
        by signing and submitting the accompanying proxy card, you declare and approve that you have no personal interest in the approval of this proposal, unless you have notified&#160;the Company of such personal interest in writing. If you believe that you
        have a personal interest in this Proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to Dana Yaacov-Garbeli, our Chief Financial Officer.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">The Board recommends that our shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">42</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="PROPOSAL_FIVE"><!-- anchor --></span>PROPOSAL FIVE&#160;&#8212;APPROVAL OF AN AMENDED AND RESTATED COMPENSATION POLICY</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Background</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Pursuant to the Israeli Companies Law, all Israeli companies, such as the Company, whose shares are publicly listed, are required to adopt a written compensation policy for their executives, which
        addresses certain items prescribed by the Israeli Companies Law and serves as a flexible framework for executive and director compensation. Accordingly, on July 31, 2024, the Company&#8217;s shareholders approved the compensation policy for the Company&#8217;s
        directors and officers. The compensation policy must further be approved once every three years by the Board, after it considers the recommendations of the Compensation Committee, and then by a Special Majority of the shareholders, to the extent
        applicable, in accordance with the provisions of the Israeli Companies Law. To the extent a compensation policy is not approved by the shareholders, then generally, following re-discussion of the matter, the Compensation Committee and the Board may
        nonetheless approve the compensation policy based on detailed reasoning, provided such approval is in the Company&#8217;s best interest. Revisions to the compensation policy require the same approval process, unless otherwise provided by applicable
        Israeli law. We note that this approval vote of the compensation policy is due to Israeli law requirements and in addition to and not in lieu of the advisory &#8220;say-on-pay&#8221; vote contained in Proposal Six.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We adopted a compensation policy on September 27, 2018. On October 4, 2021, and again on July 31, 2024, the Company&#8217;s shareholders approved amendments at the Company&#8217;s 2021 and 2024 annual meeting
        of shareholders, respectively, in order to create a relevant and appropriate compensation framework to meet the Company&#8217;s needs and in accordance with Israeli law requirements. Pursuant to our compensation policy, the compensation that may be
        granted to an executive officer may include: base salary; cash bonuses; and equity-based compensation. The cash bonus component aims to ensure that the Company&#8217;s executive officers are incentivized to reach the Company&#8217;s annual goals. The
        equity-based compensation component is intended to incentivize and reward for future long-term performance, to foster a long-term link between executive officers&#8217; interests and the interests of the Company and its shareholders, and to attract,
        motivate and retain executive officers for the long term. Our compensation policy also provides for compensation to the members of our Board in accordance with the principles determined in our compensation policy.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Unlike &#8220;say-on-pay,&#8221; which is a retrospective shareholder advisory vote based on actual executive compensation granted in the previous year, the compensation policy serves as a shareholder-approved
        prospective framework for the Compensation Committee and the Board when making compensation decisions generally for the following three-year period, which sets caps and other limitations. The Compensation Committee and the Board generally cannot
        approve any compensation that does not fall within the framework of the Company&#8217;s compensation policy without seeking shareholder approval. Therefore, and in light of our previous experience, we believe that our compensation policy must provide
        flexibility to address our various needs and challenges, including special circumstances that may arise during the applicable three-year period. The compensation elements, caps and other limitations set forth in the compensation policy do not
        create an obligation or a promise to actually grant such compensation. The actual executive compensation design and amounts granted to our Named Executive Officers in the previous year are reflected in the section entitled &#8220;Executive Compensation&#8221;
        included in this proxy statement and presented for a shareholder advisory vote under Proposal Six.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As noted above, under the Israeli Companies Law, we are required to submit the compensation policy to our shareholders at least once every three years for approval. Although the compensation policy
        was last approved in 2024, we are presenting to our shareholders a proposal to approve our Amended Compensation Policy, a form of which is attached to this proxy statement as Appendix A and which is substantially similar to our existing
        compensation policy subject to certain updated thresholds to align with market standards and to attract prospective management members such that the policy would be effective for the next three years, or such longer period as permitted and in
        accordance with the Israeli Companies Law.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">43</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">Our existing compensation policy reflects our unique status, being subject to both Israeli compensation policy requirements and U.S. compensation disclosure and &#8220;say-on-pay&#8221; requirements as well as
        providing us with a competitive compensation framework.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Compensation Committee and the Board have determined that in order to attract and retain leading candidates to management positions in the Company, it would be advisable for the Company to
        adjust certain thresholds in its existing compensation policy in order to better reflect the terms being offered by companies in a similar sector and of similar size to the Company. The changes would allow the Company to attract and retain
        highly-qualified executive officers while aligning their compensation terms with Company resources and needs.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The 2025 comparative executive compensation benchmark analysis found that the compensation terms of our executive officers are materially below that of similar companies within the market. The
        update in compensation terms is therefore critical to provide for a policy in line with comparable compensation standards, to ensure effective retention of existing management and the attraction of new leading candidates when needed.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Based on our positive experience in implementing the existing compensation policy over the past three years, the Board recommends the approval of the Amended Compensation Policy in a form
        substantially similar to our existing compensation policy, with certain amendments to ensure that the Amended Compensation Policy aligns with comparable terms on the market.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Following the recommendation of the Compensation Committee, the Board has approved, and recommends that shareholders approve, the Amended Compensation Policy in the form attached to this proxy
        statement as Appendix A.&#160;The Amended Compensation Policy submitted for shareholder approval under this Proposal Five addresses the requirements under the Israeli Companies Law and shall be in effect in accordance with the Israeli Companies Law, as
        long as such requirements are applicable to the Company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the&#160;Amended Compensation Policy, as described in Proposal Five and attached as Appendix A of the Company&#8217;s&#160;Proxy&#160;Statement&#160;for the Company&#8217;s 2025 Annual Meeting, be, and it hereby
        is, approved.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Proposal Five requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Five, and
        abstentions and broker non-votes have no effect on the outcome of Proposal Five.&#160; In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the
        Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in
        clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As part of the Special Majority vote, you must indicate whether you are a controlling shareholder or have a personal interest in the approval of this proposal. According to the Relief Regulations,
        by signing and submitting the accompanying Proxy Card, you declare and approve that you have no personal interest in the approval of this proposal, unless you have notified&#160;the Company of such personal interest in writing. If you believe that you
        have a personal interest in this Proposal and you wish to inform that Company of such personal interest, you should submit such information in advance of voting to Dana Yaacov-Garbeli, our Chief Financial Officer.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">The Board recommends that our shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">44</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="PROPOSAL_SIX"><!-- anchor --></span>PROPOSAL SIX&#160;&#8212; ADVISORY RESOLUTION REGARDING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Background</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">As required by Section&#160;14A of the Exchange Act, the Board requests your advisory vote to approve the compensation of our Named Executive Officers as described in the section entitled &#8220;Executive
        Compensation&#8221; included in this proxy statement. This proposal, commonly referred to as the &#8220;say-on-pay&#8221; vote, gives our shareholders the opportunity to express their views on the compensation of our Named Executive Officers. Your vote is solely
        advisory and, therefore, will not be binding on the Company; however, the Board will review the voting results and take them into consideration when making future executive compensation decisions.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Board encourages shareholders to read the section entitled &#8220;Executive Compensation&#8221; included in this proxy statement, including the tables included therein, to review the correlation between
        compensation and performance.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Board remains committed to sound corporate governance practices and shares the interest of shareholders in maintaining effective executive compensation. The Board believes that our executive
        compensation, which is focused on the Company&#8217;s long-term value, has a proven record of effectively driving the Company&#8217;s performance as a result of the continued leadership of these Named Executive Officers and believes that it will assist us in
        retaining our senior leadership team. Accordingly, we ask our shareholders to approve the compensation of our Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K of the Exchange Act in the section entitled &#8220;Executive
        Compensation&#8221; of this proxy statement, including the compensation tables and the related narrative disclosure, by casting a non-binding advisory vote &#8220;FOR&#8221; the following resolution.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the compensation paid to our Named Executive Officers, as disclosed pursuant to Item&#160;402 of Regulation&#160;S-K,&#160;including the compensation tables and narrative discussion, be, and it
        hereby is, approved.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Proposal Six requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Six, and
        abstentions and broker non-votes have no effect on the outcome of Proposal Six.&#160; As an advisory vote, the result will not be binding on the Board or the Company. The say-on-pay vote will, however, provide us with important feedback from our
        shareholders about our executive compensation philosophy, objectives and program. Our Board and Compensation Committee value the opinions of our shareholders and expect to take into account the outcome of the vote when considering future executive
        compensation decisions and when evaluating our executive compensation program. Following this Annual Meeting, the next advisory vote on named executive officer compensation is expected to occur at the 2026 annual meeting of shareholders, unless the
        Board modifies its policy on the frequency of holding such advisory votes.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">The Board recommends that the shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">45</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span id="PROPOSAL_SEVEN"><!-- anchor --></span>PROPOSAL SEVEN&#160;&#8212; APPOINTMENT AND COMPENSATION OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Background</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Audit Committee has selected Kesselman &amp; Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) as our independent registered public accountants for the fiscal
        year commencing January&#160;1, 2025, and until the next annual meeting of shareholders and approved its compensation, subject to our shareholders&#8217; approval of the Board&#8217;s and Audit Committee&#8217;s authorization to set their compensation. Kesselman &amp;
        Kesselman has served as our principal independent registered public accounting firm for each of the two years ended December 31, 2023 and 2024.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In selecting Kesselman &amp; Kesselman as the Company&#8217;s independent registered public accounting firm for 2025, the Audit Committee considered several factors, including:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:27pt">&#160;</td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif;width:auto">
              <div>The professional qualifications of Kesselman &amp; Kesselman, the lead audit partner, and other key engagement personnel.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:27pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Kesselman &amp; Kesselman&#8217;s independence and its processes for maintaining its independence.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:27pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>Kesselman &amp; Kesselman&#8217;s depth of understanding of the Company&#8217;s business, accounting policies and practices, and internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:27pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>The appropriateness of Kesselman &amp; Kesselman&#8217;s fees for audit and non-audit services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:27pt;font-family:'Times New Roman',Times,serif"><br/>
            </td>
            <td style="width:18pt;vertical-align:top">&#8226;</td>
            <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
              <div>The results of management&#8217;s and the Audit Committee&#8217;s annual evaluations of the qualifications, performance and independence of Kesselman &amp; Kesselman.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We expect a representative of Kesselman &amp; Kesselman to attend the Annual Meeting. The representative will have an opportunity to make a statement if he or she desires and also will be available
        to respond to appropriate questions.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Proposal</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Shareholders are being asked to ratify and approve the selection of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited as our independent registered public
        accountants for the fiscal year ending December 31, 2025, and to authorize the Board and Audit Committee to set the compensation of these auditors. Subject to the shareholders approving such authorization, the Board delegated the authority to set
        the fees of the auditors to the Audit Committee. The Audit Committee pre-approved all services to be performed by, and compensation to be paid to, the auditors as provided for in the U.S. Sarbanes-Oxley Act of 2002 and the rules thereunder.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">&#8220;RESOLVED, that the appointment of Kesselman &amp; Kesselman, a member firm of PwC, an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year
        ending December 31, 2025, be, and it hereby is, ratified and approved, and that the Board (or the Audit Committee, if authorized by the Board) be and hereby is, authorized to determine the compensation of the auditors in accordance with the volume
        and nature of their services.&#8221;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Vote Required</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The proposal requires the affirmative vote of the holders of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast &#8220;for&#8221; than &#8220;against&#8221; for Proposal Seven.
        Abstentions and broker non-votes will have no effect on outcome of Proposal Seven.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">Board Recommendation</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">The Board recommends that the shareholders vote &#8220;FOR&#8221; the adoption of this resolution.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">46</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      </div></div><div><div> <div style="line-height:1.25;font-weight:bold">Fees Paid to Kesselman &amp; Kesselman</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold">Year Ended<br/>
                December 31,</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25">&#160;</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"> 2024</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"> 2023</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:76%;vertical-align:bottom">
              <div style="text-align:justify;line-height:1.25">Audit fees <sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">196,800</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25">157,500</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-align:justify;line-height:1.25">Tax fees<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)</sup></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">5,150</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">6,700</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;vertical-align:bottom">
              <div style="text-align:justify;line-height:1.25">Total fees</div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">201,950</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">$</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">164,200</div>
            </td>
            <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;margin-left:14.2pt;line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">______________________________</sup></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:4.64%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup></div>
            </td>
            <td style="width:95.36%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Includes professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial statements and services related to the
                Company&#8217;s initial public offering and other registration statements.</div>
            </td>
          </tr>
          <tr>
            <td style="width:4.64%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">(2)</sup></div>
            </td>
            <td style="width:95.36%;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="text-align:justify;line-height:1.25">Tax consulting services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold">Audit Committee Pre-approval Policies and Procedures</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Audit Committee is responsible for pre-approving audit and non-audit services provided to us by our independent registered public accounting firm. All of the non-audit services provided to us
        by the independent auditors following the formation of our Audit Committee were pre-approved by the Audit Committee.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">47</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;font-weight:bold"><span id="AUDIT"><!-- anchor --></span>AUDIT COMMITTEE REPORT</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic">The following report of the Audit Committee does not constitute soliciting material and should not be deemed filed with the SEC nor shall this information be incorporated by
        reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, each as amended, except to the extent that the Company specifically incorporates it by reference into a filing.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Our Audit Committee consists of Chair, Gerald M. Ostrov, and members, Yonatan Malca and Sean Ellis. The Board has determined that each Audit Committee member is &#8220;independent,&#8221; as independence for
        Audit Committee members is defined in the applicable Nasdaq listing standards and rules of the SEC. The Board also determined that all members of the Audit Committee are financially literate, and Mr. Ostrov has been designated as an Audit Committee
        financial expert, as such term is defined in Item 407 of Regulation S-K. Although designated as Audit Committee financial experts, the Audit Committee Chair and members are not accountants for the Company nor, under SEC rules, an &#8220;expert&#8221; for
        purposes of the liability provisions of the Securities Act or for any other purpose.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The role of the Audit Committee is to (a) oversee the accounting and financial reporting processes of the Company and the audits of the Company&#8217;s financial statements; (b) oversee the Company&#8217;s
        compliance with legal and regulatory requirements; (c) oversee the performance of the Company&#8217;s internal audit function; (d) take, or recommend that the Board of the Company take, appropriate action to oversee the qualifications, independence and
        performance of the Company&#8217;s independent auditors; and (e) prepare the report required by the rules of the SEC to be included in the Company&#8217;s annual proxy statement.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Audit Committee influences the overall tone for quality financial reporting, sound internal controls, and ethical behavior. Management is responsible for the preparation, presentation and
        integrity of the Company&#8217;s financial statements, for the appropriateness of the accounting and reporting policies that are used by the Company, and for the establishment and effectiveness of internal controls and procedures designed to ensure
        compliance with accounting standards and applicable laws and regulations. The independent auditors are responsible for auditing the Company&#8217;s consolidated financial statements in accordance with the standards of the Public Company Accounting
        Oversight Board (&#8220;PCAOB&#8221;), expressing an opinion as to the conformity of such financial statements with generally accepted accounting principles, expressing an opinion on the effectiveness of internal control over financial reporting, and for
        reviewing the Company&#8217;s interim consolidated financial statements.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The independent auditors report directly to the Audit Committee. The Audit Committee has the sole authority and responsibility to recommend to the Board the nomination of the independent auditors
        for approval by the shareholders on an annual basis. The Audit Committee is directly responsible for the appointment, retention, termination, compensation, retention, evaluation and oversight of the work of the independent auditors for the purpose
        of preparing or issuing an audit report or performing other audit, review or attest services for the Company.</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">48</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:justify;line-height:1.25">In 2024, the Audit Committee routinely met and held discussions with management and Kesselman &amp; Kesselman, the Company&#8217;s independent registered public accounting firm. The Audit Committee
        discussed with management and Kesselman &amp; Kesselman regarding the Company&#8217;s audited consolidated financial statements and policies and procedures designed to reduce the likelihood of events of non-compliance with rules and regulations,
        including discussions of the quality, not just the acceptability, of accounting policies and principles, significant judgments and estimates, system of internal control over financial reporting, and clarity of disclosures, including items reported
        as Critical Auditing Matters in the report of the independent auditor (if required). The Audit Committee reviewed the annual plan and scope of work to be performed by Kesselman &amp; Kesselman, and met outside of the presence of management with
        Kesselman &amp; Kesselman to discuss their respective audit results, evaluations of the Company&#8217;s internal controls, and the overall quality of the Company&#8217;s financial reporting. Consistent with the requirements of the Sarbanes-Oxley Act of 2002
        and the rules promulgated thereunder, the Audit Committee discussed with the Company those matters required to be discussed pursuant to PCAOB Auditing Standard 1301, &#8220;Communications with Audit Committees,&#8221; and the rules of the SEC, and reviewed a
        letter from the Company disclosing such matters.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Audit Committee also discussed with Kesselman &amp; Kesselman the firm&#8217;s independence from the Company and its management team, and reviewed the written disclosures and letter from Kesselman
        &amp; Kesselman pursuant to applicable requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning independence, and considered the compatibility of non-audit services,
        if any, with Kesselman &amp; Kesselman&#8217;s independence.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">Based upon the reports and discussions described above, the Audit Committee, in accordance with its responsibilities, recommended to the Board that the audited consolidated financial statements be
        included in the Company&#8217;s 2024 Annual Report.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">The Audit Committee:</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">Gerald M. Ostrov (Chair)<br/>
        Yonatan Malca<br/>
        Sean Ellis</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">49</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="line-height:1.25;font-weight:bold"><span id="WHERE"><!-- anchor --></span>WHERE TO OBTAIN ADDITIONAL INFORMATION</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We maintain an internet website at https://investors.enterabio.com/. Copies of the committee charters of each of the Audit Committee, Compensation Committee and Nominating and Governance Committee
        can be found under the Company&#160;&#8212; Investors&#160;&#8212; Corporate Governance section of our website, and such information is also available in print to any shareholder who requests it through our Investor Relations department at the address below.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We will furnish without charge to each person whose proxy is being solicited, upon request of any such person, a copy of the 2024 Annual Report as filed with the SEC, including the financial
        statements and schedules thereto, but not the exhibits. In addition, such report is available, free of charge, through the Investors&#160;&#8212; SEC Filings section of our website at https://investors.enterabio.com/.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">A request for a copy of such report should be directed to Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel. A copy of any exhibit to the 2024 Annual Report will be forwarded
        following receipt of a written request with respect thereto addressed to Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem 9122002, Israel.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold"><span id="EXPENSES"><!-- anchor --></span>EXPENSES RELATING TO THIS PROXY STATEMENT</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">We will pay all expenses relating to this proxy solicitation. In addition to this solicitation by mail, our officers, directors, and employees may solicit proxies by personal interview, telephone,
        facsimile, email or other method without extra compensation for that activity. We may also retain an independent contractor to assist in the solicitation of proxies. If retained for such services, we will pay the related costs. We may reimburse the
        reasonable charges and expenses of brokerage houses or other nominees or fiduciaries for forwarding proxy materials to, and obtaining authority to execute proxies from, beneficial owners for whose accounts they hold Ordinary Shares.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold"><span id="STATEMENTS"><!-- anchor --></span>STATEMENTS OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2024</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">In accordance with Section&#160;60(b) of the Israeli Companies Law, shareholders are invited to discuss the audited Consolidated Financial Statements of the Company for the year ended December&#160;31, 2024.
        The 2024 Annual Report, including our audited Consolidated Financial Statements, is available on the Investors section of our website, at https://investors.enterabio.com. as well as at<span style="font-style:italic">&#160;</span><span style="font-weight:bold;font-style:italic">www.voteproxy.com.</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">No vote is required regarding this item.</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-weight:bold"><span id="OTHER"><!-- anchor --></span>OTHER BUSINESS</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25">The Board knows of no other business to be brought before the Annual Meeting. If, however, any other business should properly come before the Annual Meeting, the persons named as proxies will vote
        in their discretion as they may deem appropriate. </div>
      <div style="text-align:justify;line-height:1.25"> <br/>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

            <tr>
              <td style="width:50.00%"><br/>
              </td>
              <td style="width:50.00%">By order of the Board of Directors, </td>
            </tr>
            <tr>
              <td style="width:50.00%"><br/>
              </td>
              <td style="width:50.00%"><br/>
              </td>
            </tr>
            <tr>
              <td style="width:50.00%"><br/>
              </td>
              <td style="width:50.00%">/s/ Gerald Lieberman</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
              <td rowspan="1" style="width:50.00%">Gerald Lieberman</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
              <td rowspan="1" style="width:50.00%">Chairman of the Board</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width:50.00%">June 5, 2025</td>
              <td rowspan="1" style="width:50.00%"><br/>
              </td>
            </tr>

        </table>
      </div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="width:100%">
          <div>
            <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;Entera Bio Ltd.&#160;| 2025 Annual Meeting Proxy Statement</div>
          </div>
        </div>
        <div style="text-align:center"><span style="font-weight:normal;font-style:normal">50</span></div>
        <div style="page-break-after:always">
          <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/></div>
      </div>
      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="text-decoration:underline">APPENDIX A</span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold">ENTERA BIO LTD.</div>
      <div style="text-align:center;line-height:1.25;font-weight:bold">DIRECTORS AND OFFICERS COMPENSATION POLICY</div>
      <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif"> <!-- Field: Include-Text; File: PF\annex_card.htm; Date: 2025%2D05%2D28T15:25:37; Size: 0x000382D8; Options: XMLPreprocess -->
<div>

<div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.95pt; line-height: 1.25; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">PURPOSE</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 20.2pt; line-height: 1.25">This document is designed to determine,
describe and detail the policy of Entera Bio Ltd. (the &#8220;<span style="font-weight: bold">Company</span>&#8221;) with respect to the
Terms of Office and Employment of the Company's Office Holders (as defined hereunder), its components and the manner in which they are
determined, inter alia, in accordance with the provisions of the Israeli Companies Law, 5759-1999, or "<span style="font-weight: bold">Companies
Law</span>" (the &#8220;<span style="font-weight: bold">Compensation Policy</span>&#8221; or &#8220;<span style="font-weight: bold">Policy</span>&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">DEFINITIONS</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.25pt; margin-left: 20.2pt; line-height: 1.25">&#8220;<span style="font-weight: bold">Office
Holders</span>&#8221; - as such term is defined under the Companies Law, including members of the Company's board of directors, or the
Company's general manager, chief executive officer (CEO), a deputy chief officer, chief financial officer, and any person holding such
position in the Company, irrespective of his or her title, and also any manager who reports directly to the CEO of the Company (i.e.,
C-level officers).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 7.75pt; margin-left: 20.2pt; line-height: 1.25">&#8220;<span style="font-weight: bold">Officers</span>&#8221;
- the Company's general manager, CEO, a deputy chief officer, chief financial officer, and any person holding such position in the Company,
irrespective of his or her title, and also any manager who reports directly to the CEO of the Company (i.e., C-level officers).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-right: 206.3pt; margin-left: 20.2pt; line-height: 1.25">&#8220;<span style="font-weight: bold">Directors</span>&#8221;
- members of the Company's board of directors.</div>

<div style="margin-left: 20.2pt; line-height: 1.25">&#8220;<span style="font-weight: bold">Terms of Office and Employment</span>&#8221;
of Office Holders &#8211; as such term is defined under the Companies Law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 20.2pt; line-height: 1.25">Terms not otherwise defined herein shall
have the meaning ascribed to them in the Companies Law, unless the context dictates otherwise. To the extent any provision herein conflicts
with the conditions of any applicable law, the provisions of such applicable law shall prevail over this Policy, and the Company's board
of directors (the &#8220;<span style="font-weight: bold">Board</span>&#8221;) is empowered hereunder to interpret and enforce such prevailing
provisions. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">CONSTRUCTION; EFFECT</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 20.2pt; line-height: 1.25">This Compensation Policy shall take effect
as of the date of its approval by the general meeting for three years, in accordance with the provisions of the Companies Law (the &#8220;<span style="font-weight: bold">Effective
Date</span>&#8221;), and shall apply to the Terms of Office and Employment of Office Holders that are approved following the Effective
Date.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.95pt; margin-left: 20.2pt; line-height: 1.25">This Policy shall not apply, shall have
no effect with respect to, or derogate from, any Terms of Office and Employment of any Office Holder which are in effect prior to the
Effective Date.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 20.2pt; line-height: 1.25">Nothing in this Policy shall confer upon
any person, including, any Office Holder, any rights, entitlements, benefits or remedies whatsoever, including any right or entitlement
to any compensation, remuneration or benefits of any kind or nature. The Terms of Office and Employment of an Office Holder shall only
be as set in an agreement between such Office Holder and the Company or in a written undertaking of the Company or in a resolution of
the Company's Compensation Committee, Board and shareholders (to the extent shareholder approval is required by law) setting forth the
Terms of Office and Employment and their applicability to the relevant Office Holder.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 6.3pt; margin-left: 20.2pt; line-height: 1.25">The provisions of this Policy determine,
inter alia, the framework for various components of compensation. Any deviation from this Compensation Policy shall be subject to the
approval of the Company&#8217;s Compensation Committee, Board and shareholders, to the extent required by law. However, if the applicable
corporate organs of the Company determine, with respect to a specific Office Holder, that such Office Holder is entitled to compensation
components that are inferior to those indicated herein, such shall not be deemed as deviation from the Compensation Policy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.15pt; margin-left: 20.2pt; line-height: 1.25">To the extent that after the Effective
Date a relief is granted as to the mandatory or minimum requirements prescribed by applicable law to be included in a Compensation Policy,
or any limitation contained in this Policy is more stringent than that required by applicable law, then such relief or less stringent
limitation shall be deemed incorporated by reference into this Policy notwithstanding anything else to the contrary, unless otherwise
determined by the Board.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top; font-weight: bold">4.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">GENERAL BACKGROUND</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">4.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Objectives</div> </td> </tr>
  </table> <br/>

<div style="text-align: justify; margin-right: 6.15pt; margin-left: 38pt; line-height: 1.25">This Compensation Policy is designed to promote
and advance the Company's long-term objectives, work plans and&#160; policy, and&#160; to&#160; create appropriate incentives subject
to any law, taking into consideration, inter alia, the Company&#8217;s risks management policy, in&#160; view of the Company's size, the
nature of its activities and its financial state.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 38pt; line-height: 1.25">In support of this goal, compensation practices,
including variable compensation, for the Company's Office Holders, are designed to meet the following objectives:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 33.45pt; vertical-align: top">4.1.1.</td>
    <td style="width: auto; vertical-align: top">
        <div>Improve business results and strategy implementation, and support the Company&#8217;s work-plans, from a long-term perspective;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 32.8pt; vertical-align: top">4.1.2.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Align Officers&#8217; and Directors' interests with those of the Company and its shareholders and incentivize Officers and Directors
        to create long- term economic value for the Company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 32.8pt; vertical-align: top">4.1.3.</td>
    <td style="width: auto; vertical-align: top">
        <div>Create motivation for Office Holders to attain a high level of business achievements without taking unreasonable risks;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 32.8pt; vertical-align: top">4.1.4.</td>
    <td style="width: auto; vertical-align: top">
        <div>Create a clear line-of-sight between Officers&#8217; and Directors' compensation and both Company and individual performance;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 32.8pt; vertical-align: top">4.1.5.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Establish an appropriate balance between the various compensation components - fixed vs. variable compensation, quantitative and
        measurable components vs. discretionary components, short-term vs. long-term components, compensation in cash vs. equity-based compensation
        and benefits and perquisites, to ensure sustained business performance over time; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 32.8pt; vertical-align: top">4.1.6.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Utilize market benchmark compensation tools to ensure our Officers and Directors are compensated fairly and best practices are implemented.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">4.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Primary Bodies Involved in Determining the Compensation Policy for Office Holders</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 38pt; line-height: 1.25">The parties involved in determining the Company's Compensation
Policy are:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The Compensation Committee &#8211; (i) makes recommendations
        to the Board regarding the approval of the Compensation Policy for Office Holders and any extensions and updates to the Policy to the
        extent required; (ii) approves the Terms of Office and Employment of Office Holders; and (iii) subject to certain requirements prescribed
        by the Companies Law, may determine to exempt a transaction from shareholder approval.</div>
        <div style="font-family: Times New Roman,Times,serif">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Board of directors &#8211; (i) approves the Compensation Policy for Office Holders; (ii) periodically reviews the Compensation
        Policy; and (iii) is responsible for updating it as and when necessary.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The General Meeting (shareholders) - approves the Compensation Policy, as required by law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.85pt; margin-left: 38pt; line-height: 1.25">The Compensation Committee and the Board
shall review this Compensation Policy from time to time, as required by the Companies Law. This Compensation Policy shall be brought for
reconsideration and re-approval, as required by the Companies Law (currently, every three years).</div>

<div style="line-height: 1.25">

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25"> <br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 2<br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">4.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Business Environment and its Impact on Compensation of Office Holders</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.2pt; margin-left: 38pt; line-height: 1.25">The Company's Compensation Policy was designed,
inter alia, to ensure the Company's ability to recruit and retain the highly talented Office Holders with appropriate qualifications,
in accordance with and subject to the objectives of the Compensation Policy set forth in Section 4.1, including the promotion of the Company's
goals in the long-term.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top; font-weight: bold">5.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">OFFICE HOLDER&#8217;S COMPENSATION IN VIEW OF COMPANY VALUES AND BUSINESS STRATEGY</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">5.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Compensation According to the Office Holder&#8217;s Characteristics and Experience</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.85pt; margin-left: 38pt; line-height: 1.25">Office Holder's Terms of Office and Employment
shall be determined, for each of the various compensation components, while taking into account the Office Holder&#8217;s education, skills,
qualifications, expertise, professional experience and accomplishments, as well as the Office Holder's position, areas and scope of responsibilities
and his or her prior compensation agreements.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">5.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Ratio Between Office Holders Compensation and Compensation of Other Company Employees</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.6pt; margin-left: 38pt; line-height: 1.25">Nevertheless, since the Company employs a
relatively small number of employees most of whom have unique professional expertise, the Company attaches importance to the creation
of appropriate compensation for all of its employees and in preserving reasonable gaps between the overall cost of the Terms of Office
and Employment of Office Holders and the overall cost of salary (including any payment or benefit) of the other Company employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.15pt; margin-left: 38pt; line-height: 1.25">In determining the Terms of Office and Employment
of Office Holders, the Compensation Committee and the Board will examine, inter alia, the ratio between the overall Terms of Office and
Employment of Office Holders and the average and median salary of the Company's employees and contractors other than the Company's Office
Holders, as well as the possible ramifications of such ratio on the work environment in the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 38pt; line-height: 1.25">The Compensation Committee and the Board
have examined the current ratio, and believe that this ratio is appropriate and reasonable, taking into account the size and nature of
the Company, its value, scale of business, the mixture of manpower, its field of business and its ramifications on the work environment
of the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">5.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Relationship Between the Company's Business Results and Office Holders Compensation</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">The Company's policy is that the overall
Terms of Office and Employment for Officers should be considerably influenced by its business results as well as the individual contribution,
responsibility and&#160; professional&#160; expertise of each&#160; Officer to&#160; the achievement&#160; of these results. The influence
of the business results and the individual contribution on the compensation shall increase the higher the Office Holder's position is.
In accordance, the higher the position is, the weight of the variable compensation that is performance based in relation to the overall
Terms of Office and Employment shall increase, all as specified in Section 4.2 below.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top; font-weight: bold">6.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">PRIMARY CONCEPTS OF THE COMPENSATION POLICY</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">6.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Overall Compensation Concept</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">The Company's Compensation Committee and
Board believe that the overall compensation of each employee, and in particular of Office Holders, should be comprised of a number of
different components, such that each element rewards the employee for a different element of his or her contribution to the Company, thus
achieving the objectives of the Company's Compensation Policy:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Base salary </span>- designed to partially reward the Office Holder for his or her devotion and contribution
        to the performance of his or her role and the daily performance of his or her tasks. The base salary takes into account the Office Holder's
        skills, experience, expertise, education, professional qualifications etc., and the requirements of the role and the responsibilities
        and authorities it carries.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 3<br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Benefits and perquisites </span>- some of which are mandatory according to law (such as pension,
        severance pay, vacation days, sick&#160; leave, recuperation pay, etc.), some of which are common market practice (such as health insurance,
        further education funds, all which&#160; may&#160; have certain tax benefits for the employee and the Company) and others are designed
        to compensate the employee for expenses incurred in fulfilling the position (such as car lease, travel expenses, phone, etc.).</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Variable performance-based awards (e.g. annual bonus) </span>- designed to reward the Office Holder
        for his or her achievements and contribution to attaining the Company's goals during the course of the period for which the variable compensation
        is paid and to supplement the base salary. The weight of variable performance-based compensation in relation to the overall compensation
        shall increase the higher the Officer&#8217;s position is.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Equity-based compensation </span>- designed to link long-term shareholder returns and the compensation
        of Office Holders of the Company. Equity- based compensation creates a correlation between the interests of employees and Office Holders
        and the interests of the&#160; Company&#8217;s shareholders, and assists in creating motivation and in retaining the key personnel in
        the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">6.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Ratio Between Variable and Fixed Components of the Compensation Package</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 38pt; line-height: 1.25">The rate of the annual variable components
(including, without limitation, cash bonuses, performance-based awards and equity-based awards) of the Office Holders overall annual compensation
package (comprised of the base salary and variable components) shall not exceed the 80% of the Office Holder's total compensation package.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 38pt; line-height: 1.25">A deviation of up to 10% of these terms shall not constitute a deviation or deflection
from the compensation policy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.15pt; margin-left: 38pt; line-height: 1.25">Note that this refers to the planned ratio
only, assuming the receipt of the target bonus as stated in this policy. The actual ratio between the components of the compensation package,
in a given year, may be different due to underperformance or overachievement impacting the variable compensation, as stated in this Policy.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">6.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Market comparison (benchmark)</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 38pt; line-height: 1.25">To determine the salary for the recruitment
of our new Office Holders, a comparison shall be made of the acceptable salary in the market for similar positions in companies similar
to the Company (&#8220;<span style="font-weight: bold">Peer Group</span>&#8221;). For purposes of the foregoing comparative studies, companies
meeting the following characteristics shall be selected:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Companies operating in the field of biotech, pharmaceutical, drug development or other related fields;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Israeli companies whose shares are traded on the NASDAQ Stock Market or NYSE to the extent practicable, based in Israel, and preferably,
        with officers residing in the US; <span style="font-weight: bold">if the number of such companies is lower than 10, the Peer Group may
        also include US companies</span>; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.35pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Companies of similar size in the following financial dimensions: market cap, shareholder equity, balance sheet, sales turnover, operating
        profit and/or net profit, as provided in the most updated published information or the Company's last annual report.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 38pt; line-height: 1.25">The Company shall make reasonable efforts to include at least 10 companies in the Peer
Group (but in no event less than 5 companies).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 38pt; line-height: 1.25">The comparative study shall address all the components of the compensation package and
shall include (to the extent the information is available):</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the acceptable range of base salaries for similar positions (including the split within the range);</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the acceptable range for annual bonuses;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the acceptable range for equity-based compensation; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.3pt"><br/> </td>
    <td style="width: 14.65pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the benefits and perquisites that are acceptable in the market.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 4</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 14.6pt; vertical-align: top; font-weight: bold">7.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">COMPENSATION COMPONENTS</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">7.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Base Salary</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 21pt; vertical-align: top">7.1.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Determination of the base salary for Officers</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 64.65pt; line-height: 1.25">The base salary for an Officer shall be
determined during the course of negotiations for his or her employment in the Company, which shall be conducted by the person who shall
directly supervise the Officer (for the CEO - the chairman of the Board, for any other Officer - the Company's CEO, or whoever is appointed
on behalf of the chairman or CEO for such purposes). The Officer&#8217;s intended supervisor may determine the base salary within the
range determined in the directives of this policy (as detailed in the following table in Section 7.1.1.3 below) and the salary shall be
brought before the relevant Company organs for approval, as required by law.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 64.65pt; line-height: 1.25">In determining the base salary, the Office
Holder&#8217;s characteristics and experience, as provided in Section 5.1 above, shall be taken into consideration, as well as the acceptable
salary conditions for similar positions in Peer Group companies, as other companies which compete with the Company for similar talents.
The Company's financial state and cash position at the time of recruitment shall also be taken into consideration.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 64.65pt; line-height: 1.25">The base salary shall also be subject
to any requirements or restrictions prescribed by the Companies Law, U.S. securities laws, NASDAQ rules, any other applicable law from
time to time, and (with regard to U.S. based Officers) evolving best practices among shareholder advisory and institutional investor groups.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 64.65pt; line-height: 1.25">The Company believes that the emphasis
of its Compensation Policy should be on performance based compensation, and therefore, the Company's policy is to determine a base salary
which is targeted at the median salary in the relevant market for similar positions (including in Peer Group companies), alongside variable
performance based compensation and long-term compensation components that will bring the Officer&#8217;s overall compensation to a level
which will allow the Company to recruit and retain the highly talented management personnel it requires for continuation of its success.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.95pt; margin-left: 64.65pt; line-height: 1.25">Since Officers hold management positions
within the meaning of the Hours of Work and Rest Law, 5711-1951, Officers shall not be entitled to compensation for overtime work or work
on the day of rest.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.1.1.1.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="text-decoration: underline">Internal comparison</span> - in determining the salary for the recruitment of a new Officer,
        the following considerations shall be taken into account, as well as their potential impact on the Company&#8217;s labor relations as
        a whole and within the management team:</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The gap between the proposed salary of the Officer and the salary of the other Officers of the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The ratio between the proposed salary of the Officer and the salary of the other employees of the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>If there are Officers with similar positions in the Company - the gap between the proposed salary of the Officer and the salary of
        Officers in similar positions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The geographical location of the Officer.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.1.1.2.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="text-decoration: underline">Geographical Location</span> - To the extent necessary, the Company may employ an Officer
        outside of Israel. In such case, the process of determination of his or her salary, shall be adjusted to the country where such Officer
        is employed. In the event that the salary of Officers who are candidates for employment abroad deviates from this policy, the salary shall
        be considered as deviating from this Policy and shall be subject to the approval process required for compensation in deviation from the
        Policy.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 5</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageHeader">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.1.1.3.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">The maximum amount of monthly salaries for Company's Officers shall be:</span></div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 117pt">

<table cellspacing="0" cellpadding="1" border="0" style="font: 10pt Times New Roman,Times,serif; width: 70%; color: rgb(0, 0, 0); text-align: left">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 31.89%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 1.15pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Rank</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 68.11%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; margin-right: 88.85pt; margin-left: 89.9pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Maximum</div>
        </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 31.89%; vertical-align: top; background-color: rgb(204, 237, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 1.15pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">CEO</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 68.11%; vertical-align: top; background-color: rgb(204, 237, 255); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; margin-right: 88.85pt; margin-left: 89.7pt; line-height: 1.25; font-family: Times New Roman, Times, serif">$50,000</div>
        </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 31.89%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 1.15pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">C-level Officers</div>
        </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 68.11%; vertical-align: top">
        <div style="text-align: center; margin-right: 88.85pt; margin-left: 89.7pt; line-height: 1.25; font-family: Times New Roman, Times, serif">$35,000</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top">
        <div>
        <div style="line-height: 1.25">A deviation of up to 10% above and below the ranges detailed in the table shall not constitute deviation
        from the Compensation Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">The base salaries of the Company's Officers shall be linked to the Consumer Price Index (or a similar index
        customary in the country in which the employee is located, if not Israel).</div> </div> </td> </tr>
  </table> </div> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 21pt; vertical-align: top">7.1.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Periodical review and update of salary</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 64.65pt; line-height: 1.25">In order to retain Office Holders other
than non-employee and non-executive Directors, such Office Holders' base salary shall be reviewed annually by the Compensation Committee
and the Board, taking into consideration the challenges of the given year and the following year, the complexity of such&#160; Office
Holders&#8217; roles, their scope and importance to the Company's performance - all based upon the Company's resources and in comparison
to the acceptable salary for similar roles in the relevant market. To the extent necessary, a proposal regarding an increase to all or
any of the Office Holders' salaries shall be prepared and brought before the Company's relevant organs for approval, as required by law.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">7.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Variable Compensation</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 38pt; line-height: 1.25">Variable compensation components are intended to achieve, inter alia, the following
objectives:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.95pt"><br/> </td>
    <td style="width: 14pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>To link Office Holders' compensation to the Company's achievement of business goals and targets and the maximization of its profits,
        with a long-term view and in accordance with the office holder's position, and align Office Holders&#8217; interests with those of the
        Company and its shareholders.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Increase the Officers' motivation to attain a high level of business achievements without taking unreasonable risks.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 39.2pt"><br/> </td>
    <td style="width: 12.75pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Correlating some of the Company's payroll costs with its performance and enhancing its financial and operational flexibility.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 6</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 21pt; vertical-align: top">7.2.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Annual bonus</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 64.65pt; line-height: 1.25">The Company's Officers shall be entitled to an annual bonus, based upon the annual
bonuses plan, which shall be brought before the Compensation Committee and the Board for approval.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.1.1.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Principles</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="text-align: justify; line-height: 1.25">Annual bonuses for Officers shall be calculated according to an annual bonus plan,
        to the extent it is determined and approved by the Company's Compensation Committee and Board, at the beginning of each calendar year
        for which the bonus is paid. The annual bonus plan shall be comprised of the following provisions:</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Payment thresholds, based on one or more quantitative financial Company performance measure(s) during the year for which the bonus
        is paid (such as capital investments, cash balance relative to equity, obtaining approval from the authorities in the target markets,
        and other quantitative performance measures suitable to the company). The Compensation Committee and the Board shall determine the measure
        according to the Company's targets for the bonus year, based on the Company's short and long term objectives. If an Officer does not meet
        the threshold performance measures in a given calendar year, calculated on a weighted average basis, he or she will not be entitled to
        an annual cash bonus. The lower percentage threshold is 75 % for each Officer. The Compensation Committee and the Board may determine
        that in respect of any specific year, all or any particular Officer or Officers shall not be entitled to any annual bonus.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Target bonus for each Officer - the target bonus is the annual cash bonus amount to be paid to an Officer upon achievement of 100
        % of the Officer's performance measures. The target bonus shall be set in monthly employer salary cost multiplier terms. A target&#160;
        bonus shall be identical for each Officer of a particular rank and <span style="font-weight: bold"><span style="text-decoration: underline">shall
        not exceed</span>&#160;</span>the following:</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 117pt">

<table cellspacing="0" cellpadding="1" border="0" style="font: 10pt Times New Roman,Times,serif; width: 70%; color: rgb(0, 0, 0); text-align: left">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 41.93%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; margin-right: 55.3pt; margin-left: 56.7pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Rank</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 58.07%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-indent: -60.95pt; margin-left: 71.9pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Target
        bonus (multiplier of monthly employer salary cost )</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 41.93%; vertical-align: top; background-color: rgb(204, 237, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 1.15pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">CEO</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 58.07%; vertical-align: top; background-color: rgb(204, 237, 255); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 89.05pt; line-height: 1.25; font-family: Times New Roman, Times, serif">12</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 41.93%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 1.15pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">C-level Officers</div>
        </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 58.07%; vertical-align: top">
        <div style="margin-left: 89.05pt; line-height: 1.25; font-family: Times New Roman, Times, serif">10</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Maximum bonus (in terms of a salary multiplier) is the maximum annual cash bonus to be paid to an Officer upon achievement of 125
        % of the Officer's performance measures. The maximum bonus (bonus cap) for all Officers shall be 18 times the applicable monthly base
        salary ;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The measures according to which the bonus shall be calculated for each Officer and their relative weights, in accordance with Section
        7.2.1.2 below;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The performance measures and targets, for the bonus year.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 7</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.1.2.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Determining the bonus plan performance measures and targets</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="text-align: justify; line-height: 1.25">Personal targets and performance measures shall be determined by the Compensation
        Committee and the Board for the CEO, and by the CEO for each of the other Officers of the company. The Officer's performance shall be
        measured according to such personal targets and performance measures. A weight shall be assigned to each measure for determining the annual
        bonus for each Officer, and the bonus paid to the Officer shall be determined in accordance with the weighted percentage of meeting the
        targets, as described below. There shall be three main categories of performance measures for each Officer:</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Company measures - economic or strategic quantitative measures, relating to the Company's performance (capital investment, cash balance
        relative to equity, obtaining approval from the authorities in the target markets and other quantitative performance measures suitable
        to the company). These measures shall be the same for all Company Officers, and shall determine up to 40% of the total bonus of the Company's
        Officers.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Personal measures - quantifiable and measurable key performance indicators (KPIs) shall be determined for each Officer separately,
        according to his or her position. These measures shall determine up to 40% of the total bonus of the Company's Officers. The goals for
        each Officer's personal measures shall be based, to the extent possible, on performance focusing on the long-term view.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Managerial appraisal - an evaluation of each Officer&#8217;s performance in non-measurable terms. The managerial appraisal shall
        determine up to 20% of the total bonus of any Officer, including the CEO. At the beginning of each year, qualitative measures shall be
        determined on the basis of which the appraisal of each Officer shall be made.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The targets in the personal and managerial measures of each Officer shall be determined
        in accordance with the work plan targets for the bonus year.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 94.45pt; line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.1.3.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Determination of the bonus budget</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="line-height: 1.25">The total annual budget for the bonuses of Company's Officers shall be determined according to the sum
        of the maximum bonuses of all Officers.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.1.4.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Bonus calculation mechanism</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="text-align: justify; line-height: 1.25">The bonus for each Officer shall be calculated based on the achievement of the targets
        determined for each Officer for the bonus year.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25">The bonus for meeting each of such targets will be made on the basis of a pro-rata
        allocation of the Officers' bonus cap in accordance with the respective weight of each target, subject to the "payment line" formula determined
        in the annual bonus plan for Officers, which shall be multiplied by the target bonus (the personal bonus) of the Officer for the purpose
        of calculating the actual bonus.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25">The &#8220;payment line&#8221; shall determine:</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The performance threshold, up to which the Officer shall not be paid any bonus whatsoever, as stated above.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The percentage of the target bonus which shall be paid in achieving the lower performance threshold;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>A maximum bonus, as stated above.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Calculation of the target bonus percentage for each level of performance between the above-mentioned points
        shall be made by a linear method.</div> </div> </td> </tr>
  </table> </div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 94.45pt; line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 8</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.1.5.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">The approval process for the actual bonus</span></div> </td> </tr>
  </table>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">At the end of each year, the extent of meeting targets by each of the Officers shall be determined. The
        extent of meeting targets of the Officer shall be translated into a rate of target bonus, according to the payment line formula.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">The Compensation Committee and the Board shall have the right to reduce the Officers' annual bonus at their
        discretion, due to circumstances determined by the Compensation Committee and the Board.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">The annual bonuses approved by the Compensation Committee and the Board shall be paid to the Officers with
        the first monthly salary paid after the approval of the annual bonuses by the Board.</div> </td> </tr>
  </table> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 21pt; vertical-align: top">7.2.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Special bonus</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 64.65pt; line-height: 1.25">The Company's Compensation Committee and
Board shall be authorized to award any of the Company's Officers a one-time special bonus (which is only based on non-measurable criteria)
of up to an amount equal to a six month base salary (in addition to the annual bonus), in recognition of a significant achievement or
for completion of an assignment, such as completion of a major transaction or achieving a major milestone with material effect over the
Company's business, subject to applicable law. Such bonus is individual for any Officer and should be approved by the Company&#8217;s
Compensation Committee and Board. Notwithstanding the aforesaid, the Company shall be authorized to award a special cash bonus which is
only based on non-measurable criteria, only if the annual value of such bonus does not exceed an aggregate three months base salary, subject
to applicable law.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 21pt; vertical-align: top">7.2.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Equity-Based Compensation</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 64.65pt; line-height: 1.25">The Company's Compensation Committee and
Board believe that as part of the Office Holders' total compensation package, it is appropriate to offer a component of equity-based compensation,
as customary by companies whose shares are publicly listed on the NASDAQ Stock Market or any other stock exchange, for the purpose of
advancing the interests of the Company's shareholders by enhancing the Company's ability to attract, retain and motivate individuals to
perform at the highest level. By virtue of the long-term nature of equity-based compensation plans, they support the Company's ability
to retain senior managers in their position for the long term.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 64.65pt; line-height: 1.25">In view of the advantages of equity-based
compensation plans, the Company shall offer its Office Holders, including directors (subject to the provisions of the Compensation Regulations),
participation in an equity-based compensation plan according to the provision set forth below:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.3.1.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Equity Incentive Plan</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="text-align: justify; line-height: 1.25">Subject to the approval of the Company's competent organs, as prescribed by law, the
        Company may offer Officers and Directors participation in an equity-based compensation plan (&#8220;<span style="font-weight: bold">Equity
        Incentive Plan</span>&#8221;), which may&#160; include&#160; options to&#160; purchase&#160; shares, share appreciation rights, restricted
        shares, restricted share units, performance awards or other share-based awards (herein described collectively as &#8220;<span style="font-weight: bold">Awards</span>&#8221;).
        The Equity Incentive Plan may provide for granting Awards in compliance with Section 102 of the Israeli Income Tax Ordinance, 5721-1961
        in the "capital gains track", as applicable.</div>
        <div style="line-height: 1.25"><br/> </div>
        <div style="text-align: justify; line-height: 1.25">The Equity Incentive Plan, shall include the following:</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The maximum number of securities available for issuance under equity incentive awards, and the dilution rate resulting from grants;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The method of allocating the grants among grantees;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Reserve pool for grants to Office Holders who may join the Company in the future, during the course of the term of the plan;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 9</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The vesting conditions for grants under the Equity Incentive Plan will be determined by the administrator and, in the case of restricted
        shares and restricted share units, will be set forth in the applicable Award&#160; documentation.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Options and share appreciation rights will have an exercise price determined by the administrator, that is no less than fair market
        value of the underlying ordinary shares on the date of grant, and subject to applicable law, unless otherwise approved by the Company&#8217;s
        shareholders from time to time;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The expiration date of the Awards - up to 10 years from the date of grant; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Terms upon termination of employment or service (due to dismissal, resignation, death or disability) and change of control. The Equity
        Incentive Plan shall include a definition of a change of control, and&#160; the actions the Compensation&#160; Committee may&#160; take
        in the event of a change of control with respect to awards outstanding. In the event of a structural change of the Company (i.e., a transaction
        in which the Company's shares immediately prior to the transaction are converted into or exchanged for shares that represent at least
        a majority of the share capital of the surviving corporation, such as a re-domestication of the Company&#160; or a share flip), outstanding
        awards will be exchanged or converted into awards to&#160; acquire shares of the Company&#160; (if it is the surviving corporation) or
        the successor company in accordance with the applicable exchange ratio.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.3.2.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Grants</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top">
        <div>
        <div style="text-align: justify; line-height: 1.25">Awards shall be granted to Office Holders of the Company in accordance with the terms
        of the approved Equity Incentive Plan, subject to the approval process required pursuant to the Companies Law.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25">When a new Office Holder joins the Company during the course of a plan, and granted
        an Award, such Award shall be granted out of the reserve determined in the Equity Incentive Plan.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25">Awards shall be granted from time to time and be individually determined and awarded,
        inter alia, according to the following considerations:</div> </div> </td> </tr>
  </table> </div> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Office Holder's contribution to the Company's performance;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Office Holder's ability to influence the Company's future and performance;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The mix of compensation components to which the Office Holder is entitled and the desired mix of Awards;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Office Holder's performance, skills, qualifications, experience, role and personal responsibilities; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 109pt"><br/> </td>
    <td style="width: 11.5pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The desired competitive levels and dilution or pool limits.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 10</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 64.6pt"><br/> </td>
    <td style="width: 43.4pt; vertical-align: top">7.2.3.3.</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="text-decoration: underline">Maximum Value of Equity-Based Compensation</span></div>
        <div><span style="text-decoration: underline"> <br/> </span></div>
        <div>
        <div style="line-height: 1.25">The maximum value of equity-based compensation for all Officers, as of the grant date, shall be up to 25
        monthly base salaries.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">7.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Additional Benefits and Perquisites</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.95pt"><br/> </td>
    <td style="width: 34.05pt; vertical-align: top">7.3.1.</td>
    <td style="width: auto; vertical-align: top">
        <div>Benefits and perquisites (such as medical and health insurance, life insurance, savings, provident fund, vacations and sick days)
        may be granted to Officers in order, among other things, to comply with legal requirements (compensation packages may vary &#8211; based
        on the residence of the Company's Officers &#8211; US or Israel).</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.6pt"><br/> </td>
    <td style="width: 33.4pt; vertical-align: top">7.3.2.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The Company may offer additional benefits and perquisites to Officers, which will be comparable to customary market practices, such
        as, but not limited to: company car benefits; company cellular phone; meals; etc.; provided however, that such additional benefits and
        perquisites shall be determined in accordance with the Company's policies and procedures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.95pt"><br/> </td>
    <td style="width: 34.05pt; vertical-align: top">7.3.3.</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The Company may determine in its contractual engagement with the Officer that it would bear part, or all, of the expenses incurred
        by the Officer for the discharge of his or her duties, in accordance with the terms of the Company's policy in this regard.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; text-align: center">A - 11</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">8.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">TERMINATION OF OFFICE CONDITIONS</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">8.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Advance Notice</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">An Officer shall be entitled to an advance
notice period, in accordance with and subject to the provisions of the employment agreement and/or contractual engagement entered between
the Officer and the Company, and in the absence of an advance notice provision in such agreement or engagement, as determined by applicable
law. In any event, the advance notice period shall not exceed four months. During the course of the advance notice period, the Officer
shall be required to continue to fulfill his or her position, unless the CEO (and in respect of the CEO, the Board) decides to release
him or her from this obligation, and he or she shall be entitled to the continuation of all Terms of Office and Employment without change,
during such period, with the exception that equity awards continuation shall be subject to the terms of the Equity Incentive Plan.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">8.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Severance Payment</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">Officers shall be entitled to a severance
payment (other than termination under circumstances which deprive the Officers of severance pay under Israeli law) of up the greater of
(i) the minimum amount required under applicable law; (ii) any amount provided under the Officer's employment agreement and/or contractual
engagement, entered into prior to the Effective Date of this Policy; and (iii) a cap of two times the Officer's monthly salaries per each
year of service.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">8.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Retirement and Termination Awards</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 38pt; line-height: 1.25">As a general rule, no retirement and termination
awards shall be determined in the Officers' personal employment agreements. The Compensation Committee and the Board (and as required
by law, the shareholders), may approve a retirement award to Officers, in an amount not exceeding the following maximum amounts:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Employed by the Company as Officer for up to five years: up to 3 monthly base salaries.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Employed by the Company as Officer for five years or more: up to 6 monthly base salaries.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 6.15pt; margin-left: 38pt; line-height: 1.25">The retirement bonus may be granted after
examining the Terms of Office and Employment during the Officer's employment period and the Company&#8217;s performance during such period,
and may be approved in one or more of the following cases</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Certain change of control related cases;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>During his or her employment period the Officer has made a special contribution to the advancement of the Company&#8217;s business
        as shall be determined by the Compensation Committee;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.55pt"><br/> </td>
    <td style="width: 13.4pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>In respect of any Officer other than the CEO, the CEO has recommended granting a retirement bonus.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 38pt; line-height: 1.25">Retirement bonus, if such is approved, shall
be paid upon termination of employment relationship and shall be equal to the months approved multiplied by the (gross) base salary to
which the Officer was entitled upon termination of his or her employment with the Company. Retirement bonus for Officer other than the
CEO shall not include associated benefits. The retirement bonus for the CEO shall include accompanying benefits in accordance with the
CEO&#8217;s employment agreement.</div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 38pt; line-height: 1.25"> <br/> </div> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 12</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">8.4.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Non-Competition</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.5pt; margin-left: 38pt; line-height: 1.25">Officers shall undertake in writing, at the
time they enter into an employment agreement with the Company, to refrain from competing with the Company in accordance with and&#160;
subject to&#160; the provisions of the employment agreement and/or contractual engagement entered&#160; between&#160; the Officer and
the Company. The non-competition provision applies for a period which is generally not less than 12 months following termination of employment.
We have entered into written employment agreements with all of our Officers who are employed in the Company at the date of publication
of the Policy. Each of these agreements contains provisions regarding confidentiality, non-competition/non-solicitation&#160;&#160; and&#160;&#160;
ownership of intellectual property.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">9.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">NON-EXECUTIVE DIRECTORS' COMPENSATION</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.2pt; margin-left: 20.2pt; line-height: 1.25">The Company aims to attract and retain talented
directors with excellent educational background, qualifications, skills, expertise, professional experience and achievements, by providing
a fair and competitive compensation program.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.2pt; margin-left: 20.2pt; line-height: 1.25">The compensation of non-employee and non-executive
Directors of the Company shall be determined pursuant to the provisions of the Companies Law.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.2pt; margin-left: 20.2pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Elements</span>:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Board Membership Fee</span>. non-executive Directors will generally be entitled to receive an annual
        cash payment by virtue of their membership on the Board.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Committee Membership Fee</span>. non-executive Directors will generally be entitled to receive an
        annual cash payment by virtue of their membership on one or more committees of the Board (which payments may vary by committee).</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Board/Committee Chair Fee</span>. The chair of the Board and/or the chair of the Board committees
        may also receive additional annual cash payments for their extra service in such capacities.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Equity-Based Compensation</span>. non-executive Directors may also receive equity-based awards, which
        are intended to align directors&#8217; interests with those of the Company and its shareholders over the long term. Such awards will generally
        be granted on an annual basis or on such other basis or in such other intervals all as approved by the Company&#8217;s shareholders from
        time to time.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Special Contribution</span>. Any non-executive Director who takes on increased duties on behalf of
        the Company as determined by the Board, may receive additional payments, in recognition of their increased duties, subject to applicable
        law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 21.3pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Insurance, Indemnification, Release</span>. non-employee and non-executive Directors shall also be
        entitled to insurance, indemnification and release arrangements, as provided below.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 20.2pt; line-height: 1.25">The above compensation is designed to compensate
directors for their services to the Company, without payment of additional per-meeting fees. Applicable value-added tax will be added
to such compensation in accordance with applicable law.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 20.2pt; line-height: 1.25">The Company may reimburse or cover its
non-executive directors (including travel and related expenses) incurred in connection with Board and its committees meetings or performing
their services for the Company.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">10.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">OFFICE HOLDERS' INSURANCE, INDEMNIFICATION AND RELEASE</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.2pt; margin-left: 20.2pt; line-height: 1.25">Office Holders may be covered by Directors'
and Officers' liability insurance which the Company shall acquire, from time to time (the &#8220;<span style="font-weight: bold">Insurance
Policy</span>), in accordance with the Company's Articles of Association and the provisions of applicable law, including the Companies
Law and the Companies&#160; Regulations&#160; (Reliefs&#160; Regarding Transaction with Interested Parties), 2000 (the &#8220;<span style="font-weight: bold">Relief
Regulations</span>&#8221;). Subject to the provisions of the Relief Regulations, the approval of the acquisition, extension, renewal or
replacement of the Company's Insurance Policy shall only require the approval of the Company&#8217;s Compensation Committee provided that
the Insurance Policy is on market terms and the Insurance Policy is not likely to materially impact the Company&#8217;s profitability,
assets or obligations.&#160;Such insurance coverage may include &#8220;run-off&#8221; provisions covering the Directors&#8217; and Officers&#8217;
liability following termination of service or employment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.8pt; margin-left: 20.2pt; line-height: 1.25">The Company will release all current and
future Office Holders from liability for actions taken in the performance of or related to the Director&#8217;s or Officer&#8217;s duties
and provide each of them with indemnification to the fullest extent permitted by law and the Company's Articles of Association.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 20.2pt; line-height: 1.25">The Company awards, and shall continue to
award, indemnification undertakings to Office Holders, to the extent permitted&#160; by&#160; the Companies Law and the Company's Articles
of Association.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">11.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">GENERAL DISCRETION; CLAWBACK</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">11.1.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">General Discretion</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 38.6pt"><br/> </td>
    <td style="width: 14pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Compensation Committee and the Board may, at their sole discretion, approve compensation terms that are lower than the thresholds
        and benchmarks described herein.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 37.95pt"><br/> </td>
    <td style="width: 14pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>The Committee and the Board have the right to reduce any variable compensation to be granted to an Office Holder due to any circumstances
        determined by the Compensation Committee and the Board.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 13</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">11.2.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Non-Material Updates</div> </td> </tr>
  </table>

<div><br/> </div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">Subject to the provisions of the Companies
Law, (i) a non-material update to the Terms of Office and Employment of an Officer other than the CEO may be approved by the CEO of the
Company (and shall not require the approval of the Compensation Committee); and (ii) a non-material update to the Terms of Office and
Employment of the CEO may be approved by Compensation Committee (and shall not require the approval of the Board and/or the general meeting)
, provided that the updated terms are consistent with this Policy.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">11.3.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">Clawback</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 38pt; line-height: 1.25">The Company's Office Holders are required
to return any compensation paid to them (including any incentive-based compensation granted to them) on the basis of results included
in financial&#160; statements that turned out to be erroneous and were subsequently restated, during the three year period&#160; following&#160;
filing&#160; thereof. In such&#160; case, compensation amounts will be returned net of taxes that were withheld thereon, unless the Office
Holder has reclaimed or is able to&#160; reclaim such&#160; tax&#160; payments from the relevant tax authorities (in which case the Office
Holder will also be obligated to return such tax amounts).</div>

<div style="text-align: justify; margin-right: 5.3pt; margin-left: 38pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">The Officer shall refund the surplus bonuses
sums, within one year from the date of the Company's notice with respect thereto, linked&#160; to&#160; the consumer price index, and
if the Officer has received less, the Company shall pay the missing bonus amounts together with the next monthly salary. The Company,
by written notice to the Officer 60 days in advance, may set-off all or part of the surplus bonuses sums from the bonuses owing to the
Officer in respect of the following years.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-right: 5.15pt; margin-left: 38pt; line-height: 1.25">For the avoidance of doubt, the terms of
this Compensation Policy shall be in addition to, and shall not derogate from, the terms of the Company's Clawback&#160;Policy as may
adopted or in effect from time to time, in compliance with Rule 10D-1 under the Exchange Act and the appliable Nasdaq rules (the &#8220;Clawback&#160;Policy&#8221;)
or Section 304 of the Sarbanes-Oxley Act of 2002. Without limiting the foregoing, in the event of a conflict or inconsistency between
the Compensation Policy and the Clawback&#160;Policy with respect to clawback's aspects, the Clawback Policy shall prevail.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">12.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">HEDGING AND PLEDGING</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 5.65pt; margin-left: 38pt; line-height: 1.25">Officers and directors are prohibited from
hedging or pledging their equity awards and any other Company securities. The no-hedging policy applies to each director and Officer until
one year following termination of such director&#8217;s term of office or such Officer&#8217;s termination of employment, as applicable.
Furthermore, Officers and directors may not pledge or use their equity awards or any other Company securities held by them as collateral
for loans unless otherwise approved by the Compensation Committee and Board.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">13.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">RESERVED.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.95pt"><br/> </td>
    <td style="width: 15.25pt; vertical-align: top; font-weight: bold">14.</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-weight: bold">MAINTENANCE OF THE COMPENSATION POLICY</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">14.1.</td>
    <td style="width: auto; vertical-align: top">
        <div>The Company&#8217;s Compensation Committee shall be responsible for maintaining the Compensation Policy updated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 19.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">14.2.</td>
    <td style="width: auto; vertical-align: top">
        <div>Updates to the Compensation Policy shall be approved by the Compensation Committee, the Board and the shareholders, as required under
        the Companies Law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 168.05pt; margin-left: 167.4pt; line-height: 1.25">A - 14</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: center; margin-right: 112.85pt; margin-left: 112.85pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 12pt; font-weight: bold">ENTERA
BIO LTD.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 112.85pt; margin-left: 112.85pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">PROXY
CARD</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 112.85pt; margin-left: 112.95pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">FOR
ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>

<div style="text-align: center; margin-right: 112.85pt; margin-left: 112.95pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">
TO BE HELD ON WEDNESDAY, JULY 16, 2025</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 64.3pt; margin-left: 64.3pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">THIS
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); text-indent: 27pt">The undersigned hereby appoints Ms. Miranda
Toledano and Ms. Dana Yaacov-Garbeli as the true and lawful attorneys-in-fact, agents and proxies of the undersigned, with full power
of substitution to each of them, to represent and to vote, on behalf of the undersigned, all of the ordinary shares of Entera Bio Ltd.
(the &#8220;<span style="font-family: Times New Roman, Times, serif; font-weight: bold">Company</span>&#8221;), held of record in the
name of the undersigned at the close of business on Tuesday, May 20, 2025, at the Annual Meeting of Shareholders of the Company (the <span style="font-family: Times New Roman, Times, serif; font-weight: bold">&#8220;Annual
Meeting&#8221;</span>). The Annual Meeting is scheduled to be held on Wednesday, July 16, 2025, at 08:00 AM Eastern Time at Kiryat Hadassah,
Minrav Building &#8211; Fifth Floor, Jerusalem Israel 9112002.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); text-indent: 27pt; font-weight: bold">This Proxy, when properly
executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to the proposals described
below, this Proxy will be voted identical to the Board of Directors&#8217; recommendation with respect to such proposal and in such manner
as the holder of the proxy may determine with respect to any other business as may properly come before the Annual Meeting or all and
any adjournments or postponements thereof. Any and all proxies heretofore given by the undersigned are hereby revoked.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); text-indent: 27pt">The undersigned acknowledges receipt of
the Notice of the Annual Meeting of Shareholders and Proxy Statement of the Company relating to the Annual Meeting.</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); text-indent: 27pt"> <br/> </div> </div>

<div style="text-align: center; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">(Continued and to be signed on the reverse
side)</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="text-align: center; margin-right: 75.2pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">ANNUAL
GENERAL MEETING OF SHAREHOLDERS OF</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 74.8pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 14pt; font-weight: bold">ENTERA
BIO LTD.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 75.2pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">

<div style="margin-right: 74.6pt; margin-left: 76.55pt; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">Wednesday, July 16, 2025</div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; margin-right: 75.25pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">GO
GREEN</div>

<div style="line-height: 1.25">

<div style="text-align: center">e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy </div>

<div style="text-align: center">material, statements and other eligible documents online, while reducing costs, clutter and </div>

<div style="text-align: center">paper waste. Enroll today via www.astfinancial.com&#160;to enjoy online access</div> </div> <br/>

<div style="text-align: center; margin-right: 75.25pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold"><span style="text-decoration: underline">Important
Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting</span></div>

<div style="text-align: center; margin-right: 165.1pt; margin-left: 167.2pt; line-height: 1.25; color: rgb(35, 31, 32)">The Notice of
Meeting, proxy statement and proxy card </div>

<div style="text-align: center; margin-right: 165.1pt; margin-left: 167.2pt; line-height: 1.25; color: rgb(35, 31, 32)">are available
at http://www.astproxyportal.com/ast/22270</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; text-indent: -0.05pt; margin-right: 176.55pt; margin-left: 178.65pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 12pt">Please
sign, date and mail </div>

<div style="text-align: center; text-indent: -0.05pt; margin-right: 176.55pt; margin-left: 178.65pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 12pt">your
proxy card in the </div>

<div style="text-align: center; text-indent: -0.05pt; margin-right: 176.55pt; margin-left: 178.65pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 12pt">envelope
provided as soon </div>

<div style="text-align: center; text-indent: -0.05pt; margin-right: 176.55pt; margin-left: 178.65pt; line-height: 1.25; color: rgb(35, 31, 32); font-size: 12pt">as
possible.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; margin-right: 75.25pt; margin-left: 75.95pt; line-height: 1.25; color: rgb(35, 31, 32)">&#8595; Please
detach along perforated line and mail in the envelope provided. &#8595;</div> &#160;<br/>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="2" border="0" style="font: 10pt Times New Roman,Times,serif; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 1px solid; width: 4%; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; margin-right: 75.25pt; margin-left: 77.2pt; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">THE
        BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; EACH OF THE PROPOSALS ON THE AGENDA OF THE MEETING</div>
        <div style="font: 8pt/1.25 Arial,sans-serif; text-align: center; color: rgb(35, 31, 32)">
        <div style="font: bold 10pt/1.25 Times New Roman,Times,serif">PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK
        YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE<span style="font-weight: bold"> </span>&#9746;</div> </div> </td> </tr>
  </table>

<div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="2" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td colspan="1" style="border-top: rgb(0, 0, 0) 1px solid; width: 4%">&#160;</td>
    <td colspan="1" style="border-top: rgb(0, 0, 0) 1px solid; width: 33%">&#160;</td>
    <td colspan="1" style="border-top: rgb(0, 0, 0) 1px solid; width: 5.26%">
        <div style="text-align: center"><br/> </div> </td>
    <td colspan="1" style="border-top: rgb(0, 0, 0) 1px solid; width: 5.26%; text-align: center">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 1%">
        <div style="text-align: center">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 32%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 6%">
        <div style="text-align: center"><br/> </div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 6%">
        <div style="text-align: center"><br/> </div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 6%">
        <div style="text-align: center"><br/> </div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 4%; text-align: left; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 33%; text-align: left; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td style="text-align: center; vertical-align: top; width: 1%"><br/> </td>
    <td style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">
        <div>&#160;</div> </td>
    <td style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify">&#160;</div> </td>
    <td style="width: 6%; text-align: center; vertical-align: top">
        <div>FOR</div> </td>
    <td style="width: 6%; text-align: center; vertical-align: top">AGAINST</td>
    <td style="width: 6%; text-align: center; vertical-align: top">
        <div>ABSTAIN <br/> </div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="4" style="text-align: left; vertical-align: top">
        <div style="text-align: justify; text-indent: 0.5pt; margin-left: 1.45pt; line-height: 1.25"><span style="font-weight: bold">Note: </span>Please
        sign exactly as your name or names appear on this Proxy. When shares are held jointly, each owner should sign. When signing as executor,
        administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate
        name by a duly authorized officer, giving full title as such. If the signer is a partnership, please sign in partnership name by authorized
        person.</div> </td>
    <td rowspan="1" style="width: 1%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">1.<br/> </td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(35, 31, 32)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To elect Ms. Haya Taitel as a Class II member of the Board
        of Directors of the Company (the &#8220;Board&#8221;) until the 2028 Annual Meeting.</div> </div> </div> </div> </div> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td> </tr>
  <tr>
    <td colspan="1" style="width: 4%; text-align: left; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td style="width: 1%; text-align: center; vertical-align: top"><br/> </td>
    <td style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;2.</td>
    <td style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="font: 6.5pt/1.25 Arial,sans-serif; color: rgb(35, 31, 32)">
        <div style="font: 10pt/1.25 Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To ratify and approve the revised compensation terms, as described
        in the accompanying proxy statement, to Miranda Toledano, our Chief Executive Officer and a Director.</div> </div> </div> </div> </td>
    <td style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td style="width: 6%; text-align: center; vertical-align: top">&#160;&#9744;</td>
    <td style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="text-align: left; vertical-align: top; width: 32%">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="4" rowspan="3" style="text-align: left; vertical-align: top">
        <div style="text-align: justify; margin-left: 1.95pt; line-height: 1.25; font-weight: bold">PLEASE NOTE that by signing and submitting
        this proxy card, you declare that you have no personal interest in items 2, 3, 4 and 5 except for a personal interest of which you have
        notified the Company about in writing, as required under the Israeli Companies Law 5759-1999. For further information, please see the
        proxy statement.</div> </td>
    <td style="width: 1%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="3" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">3. <br/> </td>
    <td rowspan="3" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To ratify and approve the revised compensation terms, as described
        in the accompanying proxy statement, to Gregory Burshtein, our Chief of Research &amp; Development.</div> </div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div> &#9744; </div> &#160;</td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div>&#9744; </div> &#160;</td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div>&#9744; </div> &#160;</td> </tr>
  <tr>
    <td style="width: 1%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 1%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" style="width: 1%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom"><br/> </td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="3" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;4.</td>
    <td rowspan="3" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To ratify and approve the revised compensation terms, as described
        in the accompanying proxy statement, to Dana Yaacov-Garbeli, our Chief Financial Officer.</div> </div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="1" style="width: 5.26%; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top"> <br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" colspan="1" style="width: 5.26%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 1%"><br/> </td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center"> <br/> </td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%"> <br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">
        <div><br/> </div> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="3" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center"> 5.<br/> </td>
    <td rowspan="3" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To ratify and approve the amended and restated compensation
        policy for the directors and officers of the Company as described in the accompanying proxy statement and attached as Appendix A thereto.</div>
        </div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div> &#9744;</div> &#160;</td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div> &#9744;</div> &#160;</td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top">
        <div> &#9744;</div> &#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> </div> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td rowspan="3" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center; padding-bottom: 2px">6.<br/>
        </td>
    <td rowspan="3" style="width: 32%; text-align: left; vertical-align: top; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">To ratify and approve, on an advisory, non-binding basis, the
        compensation paid to our named executive officers, including the compensation tables and narrative discussion, as described in the accompanying
        proxy statement.</div> </div> </div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top; padding-bottom: 2px">
        <div> &#9744;</div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top; padding-bottom: 2px">
        <div> &#9744;</div> </td>
    <td rowspan="3" style="width: 6%; text-align: center; vertical-align: top; padding-bottom: 2px">
        <div> &#9744;</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 4%">&#160;</td>
    <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 5.26%">&#160;</td>
    <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 5.26%">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1%">&#160;</td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><br/> </div> </div> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td rowspan="5" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;7.</td>
    <td rowspan="5" style="text-align: left; vertical-align: top; width: 32%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">To ratify and approve the appointment of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers
        International Limited, or PwC, an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal
        year ending December 31, 2025, and authorize the Board, (or the Audit Committee, if authorized by the Board) to determine the compensation
        of the auditors in accordance with the volume and nature of their services.</div> </div> </div> </td>
    <td rowspan="5" style="width: 6%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="5" style="width: 6%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="5" style="width: 6%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 4%">&#160;</td>
    <td colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td colspan="1" style="width: 5.26%">&#160;</td>
    <td style="width: 1%">&#160;</td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 4%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 33%; text-align: justify; vertical-align: top">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 5.26%">&#160;</td>
    <td rowspan="1" style="width: 1%">&#160;</td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td rowspan="1" style="text-align: left; vertical-align: top; width: 32%">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="4" rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; text-align: left; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: justify">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; color: rgb(35, 31, 32)">To change the address on your account, please check the box at right and indicate
        your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via
        this method.</div> </div> </div> </div> </td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 1%; text-align: center; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid">&#9744;</td>
    <td rowspan="1" style="border-left: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 2%; text-align: center; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" style="text-align: left; vertical-align: top; padding-bottom: 2px; width: 32%"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top; padding-bottom: 2px"><br/> </td>
    <td rowspan="1" style="width: 6%; text-align: center; vertical-align: top; padding-bottom: 2px"><br/> </td>
    <td rowspan="1" style="width: 6%; padding-bottom: 2px">&#160;</td> </tr>
  </table> </div> </div>

<div><br/> </div>

<div>

<table cellspacing="0" cellpadding="3" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 14%; padding-bottom: 2px">
        <div style="text-align: left; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; margin-left: 18pt">Name &amp; Signature of</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; margin-left: 18pt">shareholder</div> </div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 14%">
        <div>&#160;</div> </td>
    <td style="width: 11%; text-align: left; vertical-align: bottom; padding-bottom: 2px">
        <div style="margin-left: 9pt">
        <div style="margin-left: 9pt">Date:</div> </div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 11%">
        <div>&#160;</div> </td>
    <td style="width: 14%; padding-bottom: 2px">
        <div style="text-align: left; line-height: 1.25">
        <div style="line-height: 1.25">
        <div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; margin-left: 18pt">Name &amp; Signature of</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; margin-left: 18pt">shareholder (if joint)</div> </div> </div>
        </div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid; width: 14%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 5.5%; text-align: left; vertical-align: bottom; padding-bottom: 2px; border-right: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="margin-left: 9pt">
        <div style="margin-left: 9pt"><br/> </div> </div> </td>
    <td style="width: 5.5%; text-align: left; vertical-align: bottom; padding-bottom: 2px">
        <div>
        <div style="margin-left: 27pt">Date:</div> </div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 11%">
        <div>&#160;</div> </td> </tr>
  </table> </div> </div>

<div style="line-height: 1.25">&#160;

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Note:</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25">
        <div style="font: 6pt/1.25 Arial,sans-serif; color: rgb(35, 31, 32)"><span style="font-family: Times New Roman,Times,serif; font-size: 10pt">Please
        sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor,
        administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate
        name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized
        person.</span></div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div>

<div><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<div>

<div style="line-height: 1.25">

<div style="font: bold 12pt/1.25 Arial, sans-serif; text-align: center; margin-right: 79.55pt; margin-left: 81.55pt; color: #231F20">ANNUAL
GENERAL MEETING OF SHAREHOLDERS OF</div>

<div style="line-height: 1.25">&#160;</div>

<div style="font: bold 24pt/1.25 Arial, sans-serif; text-align: center; margin-right: 79.55pt; margin-left: 81.55pt; color: #231F20">ENTERA
BIO LTD.</div>

<div style="font: bold 24pt/1.25 Arial, sans-serif; text-align: center; margin-right: 79.55pt; margin-left: 81.55pt; color: #231F20">

<div style="font: 400 10pt/1.25 Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0)"> <br/> </div>

<div style="margin-right: 79.6pt; margin-left: 81.55pt; line-height: 1.25; color: #231F20; font-size: 12pt; font-weight: bold">Wednesday,
July 16, 2025</div> </div>

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: 400"> <br/> </div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; margin-left: auto; width: 40%; color: #000000; text-align: left; margin-right: auto">
  <tr>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 100%; vertical-align: top; background-color: rgb(204, 204, 204); font-size: 14pt">
        <div style="text-align: center; line-height: 1.25; color: rgb(35, 31, 32); font-family: Arial,sans-serif; font-weight: bold">PROXY VOTING
        INSTRUCTIONS</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: 400">

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 49%; text-align: left; vertical-align: top; font-family: Times New Roman">
        <div style="text-align: justify"><span style="font-weight: bold"><span style="text-decoration: underline">INTERNET</span>&#160;-&#160;</span>Access
        &#8220;<span style="font-weight: bold">www.voteproxy.com</span>&#8221; and follow the on-screen instructions or scan the QR code with
        your smartphone. Have your proxy card available when you access the web page.</div>
        <div style="text-align: justify"> <br/> </div>
        <div style="text-align: justify">
        <div style="line-height: 1.25; color: rgb(35, 31, 32)"><span style="font-weight: bold"><span style="text-decoration: underline">TELEPHONE</span>&#160;-
        </span>Call toll-free <span style="font-weight: bold">1-800-PROXIES </span>(1-800-776-9437) in the United States or <span style="font-weight: bold">1-201-299-4446
        </span>from foreign countries from any touch-tone telephone and follow the instructions. Have your proxy card available when you call.</div>
        </div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%; text-align: left; vertical-align: top">
        <div>
        <div style="line-height: 1.25"><img src="image00002.jpg" alt="" style="width: 57px; height: 57px"/></div> </div> </td>
    <td colspan="1" style="width: 24%; text-align: left; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 49%">
        <div style="text-align: justify; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%"><br/> </td>
    <td colspan="1" style="width: 24%">&#160;</td> </tr>
  <tr>
    <td style="width: 49%; padding-bottom: 2px">
        <div style="font-family: Times New Roman">
        <div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32)">Vote online/phone until 11:59 PM EST the day before the meeting.</div>
        </div> </td>
    <td style="width: 2%; padding-bottom: 2px">
        <div>&#160;</div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 25%">
        <div style="font: bold 12pt/1.25 Arial, sans-serif; text-align: center; margin-right: 11.15pt; margin-left: 13.1pt; color: #231F20">COMPANY
        NUMBER</div> </td>
    <td colspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 24%; border-right: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="width: 49%; font-family: Times New Roman; padding-bottom: 2px"><br/> </td>
    <td style="width: 2%; padding-bottom: 2px">
        <div>&#160;</div> </td>
    <td style="border-right: rgb(0, 0, 0) 2px solid; width: 25%; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="font: bold 12pt/1.25 Arial, sans-serif; text-align: center; margin-right: 11.1pt; margin-left: 13.1pt; color: #231F20">ACCOUNT
        NUMBER</div> </td>
    <td colspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 24%; border-bottom: rgb(0, 0, 0) 2px solid">&#160;</td> </tr>
  <tr>
    <td style="width: 49%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman"><span style="font-weight: bold"><span style="text-decoration: underline">MAIL</span>
        - </span>Sign, date and mail your proxy card in the envelope provided as soon as possible.</div> </td>
    <td style="width: 2%; padding-bottom: 2px">
        <div>&#160;</div> </td>
    <td style="border-right: #000000 2px solid; background-color: #CCCCCC; border-bottom: #000000 2px solid; border-left: #000000 2px solid; width: 25%"><br/>
        </td>
    <td colspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 24%; border-bottom: rgb(0, 0, 0) 2px solid">&#160;</td> </tr>
  <tr>
    <td style="width: 49%; font-family: Times New Roman"><br/> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%"><br/> </td>
    <td colspan="1" style="width: 24%">&#160;</td> </tr>
  <tr>
    <td style="width: 49%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman"><span style="font-weight: bold"><span style="text-decoration: underline">IN
        PERSON</span> - </span>You may vote your shares in person by attending the Annual Meeting.</div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%"><br/> </td>
    <td colspan="1" style="width: 24%">&#160;</td> </tr>
  <tr>
    <td style="width: 49%; font-family: Times New Roman"><br/> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%"><br/> </td>
    <td colspan="1" style="width: 24%">&#160;</td> </tr>
  <tr>
    <td style="width: 49%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman"><span style="font-weight: bold"><span style="text-decoration: underline">GO
        GREEN</span> - </span>e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements
        and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via https://equiniti.com/us/ast-access
        to enjoy online access.</div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 25%"><br/> </td>
    <td colspan="1" style="width: 24%">&#160;</td> </tr>
  </table> </div>

<div style="font: bold 12pt/1.25 Arial, sans-serif; text-align: center; margin-right: 79.6pt; margin-left: 81.55pt; color: #231F20"><br/>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 100%; vertical-align: top">
        <div style="text-align: center; margin-right: 60.75pt; margin-left: 60.75pt; line-height: 1.25; color: #231F20; font-family: Arial, sans-serif; font-weight: bold"><span style="text-decoration: underline">Important
        Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting</span></div>
        <div style="text-align: center; margin-right: 150.65pt; margin-left: 150.75pt; line-height: 1.25; color: #231F20; font-family: Arial, sans-serif">The
        Notice of Meeting, proxy statement and proxy card </div>
        <div style="text-align: center; margin-right: 150.65pt; margin-left: 150.75pt; line-height: 1.25; color: #231F20; font-family: Arial, sans-serif">are
        available at http://www.astproxyportal.com/ast/22270</div> </td> </tr>
  </table>

<div style="font: 8pt/1.25 Arial, sans-serif; text-align: center; margin-right: 79.6pt; margin-left: 80.3pt; color: #231F20">

<div style="font: 10pt/1.25 Times New Roman,Times,serif">&#8595;&#160;Please detach along perforated line and mail in the envelope provided
<span style="text-decoration: underline">IF</span> you are not voting via the Internet. &#8595;</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"> <hr style="border-style: none; height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto"/></div>

<div style="line-height: 1.25">

<div style="text-align: center; line-height: 1.25; color: rgb(35, 31, 32); font-weight: bold">THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#8220;FOR&#8221; EACH OF THE PROPOSALS ON THE AGENDA OF THE MEETING.</div>

<div style="font: 8pt/1.25 Arial,sans-serif; text-align: center; color: rgb(35, 31, 32)"><span style="font: bold 10pt Times New Roman,Times,serif">PLEASE
SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.&#160; PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE</span><span style="font-family: Times New Roman,Times,serif; font-size: 10pt">
&#9746;</span></div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="2" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 38%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 5%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 2%; border-right: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 2%"><br/> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 28%"><br/> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 7%; text-align: center">FOR</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 7%; text-align: center">AGAINST</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 7%">
        <div style="text-align: center">ABSTAIN</div> </td> </tr>
  </table>

<div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="2" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td rowspan="4" colspan="1" style="width: 38%; text-align: left; vertical-align: top">
        <div>
        <div style="font: 6.5pt/1.25 Arial,sans-serif; color: rgb(35, 31, 32); text-align: justify"><span style="font: bold 10pt Times New Roman,Times,serif">Note:
        </span><span style="font-family: Times New Roman,Times,serif; font-size: 10pt">Please sign exactly as your name or names appear on this
        Proxy. When shares are held jointly, each owner should sign. When signing as executor, administrator, attorney, trustee or guardian, please
        give full title as such. If the signer is a corporation, please sign full corporate name by a duly authorized officer, giving full title
        as such. If the signer is a partnership, please sign in partnership name by authorized person.</span></div> </div> </td>
    <td style="width: 5%"><br/> </td>
    <td style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 2%; text-align: left; vertical-align: top">1.<br/> </td>
    <td rowspan="2" colspan="1" style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">To elect Ms. Haya Taitel as a Class II member of the Board of Directors of the Company (the &#8220;Board&#8221;)
        until the 2028 Annual Meeting.</div> </div> </div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 5%"><br/> </td>
    <td style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 2%; text-align: left; vertical-align: top"><br/> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify"><br/> </div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">2.<br/> </td>
    <td rowspan="3" colspan="1" style="width: 28%; text-align: justify; vertical-align: top">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">To ratify and approve the revised compensation terms, as described in the accompanying proxy statement,
        to Miranda Toledano, our Chief Executive Officer and a Director.</div> </div> </div> </div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 38%"><br/> </td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="2" colspan="1" style="width: 38%; text-align: left; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman,Times,serif; font-weight: bold; text-align: justify">PLEASE
        NOTE that by signing and submitting this proxy card, you declare that you have no personal interest in items 2, 3, 4 and 5 except for
        a personal interest of which you have notified the Company about in writing, as required under the Israeli Companies Law 5759-1999. For
        further information, please see the proxy statement.</div> </td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">3.<br/> </td>
    <td rowspan="1" style="width: 28%; text-align: justify; vertical-align: top">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)">To ratify and approve the revised compensation terms, as described in the accompanying proxy statement,
        to Gregory Burshtein, our Chief of Research &amp; Development.</div> </div> </div> </div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744; <br/> </td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744; <br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" colspan="1" style="width: 38%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top"><br/> </td>
    <td rowspan="1" style="width: 28%; text-align: justify; vertical-align: top">
        <div style="color: rgb(35, 31, 32)">
        <div style="color: rgb(35, 31, 32)"><br/> </div> </div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td> </tr>
  </table> </div> </div>

<table cellspacing="0" cellpadding="2" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 38%"><br/> </td>
    <td style="width: 5%"><br/> </td>
    <td style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 2%; text-align: left; vertical-align: top">4.<br/> </td>
    <td style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify">To ratify and approve the revised compensation terms, as described in the accompanying
        proxy statement, to Dana Yaacov-Garbeli, our Chief Financial Officer.</div> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 38%"><br/> </td>
    <td style="width: 5%"><br/> </td>
    <td style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 2%; text-align: left; vertical-align: top"><br/> </td>
    <td style="width: 28%; text-align: left; vertical-align: top"><br/> </td>
    <td style="width: 2%">
        <div>&#160;</div> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td>
    <td style="width: 7%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 38%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">5.<br/> </td>
    <td rowspan="1" style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify">To ratify and approve the amended and restated compensation policy for the directors
        and officers of the Company as described in the accompanying proxy statement and attached as Appendix A thereto.</div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 38%">&#160;</td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 5%">&#160;</td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 2%; border-right: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 28%; text-align: justify; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 38%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">6.<br/> </td>
    <td rowspan="1" style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify">To ratify and approve, on an advisory, non-binding basis, the compensation paid
        to our named executive officers, including the compensation tables and narrative discussion, as described in the accompanying proxy statement.</div>
        </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 38%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 28%; text-align: justify; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 38%">&#160;</td>
    <td rowspan="1" style="width: 5%">&#160;</td>
    <td rowspan="1" style="border-right: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="width: 2%; text-align: left; vertical-align: top">7.<br/> </td>
    <td rowspan="1" style="width: 28%; text-align: left; vertical-align: top">
        <div style="color: rgb(35, 31, 32); text-align: justify">To ratify and approve the appointment of Kesselman &amp; Kesselman, a member
        firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public accounting firm, as the Company&#8217;s
        independent auditors for the fiscal year ending December 31, 2025, and authorize the Board, (or the Audit Committee, if authorized by
        the Board) to determine the compensation of the auditors in accordance with the volume and nature of their services.</div> </td>
    <td rowspan="1" style="width: 2%">&#160;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td>
    <td rowspan="1" style="width: 7%; text-align: center; vertical-align: top">&#9744;</td> </tr>
  <tr>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 2%; border-bottom: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 38%; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="text-align: justify; line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman,Times,serif">To change the address
        on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the
        registered name(s) on the account may not be submitted via this method.</div> </td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 5%; border-bottom: rgb(0, 0, 0) 2px solid; text-align: center">&#9744;</td>
    <td rowspan="1" style="border-top: rgb(0, 0, 0) 2px solid; width: 2%; border-right: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 28%">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 2%">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 7%">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 7%">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 7%">&#160;</td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br/> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 2%; padding-bottom: 2px">
        <div>&#160;</div> </td>
    <td style="width: 12%; padding-bottom: 2px; text-align: left; vertical-align: bottom">
        <div>
        <div style="line-height: 1.25; color: rgb(35, 31, 32); font-family: Times New Roman,Times,serif">Name &amp; Signature of shareholder</div>
        </div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-left: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-right: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="width: 5%; padding-bottom: 2px; text-align: left; vertical-align: bottom">
        <div>&#160;Date:</div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 12%">
        <div>&#160;</div> </td>
    <td style="width: 2%; padding-bottom: 2px">
        <div><br/> </div> </td>
    <td style="width: 12%; padding-bottom: 2px">
        <div>
        <div>Name &amp; Signature of shareholder (if joint)</div> </div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-left: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 6%; border-right: rgb(0, 0, 0) 2px solid; border-bottom: rgb(0, 0, 0) 2px solid">
        <div>&#160;</div> </td>
    <td colspan="1" style="width: 5%; padding-bottom: 2px; text-align: left; vertical-align: bottom">&#160;Date:</td>
    <td colspan="1" style="border: rgb(0, 0, 0) 2px solid; width: 12%; text-align: left; vertical-align: bottom">&#160;</td> </tr>
  </table>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 4%">
        <div>&#160;</div> </td>
    <td style="width: 4%; text-align: left; vertical-align: top"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Note:</span></td>
    <td style="width: 92%">
        <div>
        <div style="font: 6pt/1.25 Arial,sans-serif; text-align: justify; color: rgb(35, 31, 32)"><span style="font-family: Times New Roman,Times,serif; font-size: 10pt">Please
        sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor,
        administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate
        name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized
        person.</span></div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br/> </div> </div> </div> </div> <span style="font-family: Times New Roman,Times,serif"></span></div>
<!-- Field: /Include-Text -->
<br/>
      </div>
    </div>
  </div>
  <span style="font-family:'Times New Roman',Times,serif"> </span>
  <div style="width:100%">
    <div>
      <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif"></div>
    </div>
  </div>
  <div style="text-align:center"><span style="font-weight:normal;font-style:normal"></span>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;margin-left:auto;margin-right:auto;text-align:center"/></div>


</div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>entx-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:entx="http://www.enterabio.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:dei-sub="http://xbrl.sec.gov/dei-sub/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" targetNamespace="http://www.enterabio.com/20241231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.enterabio.com/role/Cover" id="Cover">
        <link:definition>0000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" id="entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" id="entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" id="entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" id="entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" id="entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" id="entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrincipalExecutiveOfficerMember" id="entx_PrincipalExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>entx-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecd_AllIndividualsMember_0"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_PrincipalExecutiveOfficerMember" xlink:label="loc_entx_PrincipalExecutiveOfficerMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" xlink:label="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_5"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember_0" xlink:to="loc_entx_PrincipalExecutiveOfficerMember_4" order="1001" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember_0" xlink:to="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_5" order="1002" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecd_AllAdjToCompMember_0"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" xlink:label="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" xlink:label="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:label="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_9" order="1001" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_10" order="1002" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_11" order="1003" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_12" order="1004" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_13" order="1005" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>entx-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_3"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" xlink:label="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" xlink:label="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_6"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:label="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:label="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" xlink:label="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" xlink:label="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" xlink:label="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" xlink:label="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_PrincipalExecutiveOfficerMember" xlink:label="loc_entx_PrincipalExecutiveOfficerMember_13"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_PrincipalExecutiveOfficerMember" xlink:label="loc_entx_PrincipalExecutiveOfficerMember_14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_0" xml:lang="en-US">Change In Fair Value As Of The Vesting Date Of Any Awards Granted In Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied At The End Of Or During The Covered Fiscal Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_1" xml:lang="en-US">Represents about change in fair value as of the vesting date of any awards granted in any prior fiscal year for which all applicable vesting conditions were satisfied at the end of or during the covered fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_0" xml:lang="en-US">Change In Fair Value At End Of The Covered Fiscal Year Of Any Awards Granted In Any Prior Fiscal Year That Are Outstanding And Unvested As Of The End Of The Covered Fiscal Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_1" xml:lang="en-US">Represents about change in fair value at end of the covered fiscal year of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_0" xml:lang="en-US">Fair Value As Of The End Of All Awards Granted During The Covered Fiscal Year That Are Outstanding And Unvested At The End Of The Covered Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_1" xml:lang="en-US">Represents about Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_0" xml:lang="en-US">Represents about fair value as of vesting date of equity awards granted and vested in the year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_1" xml:lang="en-US">Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_0" xml:lang="en-US">Fair Value Of Equity Awards Granted Are Reported In Summary Compensation Table [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_1" xml:lang="en-US">Represents about fair value of equity awards granted that are reported in the summary compensation table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_0" xml:lang="en-US">This member stands for non principal executive officer and non executive officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_1" xml:lang="en-US">Non Principal Executive Officer And Non Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PrincipalExecutiveOfficerMember_0" xml:lang="en-US">This member stands for Principal Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PrincipalExecutiveOfficerMember_1" xml:lang="en-US">Principal Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_1" xlink:to="lab_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_2" xlink:to="lab_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_3" xlink:to="lab_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_4" xlink:to="lab_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_5" xlink:to="lab_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_6" xlink:to="lab_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_7" xlink:to="lab_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_8" xlink:to="lab_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_9" xlink:to="lab_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_10" xlink:to="lab_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_11" xlink:to="lab_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_12" xlink:to="lab_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PrincipalExecutiveOfficerMember_13" xlink:to="lab_entx_PrincipalExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PrincipalExecutiveOfficerMember_14" xlink:to="lab_entx_PrincipalExecutiveOfficerMember_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>entx-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecd_AllIndividualsMember_0"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_PrincipalExecutiveOfficerMember" xlink:label="loc_entx_PrincipalExecutiveOfficerMember_3"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember" xlink:label="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember_0" xlink:to="loc_entx_PrincipalExecutiveOfficerMember_3" order="1001" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember_0" xlink:to="loc_entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember_4" order="1002" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecd_AllAdjToCompMember_0"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember" xlink:label="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember" xlink:label="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:label="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20241231.xsd#entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember" xlink:label="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_7" order="1001" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_8" order="1002" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_9" order="1003" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_10" order="1004" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember_0" xlink:to="loc_entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_11" order="1005" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !/ (L# 2(  A$! Q$!_\0
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MN]KN2DE_1C17\_/QE_X+-^._V?OV_8/V2/BG\'/AUIGPQ_X1V'XG:Q\7-/\
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MSJ2JT,3"A3]I4Q&'J*G!NE&/VZBIQWO:SM^E=%?FEJ_[:?Q?O_!6M_%SX??
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ME_97\2^(V_X)D?\ !8KXC:+HOBK4OVB?CEXW\+W.O>#H_"OB2S\9:'\)-?\
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HK7>)G6]I46&I86G&%-4J<*5/5^[><I3F[-R<DM+*"04445^@'K'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '& O(# 2(  A$! Q$!_\0
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M9X_,H3K3AF6,HQE*-'&4Z?-[.G!2DH)S:<YN4Y2D_P">?_APS_U=7_Y@W_\
M'#1_PX9_ZNK_ /,&_P#XX:_H8HKXC_B,/B-_T47_ )B,B_\ G8?5_P#$,N"/
M^A)_YDLW_P#F\_GG_P"'#/\ U=7_ .8-_P#QPT?\.&?^KJ__ #!O_P".&OZ&
M**/^(P^(W_11?^8C(O\ YV!_Q#+@C_H2?^9+-_\ YO/YY_\ APS_ -75_P#F
M#?\ \<-'_#AG_JZO_P P;_\ CAK^ABBC_B,/B-_T47_F(R+_ .=@?\0RX(_Z
M$G_F2S?_ .;S^>?_ (<,_P#5U?\ Y@W_ /'#1_PX9_ZNK_\ ,&__ (X:_H8H
MH_XC#XC?]%%_YB,B_P#G8'_$,N"/^A)_YDLW_P#F\_GG_P"'#/\ U=7_ .8-
M_P#QPT?\.&?^KJ__ #!O_P".&OZ&**/^(P^(W_11?^8C(O\ YV!_Q#+@C_H2
M?^9+-_\ YO/YY_\ APS_ -75_P#F#?\ \<-'_#AG_JZO_P P;_\ CAK^ABBC
M_B,/B-_T47_F(R+_ .=@?\0RX(_Z$G_F2S?_ .;S^>?_ (<,_P#5U?\ Y@W_
M /'#1_PX9_ZNK_\ ,&__ (X:_H8HH_XC#XC?]%%_YB,B_P#G8'_$,N"/^A)_
MYDLW_P#F\_GG_P"'#/\ U=7_ .8-_P#QPT?\.&?^KJ__ #!O_P".&OZ&**/^
M(P^(W_11?^8C(O\ YV!_Q#+@C_H2?^9+-_\ YO/YY_\ APS_ -75_P#F#?\
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M.&?^KJ__ #!O_P".&OZ&**/^(P^(W_11?^8C(O\ YV!_Q#+@C_H2?^9+-_\
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M #!O_P".&OZ&**/^(P^(W_11?^8C(O\ YV!_Q#+@C_H2?^9+-_\ YO/YY_\
MAPS_ -75_P#F#?\ \<-'_#AG_JZO_P P;_\ CAK^ABBC_B,/B-_T47_F(R+_
M .=@?\0RX(_Z$G_F2S?_ .;S^>?_ (<,_P#5U?\ Y@W_ /'#1_PX9_ZNK_\
M,&__ (X:_H8HH_XC#XC?]%%_YB,B_P#G8'_$,N"/^A)_YDLW_P#F\_GG_P"'
M#/\ U=7_ .8-_P#QPT?\.&?^KJ__ #!O_P".&OZ&**/^(P^(W_11?^8C(O\
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M (X:_H8HH_XC#XC?]%%_YB,B_P#G8'_$,N"/^A)_YDLW_P#F\_GG_P"'#/\
MU=7_ .8-_P#QPT?\.&?^KJ__ #!O_P".&OZ&**/^(P^(W_11?^8C(O\ YV!_
MQ#+@C_H2?^9+-_\ YO/YY_\ APS_ -75_P#F#?\ \<-'_#AG_JZO_P P;_\
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MABBC_B,/B-_T47_F(R+_ .=@?\0RX(_Z$G_F2S?_ .;S^>?_ (<,_P#5U?\
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M]#%?QEXP_P#)QN(O^Z1_ZHLL/Z@\,O\ DB,D_P"ZE_ZM\>%%%%?F9]X%%%%
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MU_8.A_Z=Y?C#Q%X?EU3_ (]M%34;S_1Z\S_;O_:L^*W[(OPS\!^._A%^Q_\
M&G]L_7O%_P 8?!?PSU;X?? ^&:?Q#X-\.^*H]5;4/B9KJVVA>(YX_"_AR:PM
M+74KF;3[32K675;6?6M>T'34FOU /MVBD4DJ"5*D@$JV-RDC)4[2RY'0[69<
M]"1S2T %%%% !117D/[0'QI\'_LX? OXQ?M ?$"X^S>"/@K\,O&_Q2\4R"18
MI7T3P-X<U'Q'?VULSJX:]O(-.:SL8@DCS7D\$,<<DDBHP!Z]17XU_P#!(?\
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M9;&TM;.W\SRK6WA@1(U /8**** "BOYW?%__  6._;P\6_MB_MB_LI_L4_\
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M?@CQ1_PF7P>\=2ZNOBKPAYGC/PUXBE\/?VHMK /[?\*R:'XHL=F=.UNS+/N
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M10 4444 %%%% !1110 4444 %%%% !1110 5^>?_  57_P"3!_CS_P!TN_\
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MZ/QCL_\ @C5_P3/^/FE_%/PK^S7\<_\ @H1XW\+_  <^)_[3=W\/9_&7AO\
M9[T;P?J^K>'/C_\ &WP_\-X;+5(=7U1+GP^+WP[X;%C>6UI9:]?MISVMYIFG
MZC9]HOB/_@X<\9_L'>%?V'? W['G[,_CX?%C]G3P?\-?#7_!2K3OVE/!_@;P
M'X?^#_C[X>V.CP:SXS_9=UO1XOB?9_&#1/ =\-/\1:CX+@U_P1:>-)/[7\+^
M%_$NB6HL[CZ:_:!_X(B^-M,_X)M_\$_?V>OV1_B/X*L/VK_^"8?Q"^%WQV^
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MJ=FD_P"\$#_;G_!6+]H?]IWQW^VA^P3_ ,$I/V4_C)XE_9DU?]KZS^+'Q/\
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MXF_LZ_M/:!X.T'7_  OILGAU?%&D:QX8U&SCM-$OQI>M:7_;-U?RKH7XN?\
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M2:!J/B;PWXOT*UN7O]$M(IGU'PWJD36DEQ&D,<SQSQ?4E% ''_#SP5I7PU\
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MM;=8X$^H:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSS_P""J_\
MR8/\>?\ NEW_ *N?X=U^AE?GG_P57_Y,'^//_=+O_5S_  [KZ;@K_DLN$O\
MLILA_P#5KA3P>*O^28XC_P"Q#G'_ *K\0?QMT445_H4?Q:?T,?\ !!G_ )NK
M_P"Z&_\ O8:_H8K^>?\ X(,_\W5_]T-_][#7]#%?PWXP_P#)QN(O^Z1_ZHLL
M/ZT\,O\ DB,D_P"ZE_ZM\>%%%%?F9]X%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5^>?\ P57_ .3!_CS_ -TN_P#5S_#NOT,K
M\\_^"J__ "8/\>?^Z7?^KG^'=?3<%?\ )9<)?]E-D/\ ZM<*>#Q5_P DQQ'_
M -B'./\ U7X@_C;HHHK_ $*/XM/Z&/\ @@S_ ,W5_P#=#?\ WL-?T,5_//\
M\$&?^;J_^Z&_^]AK^ABOX;\8?^3C<1?]TC_U198?UIX9?\D1DG_=2_\ 5OCP
MHHHK\S/O HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OSS_ ."J_P#R8/\ 'G_NEW_JY_AW7Z&5^>?_  57_P"3!_CS_P!TN_\
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MJ-HK^<[_ (->/^4:7B?_ +/-_:S_ /5C&OD/_@D_X6_:"\<?\$_O^#@'P?\
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M1110 4444 %%%% !1110 4444 %?GG_P57_Y,'^//_=+O_5S_#NOT,K\\_\
M@JO_ ,F#_'G_ +I=_P"KG^'=?3<%?\EEPE_V4V0_^K7"G@\5?\DQQ'_V(<X_
M]5^(/XVZ***_T*/XM/Z&/^"#/_-U?_=#?_>PU_0Q7\\__!!G_FZO_NAO_O8:
M_H8K^&_&'_DXW$7_ '2/_5%EA_6GAE_R1&2?]U+_ -6^/"BBBOS,^\"BBB@
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MH=W?ZE;7WT#_ ,$\/^"7G[8O[!'[)/[='P1\$_M3>!X_CK\<_P!LGXH?M'?
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M  57_P"3!_CS_P!TN_\ 5S_#NOIN"O\ DLN$O^RFR'_U:X4\'BK_ ))CB/\
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MMZ%:CS7Y?:TYT^;EMS<O/%7M=7MM=7W044451B%%%% !1110 445^8'[?/\
MP6/_ .">?_!-/5O"OA7]JWX\V/AGX@^,)O#EQI?PO\(:#KWQ"^(UKX4U[Q+9
M^'[GX@Z_X6\)6.I7?AKP1H-M)K'B.ZU37FT^]\2Z3X4\2Z9\.],\;>,K.T\*
MWX!^G]%?#/C+_@I?^P;X _9)TK]NOQ3^U!\,K+]D_7XT_P"$<^,-E?ZAKNE>
M)]0>_P!0TMO#?A?P_H&FZIXR\2^-+?4M'UJPOO NA>'-0\9:?=Z'KL%]H5O)
MHNJ+:=#^QC_P4 _8[_X*%> =9^)?['/QT\,_&OPIX:U=-"\3MI>F^*/"_B3P
MMJDXN6LK?Q1X&\>:#X5\<^&TU:*RO+C0[K6_#EA::[:VES=Z-/?6T$LJ 'V+
M17XFVG_!Q;_P1LO_ (QVWP!LOVQXKKXLWOQ,A^#]IX8@^ 7[4,L%S\1+CQ2O
M@N#08?$J?!,^$Y(IO$KII\>NKKI\.NC"_75CII%Y7T1^UG_P6$_X)K?L,?%C
MPQ\#/VJ/VK_ _P *OBOXLM]-O;'P;-H7C_Q??:/8:S<0V^DZEXYN_ 'A'Q5I
M7PVTO4?/2[L]3^(=_P"%["XTQ9]7CN6TJUN;R( _2JOSS_X*K_\ )@_QY_[I
M=_ZN?X=U]Z^'_$&A>+-!T3Q5X6UG2O$?AGQ+I&F^(/#OB'0K^UU71->T+6;*
M'4=(UG1]4L99[+4M*U33[FWOM/O[.>:UO+2>&XMY9(9$<_!7_!5?_DP?X\_]
MTN_]7/\ #NOIN"O^2RX2_P"RFR'_ -6N%/!XJ_Y)CB/_ +$.<?\ JOQ!_&W1
M117^A1_%I_0Q_P $&?\ FZO_ +H;_P"]AK^ABOYY_P#@@S_S=7_W0W_WL-?T
M,5_#?C#_ ,G&XB_[I'_JBRP_K3PR_P"2(R3_ +J7_JWQY_*'^TS^RG^V'^P#
M^UYX9^+/[.7PC^ '[:OP<_:J_P""C?Q2_:AL_@IK_B2[^!_[5NI_&_QY^Q!^
MU'H?C'X/W7Q:\2Z/XS^#OC;X):;X)M?'WB[X?KXOM?"FN:-X@O;3X;&.7P_J
M\OBO2OOCX,?'C_@DIX'_ &:_@W_P5]N/A[X%_9,\-Z#\"-5_9H\#6^N:%/X2
MU?X1:#HWQ*\5S>,OV9?AM\"O!-Q>>$4^(\/Q8T#QAHT^D_"'P/=^./&C:/-8
MVMUJGAVVAL[?YE_:K_X(L_M6M^TQX7^(?[ W[?OQ8_9C^#'QC_:V\:?M$_'#
MX6V_PL^#OQ+TKX$_$_X@_L_?&7P+\1OVA/@IKOCG6O#/B7P]=?$2#Q ?AM>>
M!=#M?$UWHWC'XO3?&.RGCA^'^F6&C0_$;_@W^^-6B^+_ -CS5/V,?^"D]_\
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M2!\3/_"5_P#N^O3**[SY8\S_ .%E?]2!\3/_  E?_N^C_A97_4@?$S_PE?\
M[OKTRB@#S/\ X65_U('Q,_\ "5_^[Z]#LKG[;9VEY]GNK3[7;07/V6]B\B\M
MO/B27[/=P;G\FZAW^7/%N;RY5=-QQDV:* "OYBO^"H7['7[3OP%^/_Q4_;Y_
M9@T_]G_XT>'OVFOC#_P3'T'XS_!KXQ7/B;X??&;3/&_P!_:R^"6D_!W1?V>?
MCEI.F>,/"_A_P3\6?$\O@_1_BMX9^(/@^+2?#1T^;XAZ+J>LZF)/#=Q_3K7\
M\W_!2W_@D9^T7\7/BIXM_:8_X)_?M>^//V9OB?\ ''XC?L?W7[2'PN7X;?";
MXL?"WXD77P ^-7PYU'P'\?[71/BAJ_A:W\+_ ! ^ 7A_21\0M6M+#5]5;XOZ
M+\-M+^&<6DVL_B+4CK@![G^R1IW[,7[=?PLM_C%H'[$/@C]G3]J?]BO]HS]H
M:TF_9X\>FRTSP7\#_P!O/4/#D2^.?&'BZ+X,/;_#GXM7OB>+Q7H/BJP^-K^%
M/$7B6?3/$LOC#PL=*\4W,TK?('[#$?[5?P7_ ."E?_!0#0?VT/!'POUS_@H#
M^TQ^R'X*^.GP?U[]E'5IM)_92^(?P;^ .K:[\,])\&:7X>^).C^&OB!X1^,F
MG_$#QYH \5^(?B]XR\?66LZ7KMC;Z!XK\->&O##6^M^\R?\ !"GPYX;^!/PX
MT_X1?M@_'/X<_MU_"WX]?%+]J;0_^"A=]HG@_P <_$OQ-\=OCCH]CX;^,-Y\
M2_AGK$-IX*\<?"SQQX8T?PQX<O?A9/>Z;!'I'@OPE93>)+R"VU^/Q'[7^RW_
M ,$GCX&\1?'KXP?MV?M+^+/^"BW[2O[1WP6O?V9?'_Q4\?\ PW\'?!;P=H?[
M->H3ZM<:K\&OA?\ !_X<7=UHOP]\.^++C5FU+QY/IFOW,WB77;.TUJVBT2[>
M_P#MP!^1O[/?Q1_X+/?\$<OV$?@=XQ_:5_9>_8GO?V)_V?\ P_X9M?VA_ /@
MKXQ?$OQ1^W+X-@\?_$.2X^)WQDU3Q+:6=W^SGXH_LOQ1XPU3Q9=> ?!>H>*M
M0GL+RSTBV\:7C6^I:_:_H_\ \$H/AU\./BO=?\%=_'?Q#\%>&/%WBGXS_P#!
M3/\ :K^$WQ/O/$^AVFJ7?BSX0_#C2_!O@3X9>!?$$&LP7%S/X-T_X?/$^E^'
MKX'2/(UN]OK.RBAU,@^4^$O^"&?[0+6WPW_9[^-G_!6#]H#XZ?\ !-KX2:[X
M3O?"7[%&L_!;X7>$/%'B/PG\.]0L=8\ ?"[XO_M2>&-1B^('Q3^&NCZCIMA;
MZGX6U+PQIEIJF@Z?I>CZ>=!DTG3-0M?8/VAO^"17QZ\1?'CXV?%C]B+_ (*4
M_%W]@CP3^UE?Z;K7[6GP?\(?!CX<_&#1?B'XJM?#^G>#-6\??";Q)XVU72M7
M_9Z^(OB?P=IUOI^O^,/!T&JW]YK5II?B'RTFTV.RD .^_P""!MS=G_@EA^SU
MHLLMS-I/@GQ7^TA\./!CW4]S=.OP[^'/[3OQB\$_#NWBO+J262\LK+P7H6AV
M6G7,<AMI+"WMOL82U$*+] ?\%5_^3!_CS_W2[_U<_P .Z^EOV8_V=/AE^R-^
MS]\)/V:O@WIMYIGPU^#7@O2O!7A:'4[O^T-8O+?3T:2^US7M0\J!=0\1>)-6
MGO\ Q!XAOTM[:*]UO4[^ZBM;:*5((_FG_@JO_P F#_'G_NEW_JY_AW7TW!7_
M "67"7_939#_ .K7"G@\5?\ ),<1_P#8ASC_ -5^(/XVZ***_P!"C^+3^AC_
M ((,_P#-U?\ W0W_ -[#7]#%?SS_ /!!G_FZO_NAO_O8:_H8K^&_&'_DXW$7
M_=(_]466']:>&7_)$9)_W4O_ %;X\****_,S[P**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _#3_@HU_P2G_:L_;3_ &N/@%^U1\%/^"BFB_LL']FG
MP7J.D?"7X?>(/V*/AE^U/I'ACXA^(]4N[KQ;\8=/'Q<^)5EX3M?'6J:5#X8T
M#1=8A\ C7?!]CX:67P]X@MKC6-3:7Z4_8L_9;_X*/_ [X@^*/$G[8G_!5$_M
MS^ M4\&7.B^&_AN/V'?@3^S,?"GB^35]*O8/&X\7_"WQ!J^M:\;;2;/5-&_X
M1F^@CTR?^V/[1>47.GVZ-^F]% 'PU_P3E;]JB;]E#P==_MD^.O$OQ'^-U[XP
M^+EQ-XP\9_";P?\  SQ=K7PX'Q7\90?!O4?$_P )/ T<>B?#_7-4^%,'@_5M
M1\*3>;KV@7&H/I'B>XN?$-EJ4\DWP8_8U_X5%^VY^VI^V1_PL?\ X2'_ (;
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MX3\/Z+9/9:;ITNN-K-_96UY%_7S_ ,*6_P"IE_\ *-_]]:/^%+?]3+_Y1O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_)!]7P__ #XH_P#@J'_R)T'_  E.O?\ /]_Y*V?_ ,CT?\)3KW_/]_Y*V?\
M\CUS]?<?[/?[%GBWXG_8/%/CW[;X,\!R^5<V\31+%XE\26Q.Y?[-M;A6_LJP
MG3YDU;4(',T31RV%C=P3"ZB_/_$KQ=X/\(^&L1Q7Q_Q33R'*J/-##QK8BK5Q
M^:8M0<X9?E&7TI2Q>98ZHE=4,-3G[.FI8C$2HX6E5KT_O/#OPKXO\5N(L/PO
MP+PU5SO-*O+.NZ5&G3P.6X5R4)X_-L?54<+EV"IMV=?$U(>TJ.-##QK8FI2H
MU/!OAAX,^+7Q@U]?#_@:SEU&9#&VH:C-;6EMHNC6\A(%UJ^I-:-#:QD*YBA4
M2WEV8WCL;6ZF'E']IOV;OV8?#7P\\3?#SPS/K>F>(_B]\3?&7A?X<>%=9UM[
M+1[6;Q=X\U:R\,:/H'AFU?"V45[?ZK#9W6I3&:]-G+=7-W-9:8UQ;0^-_$S]
MH3X-_LK>'C\-_AAH>DZGXIL$:-?#FDR?\2_2;THL;7_C/6$>2[NM3(17GLVG
MN-;NPD<=Y/IT,L%T/G_]@KXG^-_BO_P4L_8N\2>.-<N=7OV_:M_9S2T@/[G3
M=*M7^./@!A8Z3I\>+>PM5PN5B7S;AU\^[EN+EY)W_AZM4\?/IH4J]3%8C/\
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MF)+,22222<U]Q?\ !-"SMM1_;_\ V--/O(_.M+[]J3]G>SNH=\D?FVUU\:O
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M%GP\^''P\\%Z5=W<7@:_CUJ/2_BS\1+\:AJ$?A*]\=V?PZE\*_$GPOX9U;4
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M=MK_ ,3-1T+0=%\.Z%=^)_$,LMA]N?L3WW[+^H^&OVP_C'JO[>GP5_X*-?\
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MOQ)\0_'Y)-8T&:R\12:[XA\0:IHZ'2H/!FBNB-%JDIFCG_9<_;._X*-_#O\
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M_P#)%'_"+_$;_HJ?_ED:%_\ )% 'IE%>9_\ "+_$;_HJ?_ED:%_\D4?\(O\
M$;_HJ?\ Y9&A?_)% 'IE%>9_\(O\1O\ HJ?_ )9&A?\ R11_PB_Q&_Z*G_Y9
M&A?_ "10!Z917F?_  B_Q&_Z*G_Y9&A?_)%'_"+_ !&_Z*G_ .61H7_R10!Z
M917F?_"+_$;_ **G_P"61H7_ ,D4?\(O\1O^BI_^61H7_P D4 >F45YG_P (
MO\1O^BI_^61H7_R11_PB_P 1O^BI_P#ED:%_\D4 >F45YG_PB_Q&_P"BI_\
MED:%_P#)%'_"+_$;_HJ?_ED:%_\ )% 'IE%>9_\ "+_$;_HJ?_ED:%_\D4?\
M(O\ $;_HJ?\ Y9&A?_)% 'IE%>9_\(O\1O\ HJ?_ )9&A?\ R11_PB_Q&_Z*
MG_Y9&A?_ "10!Z917F?_  B_Q&_Z*G_Y9&A?_)%'_"+_ !&_Z*G_ .61H7_R
M10!Z917F?_"+_$;_ **G_P"61H7_ ,D4?\(O\1O^BI_^61H7_P D4 >F45YG
M_P (O\1O^BI_^61H7_R11_PB_P 1O^BI_P#ED:%_\D4 >F45YG_PB_Q&_P"B
MI_\ ED:%_P#)%'_"+_$;_HJ?_ED:%_\ )% 'IE%>9_\ "+_$;_HJ?_ED:%_\
MD4?\(O\ $;_HJ?\ Y9&A?_)% 'IE1S30V\,MQ<2QP001O-//,ZQ0PPQ*7DEE
MD<JD<<:*SN[L%1068@ FOE7XV?%*R_9Z\(3>-/BI\>[30--S)#IE@O@C0KK7
MO$-^B!AIGA[1HKK[7JEZVY/,,:K:643?:]2NK*R26YC_  7^)O[5'[5W[>/B
MH_!7X56WB63P?JL[*OA+0[?3]+N=5TM)1"=6^)&NZ=':6-GHJ^9')=V-[J$?
MAFRF>WAGEU2^BM+V3\7\4_'#A;PR5#*G3Q'$W&V9>SIY)P3D:>)SC&U\0U'#
M/%1I0KRR_"UIRBJ=2I2J8G$KF^H8/&2IU(P_9_"[P1XI\3/;9JIX?AG@G+>>
MIG7&N>-8;)\%0H>]B8X65:=!9ABJ,%*4Z=.K3PV'?+]>QF#52FY_>G[8?_!5
MCP[X(_M3X>?LUS:=XO\ %R>=9ZE\3I5AO_!_AZ89C=?"]NZR6_B[4XCO*:E+
MGPS;.D+Q#Q%'+-#;?RS?\%#/V@_C/^S]K&BS_$OP_P"*+_XR?&3PE8?$S2=8
M^(LEP\S>$==U?Q/X>TKQ-?VEQ<?VK+)<7_@[6+?1M&NH],@CTZVLKY!_9$NG
MV][_ %F?LM_\$N-%^"TNC>//&OBW1O%'Q3M5ANX%?PK;Z[X2\(WX&X'0K;6K
MB--6U*UDPT/B#4M+MY[>:.*?2K'3)XFN9_Y<?^#H^PUK3OVUOA!!KNO_ /"1
MW;?LN?#^6.^_LJTTCRK9OBQ^T$B6OV:S=XGV2I--Y['S&\_RR-L2D^#X2> ?
M$WCAQK@>*_I*5_K&58*AB<UX>\(\KQ-6AD&5RHQC+#RX@EAZS>-Q#4[XG"QK
MUJU=*%''X^6$=7)Z7U7B7XZ\+^"_"6.X2^CCAW0S+%U*&6\0^+.:8>G7S[-5
M4DXUX9#&O1BL%ADXVP^)E0HT:+YZV P$<5[/-ZO\W/BWQAXG\=Z[>^)O%^M7
MVOZY?L#<W]_+O?8I)CMX(D"06EI &*V]E:106ELGR00QI\M<U117^HF!P."R
MO!87+<LP>%R[+\#AZ6$P6 P.'I83!X/"T(*G0PV%PM"%.AAZ%&G&-.E1I0A3
MIPBHPBHI(_S@QN-QN98S%9AF.+Q./Q^-KU<5C,;C:]7%8O%XFO-U*V(Q.)KS
MG6KUZU24IU:M6<JE2<G*4FVV%%%%=1RA1110 5]V_P#!,/\ Y2&?L4_]G6_L
MX?\ J[_ %?"5?<G_  30BN9_V_\ ]C2"SNOL-W-^U)^SO%:WWD1W7V.YD^-7
M@-(+K[-*1%<?9Y2LWD2$1R[/+<A6)K.M_N^+_P"P/&?^HM4TH_[QAO\ L*PO
M_J13/]82BO,_^$7^(W_14_\ RR-"_P#DBC_A%_B-_P!%3_\ +(T+_P"2*_CL
M_I0],HKS/_A%_B-_T5/_ ,LC0O\ Y(H_X1?XC?\ 14__ "R-"_\ DB@#TRBO
M,_\ A%_B-_T5/_RR-"_^2*/^$7^(W_14_P#RR-"_^2* /3**\S_X1?XC?]%3
M_P#+(T+_ .2*/^$7^(W_ $5/_P LC0O_ )(H ],HKS/_ (1?XC?]%3_\LC0O
M_DBC_A%_B-_T5/\ \LC0O_DB@#TRBO,_^$7^(W_14_\ RR-"_P#DBC_A%_B-
M_P!%3_\ +(T+_P"2* /3**\S_P"$7^(W_14__+(T+_Y(KT.RBN8+.T@O+K[=
M=PVT$5U?>1':_;+F.)$GNOLT1,5O]HE#3>1&3'%O\M"54&@"S117\6__  6W
M\>^-/%G[<'B?X,?M@_MT_M._L'_LQZ9XM_X)_P W[%&E_!C7;KX&_"7X[3>)
M_C_\.C^U9\7OB!^TC+X/U?P=#\2/V7K*&Z\<^%/"'COQ/HT/PYNO#/@3XN:)
M830VNO)K(!_:117X;:O^QW^V_P#'G]F[]E[X"?#_ /X*N>)?%W[.U[XK^)WB
M;XX_MO\ P6U#0_ ?[9WQ3^!D@N=0_9T^'WPI^*G@VP^(OPSO]>LKN_32OBM\
M?])E\$ZQXKTCPEH=]IGA:>Y\0>+["_\ FK]G/XI?%_\ X)T_M"_\%*/V?+C]
MKKX__P#!0#]FG]D+]A6P_;$O/&'[47BF#XL?&;X$_&TP^/=8G_9\\:_&S1]-
MTZ^\1GQ]\//!]I\3-*\,ZOIFGZEX9\/7&G2Z)HMM;7]WJ?B  _I>HK^0/Q/\
M-OV^OV5?V'OAW_P6S\3?\%+/VJ?BE\=4\-?!7]I3]HG]E'QAXNTJ[_81UWX)
M?%?7/!=_XZ^#WPR^ ]IH03X<ZQX1\!^*H;;PY\0M&UJ^UVYU;0+N[M;+3[[Q
M'/<VWTKI'P-_:E_X*W?&C]MKXV:1_P %'_VO_P!C;X??LP?M-?$']E/]D?X7
M?LH>-[+X=^!G\3_ S1_#*^,/B=^TEH-WHNH7'QSM/%/Q,U&X0>!]6N]$TZS\
M*Z5-I%GJCV&LR%0#^F>OSS_X*K_\F#_'G_NEW_JY_AW1_P $J/VF/B)^US^P
M1\ OC7\8#I,OQ?O-/\:?#WXLWN@V@L-%UCXE_!?XC^+_ (.>-O$.F62106]G
M:^)?$'@2^\0+9V4,6G6C:F]KIL:6,-NH/^"J_P#R8/\ 'G_NEW_JY_AW7TW!
M7_)9<)?]E-D/_JUPIX/%7_),<1_]B'./_5?B#^-NBBBO]"C^+3^AC_@@S_S=
M7_W0W_WL-?T,5_//_P $&?\ FZO_ +H;_P"]AK^ABOX;\8?^3C<1?]TC_P!4
M66']:>&7_)$9)_W4O_5OCSXT_:+_ ."?W[(O[5OQ,^"?Q>^.WP*^%OQ"\??
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MGI*6,%S<P6:V&M6XMH;B>.$(DLBM[W110 4444 %%%% !1110 4444 %%%%
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M7[LMN_Q'V3X<R^-N:OBE=J*O5H*\GLE>AJWT6[/T8_X65X)_Z#7_ )3=6_\
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M[?\ @F'_ ,I#/V*?^SK?V</_ %=_@"LZW^[XO_L#QG_J+5-*/^\8;_L*PO\
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MOYI+.\&MH ?T%T444 %%%% !1110 5\S_M*?MF_LG_L=:/X;U[]J;]H?X1_
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M:O\ $'3_  UK@L%AEU'P[X9\?>'/#>I:%#J/VC3- U+4)OL,-M=ZL':+P_\
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M9>PH)2U:2L[-MM)*[NK7/!O WQ8_X*(_L;_MB?L8_![]I7]MCX3?\% /A_\
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M*/6;?5TM%MK(6UI;_HG\1/VSOA'^S#X#TR/XA)X@EUJ:VU*?P_H.DVEA+?\
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M>(;=KC2M>T'583#=6LWE20W5K<1MY=UIVIZ?<6FJ:1J-O::II5[9:E9VMU"
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MX\ _$QKB"RM89V_X1<ONFB@C24[S?Y?+JQW'ENIZU=_X65_U('Q,_P#"5_\
MN^O3** /,_\ A97_ %('Q,_\)7_[OH_X65_U('Q,_P#"5_\ N^O3** /,_\
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MJG5J4^;ZQ0CS>SFX.7*T[7Y6[7?34_U>Z*_RA/\ AYY_P4,_Z/6_:M_\2/\
MC?\ _-_1_P ///\ @H9_T>M^U;_XD?\ &_\ ^;^M?^(28G_H?X/_ ,(\5_\
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M7!82EB<;F->KCZU&%.A@<)B*EJBE4C".I^[W_"EO^IE_\HW_ -]:_/W]L/\
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M"TM;S69]!\':3HVE3:M=VMA8VUSJ,EHUY/!96D,LSQV\*I]_?#7_ )$G1?\
MN(_^G:_KNJ*_1Z.'=*;FZG.W%Q^&V[3O?F?8_,<QSA8_#PP\<*J"IU8U$U5Y
MU:,*D.515*FE\=[WTM:VMT4445U'B!1110 4444 %%%% !7\#W_!U=_R?%\&
M_P#LU+X>?^K>_:)K^^&OX'O^#J[_ )/B^#?_ &:E\//_ %;W[1-?H_A;_P E
M/+_L59A_Z33/BN/O^1#_ -S^#_\ 2Y'\O%%%%?T"?C@4444 %%%% !7W;_P3
M#_Y2&?L4_P#9UO[.'_J[_ %?"5?=O_!,/_E(9^Q3_P!G6_LX?^KO\ 5G6_W?
M%_\ 8'C/_46J:4?]XPW_ &%87_U(IG^KW7R=^W'\3/&_P>_9;^*'Q&^'.M?\
M([XR\._\(5_8VL_V;I.K_8_[7^(GA+0M0_XE^NV&IZ5<?:-*U.^M?]*L9_*\
M_P ^#RKF*&:/ZQKX3_X*7?\ )DOQJ_[IQ_ZMKP'7\AX1*6*PT9)2C+$48RC)
M74DZD4TT]&FM&GHT??>.^8YAD_@?XRYME..QF5YKE?A3XAYCEF9Y=B:^"S#+
MLPP7".<8G!8[ XW#3I8G"8S"8FE3Q&%Q6'J4Z^'KTX5:4X5(1DOPG_X>7?MM
M?]%J_P#,<?"7_P"8.C_AY=^VU_T6K_S''PE_^8.OA.BOM_J>#_Z!,-_X(I?_
M "!_S3_\3$?2 _Z/GXQ?^+-XU_\ GV?=G_#R[]MK_HM7_F./A+_\P='_  \N
M_;:_Z+5_YCCX2_\ S!U\)T4?4\'_ - F&_\ !%+_ .0#_B8CZ0'_ $?/QB_\
M6;QK_P#/L^[/^'EW[;7_ $6K_P QQ\)?_F#H_P"'EW[;7_1:O_,<?"7_ .8.
MOA.BCZG@_P#H$PW_ ((I?_(!_P 3$?2 _P"CY^,7_BS>-?\ Y]GW9_P\N_;:
M_P"BU?\ F./A+_\ ,'1_P\N_;:_Z+5_YCCX2_P#S!U\)T4?4\'_T"8;_ ,$4
MO_D _P")B/I ?]'S\8O_ !9O&O\ \^S^["BBBO@#_JN"BBB@ K\P/V^?^"Q_
M_!//_@FGJWA7PK^U;\>;'PS\0?&$WARXTOX7^$-!U[XA?$:U\*:]XEL_#]S\
M0=?\+>$K'4KOPUX(T&VDUCQ'=:IKS:?>^)=)\*>)=,^'>F>-O&5G:>%;_P#3
M^OYBO^"H7['7[3OP%^/_ ,5/V^?V8-/_ &?_ (T>'OVFOC#_ ,$Q]!^,_P &
MOC%<^)OA]\9M,\;_  !_:R^"6D_!W1?V>?CEI.F>,/"_A_P3\6?$\O@_1_BM
MX9^(/@^+2?#1T^;XAZ+J>LZF)/#=P ?T,_ SX]?!O]ICX4>$/CG\ _B-X7^*
MWPC\>6%SJ/A/QYX1U!=0T+5K>QO[O2M2C64K%/9W^D:MI]_I&M:5J$%IJFC:
MO87VEZI9VE_9W%O'0^ O[1GP2_:@\%:E\1_@!\0]$^*/@+2_'/CKX<3^+_#:
M:@_A^[\6_#;Q)?>$?&%GHNIWME9VWB'3-.U_3;RTLO$V@/J7A?7X(TU/P[K.
MJZ5<6U[+^67P$\%_LR_\%5/V1_&?PJ\0_ KXF_L1:?\ #_\ :M^(7AK]MG]D
M#X4>+?#WPF7Q%\==$M+J]^*_PO\ C%XT^"-KI5K\7OAA\4AX^T'XA^)/$?A7
M5?#UY\5PWAW4=<U5K-]7T>_^2OV$ED^!W_!#W_@I5%\%]*@\)/\ "+XE_P#!
M8J#X5:)X9LY+6V\,#P)\3?CM%X)TOP_8:<8IK6#15TO3;32;6P:*2".VMXK5
MD9$( /TL\ ?\%I/^"7/Q1_:DF_8Q\ _MD?#/Q'^T6GB"[\)6G@VUL?&EOX?U
MSQ;931VLWA/PK\5+_P +6GPB\7^*7O)?[/M/#GA;QWK&M7^I0W6G6-C<WUE=
MV\&O^UG_ ,%A/^":W[#'Q8\,? S]JC]J_P #_"KXK^++?3;VQ\&S:%X_\7WV
MCV&LW$-OI.I>.;OP!X1\5:5\-M+U'STN[/4_B'?^%["XTQ9]7CN6TJUN;R+\
ME_VP/@=\&_AW_P &Q_PZF^'O@CPOI%S\$OV6OV2?C_\ !C4]'L+*'5/#_P =
M;*]^%'C#3_'_ (?U;3XX;]?&OB;Q;J^I'5]9TZYBUKQ(_B+5K*>ZG.K3K)];
M?\$E?ASX#^*W_#VWQU\4_ WACQ3XX^,W_!2O]J7X2_%R?Q/H=GJ=WXH^%GPX
MT?P7X#^'?@'Q!;ZO#=3S>#=,\".O]E^';POH_D:U>WUE:1P:D=P!^XOA_P 0
M:%XLT'1/%7A;6=*\1^&?$ND:;X@\.^(="O[75=$U[0M9LH=1TC6='U2QEGLM
M2TK5-/N;>^T^_LYYK6\M)X;BWEDAD1S\%?\ !5?_ ),'^//_ '2[_P!7/\.Z
M^?\ _@@;<W9_X)8?L]:+++<S:3X)\5_M(?#CP8]U/<W3K\._AS^T[\8O!/P[
MMXKRZDEDO+*R\%Z%H=EIUS'(;:2PM[;[&$M1"B_0'_!5?_DP?X\_]TN_]7/\
M.Z^FX*_Y++A+_LILA_\ 5KA3P>*O^28XC_[$.<?^J_$'\;=%%%?Z%'\6G]#'
M_!!G_FZO_NAO_O8:_H8K^>?_ ((,_P#-U?\ W0W_ -[#7]#%?PWXP_\ )QN(
MO^Z1_P"J++#^M/#+_DB,D_[J7_JWQX444U]Q1@A"N58(2,@-@[21W ."1W%?
MF9]X8=SXJ\,67B;1_!=YXCT&T\8^(=&U_P 1Z!X3N=8T^#Q-KGA[PI>>']/\
M4:[H^A2W":IJ>C>&[_Q;X5L=?U2RM9['1[SQ-X?MM1GMIM9TU+G>K_/"NOV:
MOV2?AG^V!X4E_P""UDG[<'[-?[7OB33_ -L>]\;_ /!1G6?B#\;M*^'GB'XI
M:C\<?@3IW[(WQ(_9"^.OPRU;QO\ "SP-X!^&7PE\6^)],_L+XD^%-!\)_"G6
M?%NE>"OBKH<P_P"$ L(OO#_@JPW[%'Q^_P""I>G_  V_:_\ V2?VS_\ @IW\
M/?V;/^"?/P?/@CX8_L:^ ?BI\2OB3??$;XT_%'Q1KVM_&?Q;J7[/_C?X+^&=
M)T5OA]X4\*"Z;4?$6B:#KE[XPM;CPMX<U!+)(M$ /[3:*_E!\3>,?V/[O_@E
M;^R%^S1_P27UWXD?LS?LY?MF?\%$/AQ^QAXV.DZW\3M+^.?P17Q[XO\ %GB[
M]ICP3J&H?%OQ#XJ^(?@3XE7ECX,UCPK<&?5=3M].M/%$5[X=>;P_J%AJ#XWQ
MW^ ?PC_X-_OCW\(_'O[ EKXZ^'GP8_:'_9S_ &]+;XQ_L]:W\1_'_P 4OA]X
MD^*W[-/[+GB;]I/X7_&FQLOBAXL\27>B^.5N?AWJ/A+Q)=Z?JD%EJGA_4[?2
M[33M-MWU"68 _K7HK^+WXC_\$Z/A[^QW_P $T/ /_!:3P!\3?CA=?\%._!7P
MX^ ?[7OQ@_:>UKXQ?$C7;OX^+X\U?X?^*/BO\&O'WP]U/Q*WPWN_A3X@\,^)
M;_PEH_AO3_"VCS6=EH_AJ*]U6ZMK.\CN_P"SFRN5O;.TO%4HMW;07*HV"R+/
M$DH5B."5#X)'&1Q0!9HHKGI_%WA2VFFMKGQ/X>M[BWED@G@GUK38IH)HG,<L
M,T4ERKQRQNK))&ZJZ.I5@""* .AHKF?^$U\'?]#;X9_\'VE__)5'_":^#O\
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MHT5$554 6*YG_A-?!W_0V^&?_!]I?_R57X>_'O\ X+)_&NT^/WQG^"G[ _\
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MSX8\/7%Q<2R3SSSZ+ILLT\TKF26::62V9Y)9'9GDD=F=W8LQ))-=#10!S/\
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M(^)^KX?_ )\4?_!4/_D3H/\ A*=>_P"?[_R5L_\ Y'H_X2G7O^?[_P E;/\
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MV-W#_P *[\FZL](L+6YB\SXK^!8I/+G@MTE3?$[QOM8;HW9&RK$']"*^$_\
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MX7?"'QCKE];?8_'VKZ]J5K'I6I^'M0@LKZ77;:RC_HEK^6W]L#XX_!OXB?\
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M -+/VD*_L4K^.O\ X-*?^0#^W%_W;1_Z6?M(5_8I7\X^)/\ R6>:?]@^2_\
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MQ'J$.KI'IOCRQ\5:?J&JV_Q'\.ZQ]DL?&::K?-/-83M!/;_JW10!^0/[&_\
MP3#^*_PA_:2N?VSOVW/VY?'W_!0+]J;2?AIJ7P8^%GC'6OA!X _9V^&7P?\
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M^-/^AL**** "OX'O^#J[_D^+X-_]FI?#S_U;W[1-?WPU_ ]_P=7?\GQ?!O\
M[-2^'G_JWOVB:_1_"W_DIY?]BK,/_2:9\5Q]_P B'_N?P?\ Z7(_EXHHHK^@
M3\<"BBB@ HHHH *^[?\ @F'_ ,I#/V*?^SK?V</_ %=_@"OA*ONW_@F'_P I
M#/V*?^SK?V</_5W^ *SK?[OB_P#L#QG_ *BU32C_ +QAO^PK"_\ J13/]7NO
MA/\ X*7?\F2_&K_NG'_JVO =?=E?"?\ P4N_Y,E^-7_=./\ U;7@.OY$P?\
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M6C>!/&7B&'PGX@UKPQ8?!S2];\%>$OA??:KX#\+6VE/^JO\ P4=_:9;]D_\
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M_P 3/_"J_P#N"@#TROX'O^#J[_D^+X-_]FI?#S_U;W[1-?W*_P#"M?\ J?\
MXF?^%5_]P5X'\5OV"/V7?COKEGXG^.'PL\'_ !E\2Z=I-OH.G^(?BMX(^'GQ
M#URPT.SO-1U"TT:SU;Q=X.UB_M=)M;_6-6OK?3H+A+."\U34;F*%9KVY>7ZC
MA'/Z/#>;/,:^'J8F#P>)PWLZ4HPG>NHI2O/2T>75;L\'B/**F=Y=]2I5H4)?
M6:%?GJ1E*-J4FW&T=;N^G0_R7Z*_U3_^'3'_  3S_P"C3?V?O_#$?!#_ .=Q
M1_PZ8_X)Y_\ 1IO[/W_AB/@A_P#.XK])_P"(KY?_ -"G&_\ @ZA_EZ_T]/B/
M^(>XW_H8X;_P55_KO_3T_P K"BO]4_\ X=,?\$\_^C3?V?O_  Q'P0_^=Q1_
MPZ8_X)Y_]&F_L_?^&(^"'_SN*/\ B*^7_P#0IQO_ (.H?Y>O]/0_XA[C?^AC
MAO\ P55_KO\ T]/\K"BO]4__ (=,?\$\_P#HTW]G[_PQ'P0_^=Q1_P .F/\
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M'96WV*SM+/[1=7?V2V@MOM5[+Y]Y<^1$D7VB[GVIYUU-L\R>7:OF2L[[1G
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MO^RFR'_U:X4\'BK_ ))CB/\ [$.<?^J_$'\;=%%%?Z%'\6G]#'_!!G_FZO\
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M[[7(/%%QJGA_6)M+DNM.T;]_J** "BBB@ HHHH **** "BBB@ HHHH ****
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M6^/"BBBOS,^\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?C#_ ,G&XB_[I'_JBRP_K3PR_P"2(R3_ +J7_JWQX4445^9GW@4444 %%%%
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MXO?_ $.U?7?VAX=]^"O_  SY5_\ .WS_ *LSYWZGQGVXI_\ #EF'_P V^?\
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M?^V_XZ^*/@OQOI>D?\$W?V+_ -I']F?]B_\ :NT*\\'^%M1C\7_$;]HSP_K
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M&?VA/'_[.GA?]J?XN?M%>%OBUXL^%_@_X#^*?'-[H?PR_9Q\6?%3PQ9Z'/\
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M?0O#5QHMQ/9?MY\#OV7/V9OV8[+Q#IO[-G[.OP*_9ZT[Q;=6%]XKL/@=\(_
M'PFLO$U[I45S;Z7>>(;7P%X?T"#6KK38+V\AL+C4H[F6SBN[F.W>-)Y0X![K
M1110 5_/W\9O^"K7[0_P[^,'Q7^'VB>#?@Q=:-X%^)7CKP=I%SJGAWQQ/J=Q
MIGACQ1JFB6$^HS6GQ%L;6:_FM;&*2\EMK*SMY+AI'AM;>,K$G] E?C%\4O\
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MG]CRZQI,'YJ?L6_MZ>"_C?\  P?$#]K+_@X5_P"&9?CE/\6_VA?#'B/X(?\
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M;_@%XF\8^!_'7Q9TW1/%7Q%M?'_Q?^*?QGO/A7XC\??"#PQK_BO4_"/@30_
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M!*?QCXG\?W?@#QZ/"/@3X20_$;QM?+X1U#[9X?T^34?#<>N?+OQA\"?M2_\
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M_9@_Z$/X]?\ A+_#W_YZ->]?\.QOV'?^B(_^9)^+O_S?4?\ #L;]AW_HB/\
MYDGXN_\ S?5X?]B?3'_Z+#P8_P#"7/O_ *%OZ^X]S^V_H=_]$AXS?^%.1?\
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MQ!I>F>+_ (>^)O%_A7Q%X=EU&">_\,:K::V]_=^';O3)-=TW0]=.I:)I_L]
M!1110 4444 %%%% !1110 4444 %%%% !1110 5^>?\ P57_ .3!_CS_ -TN
M_P#5S_#NOT,K\\_^"J__ "8/\>?^Z7?^KG^'=?3<%?\ )9<)?]E-D/\ ZM<*
M>#Q5_P DQQ'_ -B'./\ U7X@_C;HHHK_ $*/XM/Z&/\ @@S_ ,W5_P#=#?\
MWL-?T,5_//\ \$&?^;J_^Z&_^]AK^ABOX;\8?^3C<1?]TC_U198?UIX9?\D1
MDG_=2_\ 5OCPHHHK\S/O HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OSS_ ."J_P#R8/\ 'G_NEW_JY_AW7Z&5^>?_  57_P"3
M!_CS_P!TN_\ 5S_#NOIN"O\ DLN$O^RFR'_U:X4\'BK_ ))CB/\ [$.<?^J_
M$'\;=%%%?Z%'\6GU]X1^./[1G["GQ"^+WP[^$GQ(L_#.I-XDA\-^-+_3_"WA
M+Q)9:_/X%O-=M-(N;4>-_#&LSV$4!UO5I%6TCLGF^V;;S[1]GMFB]._X>K_M
M\?\ 1>?_ #%WP9_^=W117R\.'.'<WHX;,LUX?R/,<PQF$P=7%8W&9/EV(Q->
M?U6C%2J5:N&E.7+",803=H4XQA!1A&,5]!4SO.\LK8C 9=G.;X+!87%8JGA\
M+A<RQM&A1A]8JR:A3A745S2E*<G:\YRE.3<I-L_X>K_M\?\ 1>?_ #%WP9_^
M=W1_P]7_ &^/^B\_^8N^#/\ \[NBBJ_U*X._Z)+AG_PPY7_\R$_ZU<3_ /11
MY]_X=\P_^: _X>K_ +?'_1>?_,7?!G_YW='_  ]7_;X_Z+S_ .8N^#/_ ,[N
MBBC_ %*X._Z)+AG_ ,,.5_\ S('^M7$__11Y]_X=\P_^: _X>K_M\?\ 1>?_
M #%WP9_^=W1_P]7_ &^/^B\_^8N^#/\ \[NBBC_4K@[_ *)+AG_PPY7_ /,@
M?ZU<3_\ 11Y]_P"'?,/_ )H#_AZO^WQ_T7G_ ,Q=\&?_ )W='_#U?]OC_HO/
M_F+O@S_\[NBBC_4K@[_HDN&?_##E?_S('^M7$_\ T4>??^'?,/\ YH#_ (>K
M_M\?]%Y_\Q=\&?\ YW='_#U?]OC_ *+S_P"8N^#/_P [NBBC_4K@[_HDN&?_
M  PY7_\ ,@?ZU<3_ /11Y]_X=\P_^: _X>K_ +?'_1>?_,7?!G_YW='_  ]7
M_;X_Z+S_ .8N^#/_ ,[NBBC_ %*X._Z)+AG_ ,,.5_\ S('^M7$__11Y]_X=
M\P_^: _X>K_M\?\ 1>?_ #%WP9_^=W1_P]7_ &^/^B\_^8N^#/\ \[NBBC_4
MK@[_ *)+AG_PPY7_ /,@?ZU<3_\ 11Y]_P"'?,/_ )H#_AZO^WQ_T7G_ ,Q=
M\&?_ )W='_#U?]OC_HO/_F+O@S_\[NBBC_4K@[_HDN&?_##E?_S('^M7$_\
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M\&?_ )W='_#U?]OC_HO/_F+O@S_\[NBBC_4K@[_HDN&?_##E?_S('^M7$_\
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M\&?_ )W='_#U?]OC_HO/_F+O@S_\[NBBC_4K@[_HDN&?_##E?_S('^M7$_\
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M\&?_ )W='_#U?]OC_HO/_F+O@S_\[NBBC_4K@[_HDN&?_##E?_S('^M7$_\
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&9)+L?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  X #@# 2(  A$! Q$!_\0
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4&%8U==\2@;6.\ Y//3BBBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENTERA BIO LTD.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">
            <div style="font-size:10pt;font-family:Times New Roman">
              <div>
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pay versus Performance</span></span></div>
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are required by SEC rules to disclose the following information regarding compensation paid to our Principal Executive Officer (the &#8220;PEO&#8221;) and our other Named Executive Officers (such other Named Executive Officers collectively referred to hereinafter as the &#8220;Non-PEO NEOs&#8221;). The amounts set forth below under the headings &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to Non-PEO NEOs&#8221; have been calculated in a manner prescribed by the SEC rules and do not necessarily align with how we or the compensation committee views the link between our performance and pay of our named executive officers. The footnotes below set forth the adjustments from the total compensation for each of our NEOs reported in the Summary Compensation Table above. As permitted under the rules applicable to smaller reporting companies, we are including two years of data and are not including a peer group total shareholder return or company-selected measure, as contemplated under Item 402(v) of Regulation S-K. For further information concerning our executive compensation philosophy and how executive compensation is aligned with the Company&#8217;s performance, refer to the section entitled &#8220;Executive Compensation&#8221; included in this proxy statement.</span></span></div>
              </div>
            </div>

              <div>&#160;</div>

            <div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>PEO and Non-PEO NEOs&#8217; compensation is designed to provide a mix of compensation to reward Officers for individual and company performance as well as to align their interests with the interests of shareholders. To achieve our goal of appropriately rewarding our Officers for their efforts, the compensation generally includes: (i) annual base salary, benefits and perquisites; (ii) annual bonus based on target and above-target performance; and (iii) equity-based compensation and retirement benefits.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the years 2023 and 2024, in order to preserve Company&#8217;s cash, PEO and Non-PEO NEOs were granted RSUs in lieu of an annual cash bonus.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A significant portion of the PEO and Non-PEO NEOs total compensation is &#8220;at-risk&#8221; in the form of equity compensation and is directly tied to the Company&#8217;s share performance<span style="font-weight:bold">.</span> As a result, this component of compensation aligns the PEO and Non-PEO NEOs interests with those of shareholders by linking potential rewards to long-term stock price appreciation.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table sets forth additional compensation information of our PEO and Non-PEO NEOs, along with total shareholder return, and net loss results for the years ended December 31, 2024 and 2023:</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Year(1)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Summary</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Table Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>for PEO<br/>(in 000s)(2)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Actually Paid</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>to PEO<br/>(in 000s)(3)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Summary</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Table Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>for Non-PEO</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>NEOs<br/>(in 000s)(4)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Compensation</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Actually Paid</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>to Non-PEO</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>NEOs<br/>(in 000s)(3)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Value of</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Initial Fixed</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$100</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Investment</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Based on</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Total</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shareholder</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Return(5)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Net Loss</strong></span></span></span></span></span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>(in 000s)(6)</strong></span></span></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,149</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,187</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>485</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>849</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>212</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(9,541</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>950</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>483</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>385</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>314</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>21</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(8,889</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="width:7.85pt">&#160;</td>
                      <td style="text-align:right;vertical-align:top;width:28.15pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(3)</span></span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported below represent the amount of &#8220;compensation actually paid&#8221; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year.</span> <span style="font-size:10pt;font-family:Times New Roman">For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#8220;compensation actually paid&#8221; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant.</span> The following table details the applicable adjustments that were made to the determine &#8220;compensation actually paid&#8221; (all amounts are averages for Non-PEO NEOs).</span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>

              <div>&#160;</div>

            <div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The below figures are represented in thousands.</span></span></div>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.85pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.15pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</span></span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.8pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt;font-family:Times New Roman">Cumulative total stockholder return (&#8220;TSR&#8221;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</span></span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:7.8pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                      <td style="width:28.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
              </div>

                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">PEO</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">Non-PEO NEO Average</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Summary Compensation Table Total</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">1,149</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">950</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">485</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">385</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">-the fair value of equity awards granted that are reported in the Summary Compensation Table</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(742</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(532</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(246</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(141</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">360</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">126</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">245</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">72</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">863</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(81</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">222</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(9</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">112</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">28</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the vesting date (from</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">the end of the prior fiscal year) of any awards</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">granted in any prior fiscal year for which all</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">applicable vesting conditions were satisfied at the</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25">end of or during the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">445</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">20</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">115</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">7</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
                          <div style="line-height:1.25;font-weight:bold">Compensation Actually Paid</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">2,187</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">483</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">849</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">314</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>

              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;margin-right:7.9pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pay versus Performance Comparative Disclosure</span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with SEC rules, the Company is providing the following narrative disclosure regarding the relationships between information presented in the pay versus performance tables above.</span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

                <div style="font-size:10pt;font-family:Times New Roman">
                  <div>
                    <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation Actually Paid and Cumulative Total Shareholder Return</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023 and 2024, compensation actually paid (&#8220;CAP&#8221;) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024.</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years.</span></span></div>
                  </div>
                </div>

              <div style="display:none">

                  <div>&#160;</div>

              </div>
            </div>

              <div>&#160;</div>

            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
                <img alt="image1.jpg" height="363" src="image1.jpg" width="603"/>
              </div>
              <div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic">&#160;</div>
              <div>

                  <div style="font-size:10pt;font-family:Times New Roman">
                    <div>
                      <div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic">Compensation Actually Paid and Net Loss</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="text-align:justify;line-height:1.25">During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).</div>
                    </div>
                  </div>

              </div>
            </div>
          <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeerGroupIssuersFnTextBlock', window );">Peer Group Issuers, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">Cumulative total stockholder return (&#8220;TSR&#8221;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">$ 2,187<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">PEO</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">Non-PEO NEO Average</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Summary Compensation Table Total</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">1,149</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">950</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">485</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">385</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">-the fair value of equity awards granted that are reported in the Summary Compensation Table</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(742</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(532</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(246</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(141</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">360</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">126</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">245</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">72</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">863</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(81</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">222</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(9</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">112</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">28</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the vesting date (from</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">the end of the prior fiscal year) of any awards</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">granted in any prior fiscal year for which all</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">applicable vesting conditions were satisfied at the</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25">end of or during the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">445</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">20</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">115</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">7</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
                          <div style="line-height:1.25;font-weight:bold">Compensation Actually Paid</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">2,187</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">483</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">849</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">314</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">$ 849<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">
                <div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">PEO</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">Non-PEO NEO Average</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Summary Compensation Table Total</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">1,149</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">950</div>
                        </td>
                        <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">485</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">385</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">-the fair value of equity awards granted that are reported in the Summary Compensation Table</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(742</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(532</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(246</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(141</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">360</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">126</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">245</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">72</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">863</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(81</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">222</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">(9</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25">)</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">112</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">28</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25">-</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">+/- Change in fair value as of the vesting date (from</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">the end of the prior fiscal year) of any awards</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">granted in any prior fiscal year for which all</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom">
                          <div style="line-height:1.25">applicable vesting conditions were satisfied at the</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25">end of or during the covered fiscal year</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">445</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">20</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">115</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">7</div>
                        </td>
                        <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
                          <div style="line-height:1.25;font-weight:bold">Compensation Actually Paid</div>
                        </td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">2,187</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">483</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">$</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">849</div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">314</span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_EquityValuationAssumptionDifferenceFnTextBlock', window );">Equity Valuation Assumption Difference, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#8220;compensation actually paid&#8221; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">
                <div style="font-size:10pt;font-family:Times New Roman">
                  <div>
                    <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation Actually Paid and Cumulative Total Shareholder Return</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023 and 2024, compensation actually paid (&#8220;CAP&#8221;) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024.</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years.</span></span></div>
                  </div>
                </div>

                  <div>&#160;</div>
                <img alt="image1.jpg" height="363" src="image1.jpg" width="603"/><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">
                  <div style="font-size:10pt;font-family:Times New Roman">
                    <div>
                      <div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic">Compensation Actually Paid and Net Loss</div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="text-align:justify;line-height:1.25">During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).</div>
                    </div>
                  </div>
                <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[6]</sup></td>
<td class="num">$ (9,541)<span></span>
</td>
<td class="num">(8,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Miranda Toledano<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Additional402vDisclosureTextBlock', window );">Additional 402(v) Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman">The dollar amounts reported below represent the amount of &#8220;compensation actually paid&#8221; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure:: 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Net loss<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member] | Fair Value Of Equity Awards Granted Are Reported In Summary Compensation Table [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member] | Fair Value As Of The End Of All Awards Granted During The Covered Fiscal Year That Are Outstanding And Unvested At The End Of The Covered Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">360<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member] | Change In Fair Value At End Of The Covered Fiscal Year Of Any Awards Granted In Any Prior Fiscal Year That Are Outstanding And Unvested As Of The End Of The Covered Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">863<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember', window );">Principal Executive Officer [Member] | Change In Fair Value As Of The Vesting Date Of Any Awards Granted In Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied At The End Of Or During The Covered Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">445<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">849<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member] | Fair Value Of Equity Awards Granted Are Reported In Summary Compensation Table [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member] | Fair Value As Of The End Of All Awards Granted During The Covered Fiscal Year That Are Outstanding And Unvested At The End Of The Covered Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member] | Change In Fair Value At End Of The Covered Fiscal Year Of Any Awards Granted In Any Prior Fiscal Year That Are Outstanding And Unvested As Of The End Of The Covered Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember', window );">Non Principal Executive Officer And Non Executive Officer [Member] | Change In Fair Value As Of The Vesting Date Of Any Awards Granted In Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied At The End Of Or During The Covered Fiscal Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The dollar amounts reported below represent the amount of &#8220;compensation actually paid&#8221; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year. For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#8220;compensation actually paid&#8221; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant. The following table details the applicable adjustments that were made to the determine &#8220;compensation actually paid&#8221; (all amounts are averages for Non-PEO NEOs).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Cumulative total stockholder return (&#8220;TSR&#8221;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Additional402vDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Additional402vDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_EquityValuationAssumptionDifferenceFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_EquityValuationAssumptionDifferenceFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeerGroupIssuersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeerGroupIssuersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=entx_PrincipalExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>27</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>8</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="zk2533282.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2533282.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2533282.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>entx-20241231.xsd</File>
    <File>entx-20241231_def.xml</File>
    <File>entx-20241231_lab.xml</File>
    <File>entx-20241231_pre.xml</File>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="zk2533282.htm">zk2533282.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
    <File>image00002.jpg</File>
    <File>image1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="50">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2533282.htm": {
   "nsprefix": "entx",
   "nsuri": "http://www.enterabio.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "entx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "entx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "entx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "entx-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2533282.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 7,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 27,
   "entityCount": 1,
   "segmentCount": 8,
   "elementCount": 273,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 50,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20241231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533282.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "entx_ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value As Of The Vesting Date Of Any Awards Granted In Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied At The End Of Or During The Covered Fiscal Year [Member]",
        "documentation": "Represents about change in fair value as of the vesting date of any awards granted in any prior fiscal year for which all applicable vesting conditions were satisfied at the end of or during the covered fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "entx_ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value At End Of The Covered Fiscal Year Of Any Awards Granted In Any Prior Fiscal Year That Are Outstanding And Unvested As Of The End Of The Covered Fiscal Year [Member]",
        "documentation": "Represents about change in fair value at end of the covered fiscal year of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "entx_FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value As Of The End Of All Awards Granted During The Covered Fiscal Year That Are Outstanding And Unvested At The End Of The Covered Year [Member]",
        "documentation": "Represents about Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year."
       }
      }
     },
     "auth_ref": []
    },
    "entx_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about fair value as of vesting date of equity awards granted and vested in the year.",
        "label": "Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "entx_FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Equity Awards Granted Are Reported In Summary Compensation Table [Member]",
        "documentation": "Represents about fair value of equity awards granted that are reported in the summary compensation table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "entx_NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for non principal executive officer and non executive officer.",
        "label": "Non Principal Executive Officer And Non Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "entx_PrincipalExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.enterabio.com/20241231",
     "localname": "PrincipalExecutiveOfficerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Principal Executive Officer.",
        "label": "Principal Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001178913-25-002111-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-25-002111-xbrl.zip
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M04(0]0).QC0D$A(.Y.W=G=@<+^*T0E'JQ([';R)_JF/=8/EPN_P'4$L#!!0
M   ( *V Q5KC%C[I70,  ($5   5    96YT>"TR,#(T,3(S,5]D968N>&UL
MU5A;;]HP%'[?K\C2YQ "11H5M&*45DAMJ5IZV5-D8H=X<^S,=KCLU\\.I(06
M"F'I"B^0V.?RG?N!QMDD),8(<8$9;9I.J6P:B'H,8CILFK'TK6_FV>F7!L'T
MUXG^& "!#,5#1=,,I(Q.;'L\'I<F TY*C _M2KE<M5-"<T:9,.8@GPB\1#VN
MIK2._7Q]=>\%* 06ID("ZBVXWFB9\SGU>MU.;A6IP"<BX;]B'I")T1MQ&6LI
M])N5DEGZR'(J5M4I300T3[\81N.K91G=FW[GLOML#*9&YX_U_/WNRK"LY#9Q
M*V<$W2'?T-\/=]T70(DJ@;S2D(ULY$%;$]A="O$(PQ@0T:-DJDQ*A,AIA)JF
MP&%$4'H6<.3/I(E5XBKERK%^L/2#1GST6K:]*\C;4=2"/V,A0T1E\3A7B,]
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MS<RT817CL891PHE(1VM<1ZD@[*YPK=RD20NN9L<5T-7?@Z[?0C_T,*39BXT
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MH$N.K.:W[G]X)C\#B> CX5<;GRZ1'*<Q52."NW8SZLQ2F&^!*^D1K_(*0.E
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M%Z.FI3]<\EO0I2#+[2(W=VMCC%OJD[\T30A\:2-FMSB?U,H10;TN[,24+$3
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M..P)T*"+JHEV77/$]&V<A*TZ+#>V?G02D,\!>VD\0M=D]C)?#]8?7^ZOW@F
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MT9&NE^E(#78ZTI-,Z%8.?D9'DJ4!GQ+!+S[@EX<#G[^EMX5_HR,]:U-0-7?
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M53+2@QN]T.SB28+:=:2:8*YG%"CO3*/;G\I+:/5>@QRX!2>(BIR0CM\;UFU
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M',P:_M122,DFZ.%#;)-B=T0+VQKOZ&.HG-DOE%[+Q0)!$8-7.A06VK[NF5J
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M(%\Q@$66,/V)K$@_JK4EUZ 1X?V5=>5GA YI!]*SYQH2ZV&0I+T%QO"R*/7
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M156 .<=_[)T(W_%GPXK@C=-WI(."<YC]'98'#*1Y4YC,MS?TGPHMX,FT4QO
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M)BE4YLT.5)0N!Q?$!;VXUR%3!>]%T@OJK?)=[YJ$Z?LU-%V=;/DR[(089I.
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M9LOJ!,BD>&C1+Z*?0P(Z;9GT;?7[+U(W77B4NF/5MYV4]U<L]+X2@F+V8U1
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MVRE.1F=.76AKYEC+&-E=[5=5?")VQA*Z9F#BAN8?^""E=@0SCU D33@IZ!Q
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M*R)"5 0$A*BHJ QQ +$9DE8$1!JCHB(@I!61(4+:!B1"R%81(B"D'6E%B(J
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MIKAT&J:RAC.3_KX>5U5;45%S+NB0Z( 6%TGHK1YJG8@%:9B4JIB<T!WZP03
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MOV,JBJT2G:."/)'<4J;F3DS"NT48=%< 'W@J$<*,_2CM%H&>DT^2KZ#S\S#
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M@-"$KH&X;-LXSOQ(TD_MM\M%==(U:/=WSGPXM,E_T+3+=9N\7B>X$S%ZY*,
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ME[<;?@..U=ECVE(-7<3?YIE Y$:E@_RJ,IIA&5)9D>1H^@SY!8Z2XN\8:T+
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MK@B= K^D[I)L'32!H4L_ %8T$F-)*] M-(-1RL0BY AH=QM=1W.>_(HO.3E
M(S>FJ3'CK3=]"Z]X+Z<\N-SBUC54L7W7K=.0[NG;G"^J<A)FZ/&,=T#Q=T3#
M"<,($9! ZA+MJ*$XB?Y%6*$LG,,%\S49S;PUW>/6K/D9S\VC"25W4T2J1"9G
M61&9NHHF<(:3\'<<-ST;-EX/-K(+:><&ZTY$)3F=N*5FYY4FG-TU7[4(L80\
MWTY\LI-O@6VDZ;M*A09T"V4*#X<0H2OIE]1[OUT6:M'<Q=28TMV1AUY'_\5^
M__I%YWA1H=D=]S6NCR-6B!:OP?_JM?^J;(+I&+7[RV<YH$FH"[7IG.S[-(>K
MQ3\9N'ZWSS5 5*8X6!)_CB#0.$'_@?LC(#/HQE_[<==T=+X"8"+B/(=[DCN'
M2W7&H.U[;:#6"C)$$SBHKP&F8>L/J^1X!9+G<$OX]=19<^#'F1 2DNR"K)O#
M:?"'\S PG?P8F,1D!?^7K/^2]5^R_N_)<K%N[:^S;*@OKEFH4=4AV%%PN&ZY
M6Z!K</*'IQ<:$SY^&]?1UCV-V\ [!O=";LWR:^#M06LX#_K6\4O'I?7VP;=@
MD[V5/55.C+A5H9G&;4\J%8%YU_KO_;7M>9_O/B&ELZB@X __/S'$A&Y N_!E
MD3*I) OT$1^KB#\#,O(=S&%WIXJ.Z3<9/NZN^\R.P\E%(VU])WJ'\[^ZF XD
M?7N,C_TM)XI&9A_E);3+/1L0;Z@NIFK[T>VYGAKUG\,?1-E?-5OX=ZCDTIUP
MNI-7G>/1T+U5+Q'+T _F&6[WGY^^8)$^NLKQ3%[G'2(9?%-CO G:T7_V.8VA
M+WI8D9D3T?A:>N(WSJ*]S.KXN[K'<O><7?5\ZY'[(QWYGFI,.C^P\=<NMW/
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M0HS4ZUF]USX8<E?#WK7&#A A2;TNG;L<UI)\C3]E;5LY25F#[]NO X?GHTU
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M39XK:.K[(>/768B^\@51]&36+-K180&%L0TZ5YR#."B?,,P^T2+WQ_26J6O
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M>>QXNJO$*HZA#DY+:_ON)H+^#9EK(&),D8VZ1EAK?^CO(8SUD&W>HY$60#Y
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M\_)\V,!@:B##9615FEO68YL5H1U<UUS**Y>,7>])^[_EVY:5LTN*)X'Q9O$
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M-N2N<,$P<L<,2UV9Z!']GE_&46X8DUW\$4A-^;MNTO;'WPD$N[\9]AC9)U*
M.$ZQW?@IJ? NL,R:NGB4N'(=1*RC,E'#+G1]RS-_9 =H^;U^PF@X4(441]0P
M:^^S>%5E*M;I3C_*7_>U7=_,_<"Y<[I+U]_U_.P93YI</T;ZO@(;NRP&V F
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MJSX41%[^H]U@K^VV-PW7VZ9>;[U:/#'E\NNF!,S$Y7(_1(DH [P?YM%AG#\
MI]G#VYEKI)A'M<UXR+I;BOFQ\U?\FQ)$+DR*T5.05+-FIH'+4HS$$\$SHDJ^
MTB"]4O#C4G8@5I!&EO^%Y[7/4?B\_)J;(ZMZQB^&F)QSX)[>H_0]K[<ZZ>BW
M;]FKD[?*Z> JIAICQ@HO+L<BKYX2%Q,/(P$E\!5[210?F)?\G)N@[_33$C-
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M8B2'_@$J^$3!1(V%&ZR:A:SV+[T<:F[F92+\"67"\&:^2\^IAA$_7A!K9KH
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M38:-2S["0?_: OXK;I5)IS;R)LBY!:=%(E&5R7@"!/ DNH1[@2(A(X;B\3C
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MZPI%B>IJVW#9;ZX^)V_SH(-97C\.[FF!H5O_!">A+N"R"%LCU)S3;0-W$0]
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M C;:5V4#_JW!%;IO68E%^)=$KIY&];TW5IM&_,PW B&*:.0A'MK5+TAZ-WX
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M3A,LZ11O*.*'@S98A2X<DY.&"]4PMMKC$J2X);0%S5!&+7\J<5.RJDEI$Z2
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M90:*CU(X;P2T4WQ*L;&_MIOMUPWOKUO-EULT(/SU:KL!)Y>-@33#-433)B"
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MO+%9FE]_5$<U]^2VS<EM/X63V[[%R6W?S\E58.[?T@] AT?Z ;)#YS+,_HV
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MO=CJO)]<PMMP0CFU$)^N_^CVWJWG(;S=E?;^JOUTA+=7S?;#KO8>+N\P\0:
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MU(S02.6[658>BDSU85.5N.HJ4^FB,DWOD'>6+2)<JD *KH$[?#"U\@%F@*0
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M<2M/A9BVGCPQG8D*^I'IYZ<0>'OD?83EY?^]UE$\&>KY\H>@GD=CF7)BQ^-
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MY2@6:PL LA6]PA:>/:ZTM#Q4G54"4>U$=&C_*4+_&_9^Q(Z-+MV:LVR3RJ@
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M['@7HBPY&8QTC7=E!(%A$#=UI>.E+;'_XOW7JWP<PE"4,9%I=Z.:!A%-IXH
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MZP$B\BT'U@0B-+ 7Z%Y3DB):^4#4YEB(5!7L,(U91[BK595K;AL":\[ $MI
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MO37#I=DB9/SF@K#2N#^I$2,3 4* V@VE'%6+O[OG$ X0GU&:3M#*;<-Z6<<
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M2WH"FM6MV(8$&*.:XL4&'QLUIO0%:W@[$PO^;L:^_\[Q +RKI-G0/F?!_GJ
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M,Y%82),6)28EO-/OE@4"N43&'I$17FEP4UT"N1Q07HX3DC[*RZ]'@%AOXH\
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MHHZY$;!+-5RLS,;EF9+EEC56LF2U9LN;Y559-EMB8^8DCKI!]N1F,XZ#,=F
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M+SYCUNH$$":^(4E-V#M/XNL +U6 VH$IN2";)TBT)"U\$FPUUN_5A$6A9H!
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M:TQ'\9RV@6HW,B;B6ZI@/B&NX1F78P2@,1(MDF2;B-@.^H^)=6#Y_<*Z6.$
MP)_9Z'<4/=;#<N0@#FOMK_QTRFQ.%7,N6//<#\:*$8:L]>+OMBZO=$-#"06C
M;"2'D@:M):\1VZCP@N69$XZSJ:O8*W-A,%?SJ&C580UO$'T&V)OK=EO\,9.G
M36BTB[+W?EU,U*Z2(5@($56-U($*ZK> ,[&JY*LUHR@>2H(DTHD.76#+#IKS
MS0?R^S 1WK L-DNCQR5!9(/4WJL!@+UG-'+,R;"53UU'\#?X(Y7AQ%7*XH+G
MRW9;VB78&C*XUDZ'$K2JV#K4PY"7  <"OAJA4],\P/,R_A'4!>,\$V$ N$!X
MP4J*91EJ"3[RY\@!X%MX2JS0*QQQ1&' #W$?W&T%;:]8B7U0DLB11S5(M2_/
M..I4:75BO '3E2(*94<9?>-0?)5E?1=I"T0&&<,6OM?H(95S/R'-SBL\6]K-
M4I5.6E8P@9;AC?JP,1)\ X HCHX*P"MIEC$84##%D7((Y7.<M:>ZXD2UN>W9
M/$5I@<5UX!,)T,N9ABMR2C2X^>R5& Q3VOI8P[NTQRNL6>PNV;PK J3Z ,M
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MF@)!L[UFJ:("[_H;S#8' AIQ"OPPB(_F4Q\4&N52\814<4M4T,C37 BZ8P.
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M@AR60*@N?T\1< I_:$=%%%"Q=7HE+;U#'B+:GK4T Z'"4Z* 01G+1EH5U[J
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MY^/.\_LE"$,9BI]AB.P_C3G&;:I>FZJW_^[S/5SR[CW^O<'3\?<[O(MVR?M
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M BO6=#R!_UM:VZEJV6RFS;WW9[+!0EJ[%$+SSM6Y61NZ4W&)WC>F6PM\#3;
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M?.T3H;CS@3*>@/' R+4)*/.%+: *]S_D6R?L\R4_"@@!N?K 2H< (CO#X8H
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M<4,=G!%9L?T/3F2560$6%X"1X*A\=O:&QB':3.'6 VX23&Y9CT):*GF2DHV
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MWWX \^O&\[=!:V,^+_\M2Z*R;F4ORAAGBN9?8I,4ZWRLAC]]T7TL2.PZ'[W
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M^UD3!F169+#:4MK,;INA=]MZD\43C=-<6 )\]T<@*ATP!41X[T4H"J,X3 ;
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M2J ?#<5 PO_>4U0;J8>@_SO.*>N-I)_+LV_:RJC">Z/53/!HN"820H^*)Q)
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M<U:@VA05AWNL1F"[?VJIOB*I7CVQ?L&!B&,9B)A?C*/[)H>\VY7>&%-(?Y=
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M1S"T;F/A^76YH;K<T K*#<&UP@AS0]<;(L68TN$CD(*PQ=PWX!.8 *-@PDB
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MU^.C/Q]G&O5:K47VSR&;Z;,G1L/WCBROM'T)"_N 80SQWCG[_/^[OB]^_FL
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MB0Q8 (M+(7J> @?#._(KV*K\*/!OMLFW'.CU-;@T&%8,HZ@[$Z6$%32,3^)
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MJ@C*@NN81B*;H&1T7O<!5%'N6B[9"W$[0Q6F_"O_%M./4*V/S60D:D^B>J[
MOZ]10^<&J3F7PM,UA>>-O._6D??%(N^UXT,[/CJK3[$^-"H//8LR/F=B5Z$?
MS\Q*<7VK:E(C:V7SEQNRI!+5[<YE/I>8J+/:REO6:IWD\EC@1F=I)03F!VZ<
MA1Z(G,GH_[;WK5UM*UG:W_TK]&;63,-:QN%.2&;.6@XX"1,P#';.Z7P4=@$Z
MD26W)$/H7__6OE2I=+,EW[ 3]^INXIM4JMJU:U^?1V-YYD2?RU_-4G-0>*F)
M.2 =[LL[/A*H8&FB<M6];[M OHI-A28I6FI_T :(6VX2H2$'R;*-;G9T)5#
MTVVNXQEE5?".RP7OA-SWJB<-:5Q[T+;7MP.,R,4YA02=$HV7:9,8&C_])"9Z
M08J;(8[Z87\WH7>6";S_/EOX]>NM2SGJ-_8+\V1)MQ6<4*WED80>:0L&H+C_
M-;+A9""@S=BL5,ZL:88.I/\Q"L16N&U":F#8.$<*S=I8)/$RR.V&3J3[I0?$
M64P4)8P#2R;S$P93%4:L?Z>8@'1%JLZG):A.56(.R2,HGFL$#32=7_+)<YX3
MVEP=$E1="$R<@+2Q2AUWM->2N!A\_7A(INY)J@L5%U%-@;2+*22OES/Y$[G:
M0:1[D9%UQ*!C;E@7]R9>2M^7SPEI-H"JCU4<3*"2G/RY,0@S$HJI;FI5:(IF
M5C;0C-#5_( Y2$>N^",*8?@HJ)$YVSUKK)GFF-%$-K0&!$PM!PA^!UP['K44
MNY,CZS^IHMJ.:[8K+%X"TL28'#LB:JIP"'72T)P)H+SR!3#Y\BQ0#@ _,5B^
MU;1GCZ.<YF$*)L7:>^/OKZ4J[IHT-FEIY)ZI!-6-$QI6N"'RJEPV0N -U*ED
MK*AKH0&?"K;*J=;#2=$G!:F,F]K;M$,20S(H*E#V5;DN)SY5$P4&,:S!R(VD
MG>A  A4XCQI6DZ_&Y2YJ/*EK.WV0?L@C9V8)&Z"-?138'O7E3P*W+VV/)ILG
M8N8I30A"FP9?)$RE^78S_Z:EQX=[C=.#^9<>3XY,'1T!JFHJ+G5T/(>"L0E%
MRF5JZ$I-W=&[QN[)JQ8K0\4/R-;.\6X>5L?)WJ(*DTFSIM3)EJ%^C,:"7$U5
M0,:T2%G>U#)7$=^5J&5.%Y/NSCZI;_[8VU^^[&V*DF>0QJ4*QVZ9,L>-I;]B
MECXWRJB#""(1R/F)UBN?._'IM*T,?=T-ES'XJUGZ^T?36?J#Y+#I3\\>;E.P
MWG5S0J=[[Q!B+U0MP@J(3QVW$)S0H^%'WW SK)4T=Q^-<$\B1I6.-^<%U#,N
M'(=6G"".[I%:#^MY]3H,*JJ'1#F/?:K(WTC2JDA2GM#DQ@N-*J]Z3CAS_6 !
M3C;%"2L "["^>W>NN>#Y5""7CY:=IX&EX^SBI-V_!LGC&P1#E::869::GR%2
M)Y^1 ,YIU3!K1 NK(O!' -^.'0 OZG5\DH[%UN/<5 *O/67U:>1S-1I^C%3V
MFP#@RTX!!'?I'#< =,)0SC$E,7#D_&5\E#3L)1>;J#'EA\DUDK"2-#:)32"Q
MO+4H* 36*2DC<P2QHIBN.<[VJ#,+$70T?#58(3C7@3!@-A\# >8T=*-((^C!
M5TUVN;*3?L9-HGW%;)L*W*@O\;+N6%)G>?[ Z6%Z,PI $N2+1+I9?;MNZ>K0
ML<U06]F<>3)EK@<U]]3Y5!GS=+%,(G,>YBE0PK$:".USJHE5BJYNH%3%^71J
MVCW<U0YOY$>ZVB5=:ZM'I:ZY@:!;J[VFSV5CLY%,WE,O$D@(?88O?XAD 8OC
M09LJ-&-:6U]O+L+MW#,CX[F& IEHA4F[G3@Q#3 YU5)2(.A3"FXLL'B\4]^,
M'*<>CCE>4AVIB8KK-J%JI)ZF'O?EB8V\XRE,_WN_![T)#ZK,)-EKL]D^:[5]
MKA"&.\"N 7D.V XTL>Y 6%'((R%&^#>%2:-^)_<1-CD;.XWS_%T-]IVZ2S*[
MGMX%^X6[P#@ ZE:2PU>:QM+V+"J6I"(<J1S<])&;-8.-O<]BCA5*<*TXTA4_
M2VJ&XJTUL/MB82SA^5UAZ[MG5@XVI*J3&-?(:,-)JUT\A^)]H$6O4'1B$8S+
M)@M<%^"-0$>[N#9PO!!.#),5PBAD*R5.#QN'11T)OTP_^5PC-<N&6\SG 411
MN1OUI0"]8CRF:%?A&: J'W&022&GG32NV\6LQT]7UX:C@1X-ST<B T97-]->
MI;!G?A]S9Z[[X7#)^^$C9S<I405[8B!ZC[;GA(,UB$QV]>;->BDY2;A$B7@J
M71Q[^F&>)92Y?N$Q4W9K3X2LFFX25-!.A4@Q?*G.1N+9(M,L8]PAE,N.7$0[
M=NO< K!Z0.I1>?&BHYD+PN/,IC[O:3CU-+3VFR%W::#LP-,,Y,(5& -&2; 1
M;3<;FS(]>KK60,>3$T6]6PF;!=_;3K,SJ%5G0E!3<>H]I *YO2A=JOXJHH%^
MU.X'<V[QK;T/:2=\$W%=,3=V4C99=W?4V7.,_;.D&N1N"DP3(-4A"OSSHQV%
MR(N+X7SD\>P3VM\FE+'B,F"D:3**+*7V<-4=51^EU)-N%<I*TZ:<9%47OYDT
MS1>\;3?AEM4-MY0U)<X,RSY/5QBJ1)NX&H@G0?!J4%BAK.V .2$O"VEC(%2/
MS>9$!!!,+1N?P ;C-'KT^U6P2^?" %PA++.,4JEWFU*I3:G4ZRLO"C@<O0+?
M289#2;E5IL^4PVA2<*)M0JL+/Y;R-!ESI'O]5);)2*2:140<@I#'@5F]-2Y6
MB0FT.*=;>,F4CQ[74 2V%U+DA[A^@<R33&;C"*QG0Z*FKZS"$$L")*^ HO!H
M/U&=")Y&!,[<'_72D'N)( FAJ3AQIKSOA+U $.IC?X1E,CTGZ(T&(6(2AQ,J
M^8J&N*39LI.P-GDX,R4GT^@K28@E1+/BZAUH='8"Z.DV^9E>V+&&0U0G1U&_
ML62FALFC,R>JT C: )CILVKAL,(=@*Q8-(+9(@#:E>*8A*E42TD\%[O]F_$U
MGN%# Z4[)Z-D UC.#K0Z$<"'5BQ;%'2 2++'_4X8:4\51O0")X(D\'9-,TP
MF@D!.0BH3\"WK-#Y27LL 0@/+60@[B:LKKFWMNL$1-+S'SQ'N3QP,?E2/@"
MA">B_D%-<3:Z0G_=XWI=*BK4(#W)+\FU^1ML%CAA[!Z]'1@1%O6%@>.*, *
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M A.!'"D$2.3?C56V*N*>IWG%SZ'#?.!*6F"I.>ZPPVGJO5TL;PICJ)B$:'T
MT=HL\XHL<[E3%\%HB>4MV1-,X.A<(P!3] 0Z;(OKH_I..)#N.+"+2T4C[V!S
M^92PY2D(D%Y.R*F7;50XE*G"'C&Y(('O-HPX6$&0,17;@2ZX>\<L:LA<%)4;
M'[9<2TEQQU0Z@K\2IQ+CP&5D_XCCL'R<BR?.^N7<DL)PBOA%)?>E_AQ%JD*@
M(9\K?1VI]$<]Z<- *E)?TG1TMIR&: "WO%%?88XK;G-*I?)"RQD,1-]!=!HX
M>B";14%JLU0#3C#Y"" XJC80:M\YI4C-GGP]/)<" 3%K&+\-V3L[C(\C+O0
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M;G8OKMO6]2?YWT\79RWK[+I]?@'O=38'QVMXD^_FY'6,]2:?4#.W?;"+5@W
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M;JG@E)TLR:?NMR0N*<4*^F(8.$])R%/JHU>S)J_-OU?8$%)=(J\+Q. Q/B\
ME0]PH[:<;7P+.I,@\L^XA%J?T76234-0#^ULH^[EK^MH0=RT%U.1ECQZ:J;N
M5V</5FPGBMI;"",($W"N.U>DMKM!UPOSUC Z&!X2]<#GSU3E%J;&E0 TA6C#
M4! :? VZ7FA*L0UBHU(6K5(6GG6X%1&'=U%"NL9.4_ MKZAB<I# BDU':)UX
M$)Z 7I)@!(R]'H*=F<]G:)*:G:H"S1:MQL#)NB D;\\RNVLIA&&T9>RXJ+AF
MP!XE.@>WZQ@9XN)E[ J)GP0+<1/A4H(\8JT36W3*@(O+3E4FD[X:_G8@814
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MX/B>^Z):C'+OFW;P"GJ7M 4";<E8,9"YH8,&/>,P41>R6MJ\[Q(2TP^@Y(F
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MCK@F>DGA(!H- %(WH.+8OOB)\=^:<Y^!1^%JJCYV;M9SLI" FHG0"TX8(K8
M A$H*8_\!X%6ALX>>G*>DQB2+S% 'A1P .:=:NSD)V1#0(WK>!=);3 _2= L
M5/D5B@AR-M3S250':M)2\VW!?,?3J][EU S>K:;NEH46CK,X"+[U>A4>A;+W
MB4T5^\EW^BJ)TO='=PSXK/" :VB$)&RD1*80R:UU^8P%<I4TG.1>]V%KXUPF
MKYT25G4^DB#R71!_YZ5F]_UAQ"K+LP1"E6:SVG4J(Y&6GQ,GI&]'4K_M[9[O
M[!D@JJV?#.+4Y"9#MNM<"C*T[;!O_PM1(,-$[C=OC"JM6Y.#ZW !R\'NH7K
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M-*4Z7YJW+>Z"6<GAU[K7UL>6]:5U>6Y)2^^OUGF[U3EO?J];__OM\KM4:=!
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MQSNGAP<GVRI1^<V#8DJK VU8N-R3K[Z_*_]W>KIS>'AXG![J?> /H&12@->
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M,#(T,3(S,5]D968N>&UL4$L! A0#%     @ K8#%6HTD8[O3!0  WCL  !4
M             ( !20@  &5N='@M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( *V Q5HD5+!J0P,  *@5   5              "  4\.  !E;G1X+3(P
M,C0Q,C,Q7W!R92YX;6Q02P$"% ,4    " "M@,5:=:'X-=P<  #='0  "@
M            @ '%$0  :6UA9V4P+FIP9U!+ 0(4 Q0    ( *V Q5H$E0%_
M@ @   L)   .              "  <DN  !I;6%G93 P,# R+FIP9U!+ 0(4
M Q0    ( *V Q5J=V21ATT,! -R1 0 *              "  74W  !I;6%G
M93$N:G!G4$L! A0#%     @ K8#%6NLI7TUXD0$ 9],-  T
J ( !<'L! 'IK,C4S,S(X,BYH=&U02P4&      @ " #O 0  $PT#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>zk2533282_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:entx="http://www.enterabio.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="entx-20241231.xsd" xlink:type="simple"/>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:PrincipalExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">entx:ChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">entx:NonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ecdMeasureAxis_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentType
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528100047787">DEF 14A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20241231" id="F20250528042836232_0">0001638097</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_20240101to20241231" id="F20250528042836232_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528100107936">ENTERA BIO LTD.</dei:EntityRegistrantName>
    <ecd:PeoName
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528113155573">Miranda Toledano</ecd:PeoName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250605224610609">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:PvpTableTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528101351118">
            &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pay versus Performance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We are required by SEC rules to disclose the following information regarding compensation paid to our Principal Executive Officer (the &#x201c;PEO&#x201d;) and our other Named Executive Officers (such other Named Executive Officers collectively referred to hereinafter as the &#x201c;Non-PEO NEOs&#x201d;). The amounts set forth below under the headings &#x201c;Compensation Actually Paid to PEO&#x201d; and &#x201c;Average Compensation Actually Paid to Non-PEO NEOs&#x201d; have been calculated in a manner prescribed by the SEC rules and do not necessarily align with how we or the compensation committee views the link between our performance and pay of our named executive officers. The footnotes below set forth the adjustments from the total compensation for each of our NEOs reported in the Summary Compensation Table above. As permitted under the rules applicable to smaller reporting companies, we are including two years of data and are not including a peer group total shareholder return or company-selected measure, as contemplated under Item 402(v) of Regulation S-K. For further information concerning our executive compensation philosophy and how executive compensation is aligned with the Company&#x2019;s performance, refer to the section entitled &#x201c;Executive Compensation&#x201d; included in this proxy statement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

              &lt;div&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;PEO and Non-PEO NEOs&#x2019; compensation is designed to provide a mix of compensation to reward Officers for individual and company performance as well as to align their interests with the interests of shareholders. To achieve our goal of appropriately rewarding our Officers for their efforts, the compensation generally includes: (i) annual base salary, benefits and perquisites; (ii) annual bonus based on target and above-target performance; and (iii) equity-based compensation and retirement benefits.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the years 2023 and 2024, in order to preserve Company&#x2019;s cash, PEO and Non-PEO NEOs were granted RSUs in lieu of an annual cash bonus.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A significant portion of the PEO and Non-PEO NEOs total compensation is &#x201c;at-risk&#x201d; in the form of equity compensation and is directly tied to the Company&#x2019;s share performance&lt;span style="font-weight:bold"&gt;.&lt;/span&gt; As a result, this component of compensation aligns the PEO and Non-PEO NEOs interests with those of shareholders by linking potential rewards to long-term stock price appreciation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following table sets forth additional compensation information of our PEO and Non-PEO NEOs, along with total shareholder return, and net loss results for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year(1)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Compensation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Table Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;for PEO&lt;br/&gt;(in 000s)(2)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Compensation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Actually Paid&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to PEO&lt;br/&gt;(in 000s)(3)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Compensation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Table Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;for Non-PEO&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;NEOs&lt;br/&gt;(in 000s)(4)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Compensation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Actually Paid&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Non-PEO&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;NEOs&lt;br/&gt;(in 000s)(3)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Initial Fixed&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$100&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Investment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Based on&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shareholder&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Return(5)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Net Loss&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(in 000s)(6)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,149&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,187&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;485&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;849&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(9,541&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;950&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;483&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;385&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;314&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(8,889&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:7.85pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.15pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:7.85pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.15pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#x201c;Total&#x201d; column of the Summary Compensation Table for each applicable year.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="width:7.85pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:28.15pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(3)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;The dollar amounts reported below represent the amount of &#x201c;compensation actually paid&#x201d; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year.&lt;/span&gt; &lt;span style="font-size:10pt;font-family:Times New Roman"&gt;For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#x201c;compensation actually paid&#x201d; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant.&lt;/span&gt; The following table details the applicable adjustments that were made to the determine &#x201c;compensation actually paid&#x201d; (all amounts are averages for Non-PEO NEOs).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;

              &lt;div&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The below figures are represented in thousands.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:7.85pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.15pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#x201c;Total&#x201d; column of the Summary Compensation Table for each applicable year.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:7.8pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.2pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Cumulative total stockholder return (&#x201c;TSR&#x201d;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:7.8pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.2pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;/div&gt;

                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;PEO&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;Non-PEO NEO Average&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Summary Compensation Table Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;1,149&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;950&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;485&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;385&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-the fair value of equity awards granted that are reported in the Summary Compensation Table&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(742&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(532&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(246&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(141&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;360&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;126&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;245&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;863&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(81&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;222&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;112&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;28&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the vesting date (from&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;the end of the prior fiscal year) of any awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;granted in any prior fiscal year for which all&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;applicable vesting conditions were satisfied at the&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;end of or during the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;445&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;20&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;115&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;7&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-weight:bold"&gt;Compensation Actually Paid&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;2,187&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;483&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;849&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;314&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;

              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-right:7.9pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pay versus Performance Comparative Disclosure&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with SEC rules, the Company is providing the following narrative disclosure regarding the relationships between information presented in the pay versus performance tables above.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;

                &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                  &lt;div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation Actually Paid and Cumulative Total Shareholder Return&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2023 and 2024, compensation actually paid (&#x201c;CAP&#x201d;) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

              &lt;div style="display:none"&gt;

                  &lt;div&gt;&#160;&lt;/div&gt;

              &lt;/div&gt;
            &lt;/div&gt;

              &lt;div&gt;&#160;&lt;/div&gt;

            &lt;div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
                &lt;img alt="image1.jpg" height="363" src="image1.jpg" width="603"/&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic"&gt;&#160;&lt;/div&gt;
              &lt;div&gt;

                  &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic"&gt;Compensation Actually Paid and Net Loss&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25"&gt;During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
            &lt;/div&gt;
          </ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528111816153"
      unitRef="USD">1149000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528111840911"
      unitRef="USD">2187000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528111909715"
      unitRef="USD">485000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528111932493"
      unitRef="USD">849000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528112422091"
      unitRef="USD">212000</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250528112502844"
      unitRef="USD">-9541000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528111816153"
      unitRef="USD">950000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528111840911"
      unitRef="USD">483000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528111909715"
      unitRef="USD">385000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528111932493"
      unitRef="USD">314000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528112422091"
      unitRef="USD">21000</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250528112826678_xbrl_20250528112502844"
      unitRef="USD">-8889000</us-gaap:NetIncomeLoss>
    <ecd:Additional402vDisclosureTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528113329169">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;The dollar amounts reported below represent the amount of &#x201c;compensation actually paid&#x201d; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year.&lt;/span&gt;</ecd:Additional402vDisclosureTextBlock>
    <ecd:EquityValuationAssumptionDifferenceFnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528113425486">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#x201c;compensation actually paid&#x201d; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant.&lt;/span&gt;</ecd:EquityValuationAssumptionDifferenceFnTextBlock>
    <ecd:NamedExecutiveOfficersFnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528120504161">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#x201c;Total&#x201d; column of the Summary Compensation Table for each applicable year.&lt;/span&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeerGroupIssuersFnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528120600942">&lt;span style="font-size:10pt;font-family:Times New Roman"&gt;Cumulative total stockholder return (&#x201c;TSR&#x201d;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.&lt;/span&gt;</ecd:PeerGroupIssuersFnTextBlock>
    <ecd:MeasureName
      contextRef="C_20240101to20241231_ecdMeasureAxis_1"
      id="Fxbrl_20250528120647757">Net loss</ecd:MeasureName>
    <ecd:AdjToNonPeoNeoCompFnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528114213620">
                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;PEO&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;Non-PEO NEO Average&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Summary Compensation Table Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;1,149&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;950&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;485&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;385&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-the fair value of equity awards granted that are reported in the Summary Compensation Table&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(742&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(532&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(246&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(141&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;360&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;126&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;245&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;863&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(81&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;222&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;112&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;28&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the vesting date (from&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;the end of the prior fiscal year) of any awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;granted in any prior fiscal year for which all&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;applicable vesting conditions were satisfied at the&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;end of or during the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;445&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;20&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;115&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;7&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-weight:bold"&gt;Compensation Actually Paid&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;2,187&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;483&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;849&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;314&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:AdjToPeoCompFnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528114049594">
                &lt;div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;PEO&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;Non-PEO NEO Average&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Summary Compensation Table Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;1,149&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;950&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;485&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;385&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-the fair value of equity awards granted that are reported in the Summary Compensation Table&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(742&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(532&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(246&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(141&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+ Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;360&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;126&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;245&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the end of the covered fiscal year (from the end of the prior fiscal year) of any awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;863&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(81&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;222&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;(9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;112&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;28&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;+/- Change in fair value as of the vesting date (from&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;the end of the prior fiscal year) of any awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;granted in any prior fiscal year for which all&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;applicable vesting conditions were satisfied at the&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:52%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;end of or during the covered fiscal year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;445&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;20&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;115&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;7&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-weight:bold"&gt;Compensation Actually Paid&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;2,187&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;483&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;$&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;849&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;314&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114431879"
      unitRef="USD">1149000</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114442031"
      unitRef="USD">950000</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114446705"
      unitRef="USD">485000</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114508564"
      unitRef="USD">385000</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114728782"
      unitRef="USD">-742000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114904139"
      unitRef="USD">-532000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114805203"
      unitRef="USD">-246000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueOfEquityAwardsGrantedAreReportedInSummaryCompensationTableMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115009047"
      unitRef="USD">-141000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114738319"
      unitRef="USD">360000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114920317"
      unitRef="USD">126000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114816681"
      unitRef="USD">245000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfTheEndOfAllAwardsGrantedDuringTheCoveredFiscalYearThatAreOutstandingAndUnvestedAtTheEndOfTheCoveredYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115016165"
      unitRef="USD">72000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114749141"
      unitRef="USD">863000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114928847"
      unitRef="USD">-81000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114820959"
      unitRef="USD">222000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAtEndOfTheCoveredFiscalYearOfAnyAwardsGrantedInAnyPriorFiscalYearThatAreOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115022336"
      unitRef="USD">-9000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114754065"
      unitRef="USD">112000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114943565"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114825572"
      unitRef="USD">28000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115029871"
      unitRef="USD">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114759616"
      unitRef="USD">445000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114957783"
      unitRef="USD">20000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20240101to20241231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528114840025"
      unitRef="USD">115000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="C_20230101to20231231_ecdAdjToCompAxis_entxChangeInFairValueAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorFiscalYearForWhichAllApplicableVestingConditionsWereSatisfiedAtTheEndOfOrDuringTheCoveredFiscalYearMember_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115035703"
      unitRef="USD">7000</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20240101to20241231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115208330"
      unitRef="USD">2187000</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20230101to20231231_ecdIndividualAxis_entxPrincipalExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115305065"
      unitRef="USD">483000</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20240101to20241231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115259742"
      unitRef="USD">849000</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="C_20230101to20231231_ecdIndividualAxis_entxNonPrincipalExecutiveOfficerAndNonExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20250528115315683"
      unitRef="USD">314000</ecd:PeoActuallyPaidCompAmt>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528120736418">
                &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                  &lt;div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation Actually Paid and Cumulative Total Shareholder Return&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2023 and 2024, compensation actually paid (&#x201c;CAP&#x201d;) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                  &lt;div&gt;&#160;&lt;/div&gt;
                &lt;img alt="image1.jpg" height="363" src="image1.jpg" width="603"/&gt;</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock
      contextRef="C_20240101to20241231"
      id="Fxbrl_20250528120815262">
                  &lt;div style="font-size:10pt;font-family:Times New Roman"&gt;
                    &lt;div&gt;
                      &lt;div style="text-align:justify;margin-right:7.75pt;line-height:1.25;font-style:italic"&gt;Compensation Actually Paid and Net Loss&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25"&gt;During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                </ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20250528111816153"
          xlink:label="Fxbrl_20250528111816153"
          xlink:type="locator"/>
        <link:footnote id="FN20250528115937877" xlink:label="FN20250528115937877" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Non-PEO NEOs for both years are Hillel Galitzer and Dana Yaacov-Garbeli.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111816153"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnote id="FN20250528120032302" xlink:label="FN20250528120032302" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dollar amounts reported herein represent the amount of total compensation reported for each covered fiscal year in the &#x201c;Total&#x201d; column of the Summary Compensation Table for each applicable year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111816153"
          xlink:to="FN20250528120032302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528111840911"
          xlink:label="Fxbrl_20250528111840911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111840911"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnote id="FN20250528120053271" xlink:label="FN20250528120053271" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dollar amounts reported below represent the amount of &#x201c;compensation actually paid&#x201d; to our PEO and Non-PEO NEOs (as an average) as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs and Non-PEO NEOs during the applicable fiscal year. For purposes of the equity award adjustments shown below, no equity awards were cancelled due to a failure to meet vesting conditions and no dividends or other earnings paid on share or option awards in the covered fiscal year prior to the vesting date were not otherwise included in the total compensation for the covered fiscal year. In calculating the &#x201c;compensation actually paid&#x201d; amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The valuation assumptions used to calculate such fair values did not materially differ from those disclosed at the time of grant. The following table details the applicable adjustments that were made to the determine &#x201c;compensation actually paid&#x201d; (all amounts are averages for Non-PEO NEOs).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111840911"
          xlink:to="FN20250528120053271"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528111909715"
          xlink:label="Fxbrl_20250528111909715"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111909715"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnote id="FN20250528120119793" xlink:label="FN20250528120119793" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the &#x201c;Total&#x201d; column of the Summary Compensation Table for each applicable year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111909715"
          xlink:to="FN20250528120119793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528111932493"
          xlink:label="Fxbrl_20250528111932493"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111932493"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528111932493"
          xlink:to="FN20250528120053271"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112422091"
          xlink:label="Fxbrl_20250528112422091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112422091"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnote id="FN20250528120204617" xlink:label="FN20250528120204617" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Cumulative total stockholder return (&#x201c;TSR&#x201d;) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112422091"
          xlink:to="FN20250528120204617"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112502844"
          xlink:label="Fxbrl_20250528112502844"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112502844"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnote id="FN20250528120224259" xlink:label="FN20250528120224259" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net loss is reflected as reported in our audited consolidated financial statements for the applicable fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112502844"
          xlink:to="FN20250528120224259"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528112502844"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528112502844"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528112502844"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528112502844"
          xlink:to="FN20250528120224259"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528112422091"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528112422091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528112422091"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528112422091"
          xlink:to="FN20250528120204617"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528111932493"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528111932493"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111932493"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111932493"
          xlink:to="FN20250528120053271"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528111909715"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528111909715"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111909715"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111909715"
          xlink:to="FN20250528120119793"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528111840911"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528111840911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111840911"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111840911"
          xlink:to="FN20250528120053271"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20250528112826678_xbrl_20250528111816153"
          xlink:label="Fxbrl_20250528112826678_xbrl_20250528111816153"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111816153"
          xlink:to="FN20250528115937877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20250528112826678_xbrl_20250528111816153"
          xlink:to="FN20250528120032302"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
